22_CD
17h_JJ
NOTES_NN
TO_PIN
GROUP_NN
FINANCIAL_NN
STATEMENTS_NOMZ
31_CD
December_NN
2002_CD
1_CD
Accounting_GER
policies_NN
A_DT
summary_NN
of_PIN
the_DT
more_EMPH
important_JJ
accounting_GER
policies_NN
,_,
which_WDT [SERE]
have_VPRT [PEAS]
been_VBN [BYPA]
reviewed_VBN
by_PIN
the_DT
Board_NN
of_PIN
Directors_NN
in_PIN
accordance_NN
with_PIN
Financial_NN
Reporting_GER
Standard_NN
FRS_NN
18_CD
,_,
Notes_NN
to_PIN
Group_NN
financial_JJ
statements_NOMZ
Accounting_GER
Policies_NN
,_,
and_ANDC
have_VPRT [PEAS]
been_VBN [SPAU] [PASS]
consistently_RB
applied_VBN
,_,
is_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
FRS_NN
19_CD
,_,
Deferred_NN
Tax_NN
,_,
has_VPRT [PEAS]
been_VBN [PASS]
adopted_VBN
in_PIN
the_DT
year_NN
,_,
but_CC
has_VPRT [PEAS]
had_VBN
no_SYNE
impact_NN
on_PIN
the_DT
amounts_NN
The_DT
notes_NN
to_PIN
Group_NN
financial_JJ
statements_NOMZ
included_VBN [WZPAST]
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
and_PHC
balance_NN
sheet_NN
._.
are_VPRT [PASS]
intended_VBN [SUAV]
to_TO
provide_VB
additional_JJ
analysis_NN
and_PHC
detail_NN
required_VBN [SUAV]
to_TO
meet_VB
Basis_NN
of_PIN
accounting_GER
statutory_JJ
obligations_NOMZ
._.
The_DT
preparation_NOMZ
of_PIN
our_FPP1
financial_JJ
statements_NOMZ
requires_VPRT [SUAV]
us_FPP1
to_TO
make_VB
estimates_NN
and_PHC
judgments_NOMZ
that_TSUB
affect_VPRT
the_DT
reported_VBN [PUBV]
amount_NN
of_PIN
net_JJ
assets_NN
at_PIN
the_DT
date_NN
of_PIN
our_FPP1
financial_JJ
statements_NOMZ
and_CC
the_DT
reported_VBN [PUBV]
amounts_NN
of_PIN
revenues_NN
and_PHC
expenses_NN
during_PIN
the_DT
period_NN
._.
The_DT
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
under_IN
the_DT
historical_JJ
cost_NN
convention_NOMZ
and_CC
in_PIN
accordance_NN
with_PIN
the_DT
Companies_NN
Act_NN
1985_CD
and_CC
United_NN
Kingdom_NN
generally_RB
accepted_VBD [PRIV]
accounting_GER
principles_NN
UK_NN
GAAP_NN
._.
Where_RB
there_EX
are_VPRT
significant_JJ
differences_NN
to_PIN
United_NN
States_NN
generally_RB
accepted_VBN [PRIV]
accounting_GER
principles_NN
US_FPP1
GAAP_NN
these_DEMP
have_VPRT [PEAS]
been_VBN [PASS]
discussed_VBN
in_PIN
note_NN
29_CD
._.
Basis_NN
of_PIN
consolidation_NOMZ
The_DT
Group_NN
financial_JJ
statements_NOMZ
include_VPRT
and_PHC
consolidate_VPRT
the_DT
financial_JJ
statements_NOMZ
of_PIN
Acambis_NN
plc_NN
and_CC
each_QUAN
of_PIN
its_PIT
subsidiary_NN
undertakings_GER
._.
Acquisitions_NOMZ
made_VBN [WZPAST]
by_PIN
the_DT
Group_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
under_IN
the_DT
acquisition_NOMZ
method_NN
of_PIN
accounting_GER
and_CC
the_DT
Group_NN
financial_JJ
statements_NOMZ
include_VPRT
the_DT
results_NN
of_PIN
such_JJ
subsidiaries_NN
from_PIN
the_DT
relevant_JJ
date_NN
of_PIN
acquisition_NOMZ
._.
Intra-group_JJ
transactions_NOMZ
and_PHC
profits_NN
are_VPRT [PASS]
eliminated_VBN
fully_AMP
on_PIN
consolidation_NOMZ
._.
The_DT
loss_NN
for_PIN
the_DT
financial_JJ
year_NN
,_,
dealt_VBN [PASTP]
with_PIN
in_PIN
the_DT
financial_JJ
statements_NOMZ
of_PIN
the_DT
Company_NN
,_,
was_VBD [BEMA]
1.6_CD
m_NN [BEMA]
2001_CD
profit_NN
of_PIN
4.6_CD
m._FW
Under_IN
the_DT
provisions_NN
of_PIN
Section_NOMZ
230_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
,_,
no_SYNE
profit_NN
and_PHC
loss_NN
account_NN
is_VPRT [PASS]
presented_VBN
for_PIN
the_DT
Company_NN
._.
Turnover_NN
Group_NN
turnover_NN
comprises_VPRT
the_DT
value_NN
of_PIN
sales_NN
excluding_VBG [WZPRES]
VAT_NN
and_CC
similar_JJ
taxes_NN
,_,
trade_NN
discounts_NN
and_CC
intra-group_JJ
transactions_NOMZ
and_PHC
income_NN
derived_VBN [WZPAST]
from_PIN
product_NN
sales_NN
,_,
licence_NN
fees_NN
,_,
contract_NN
research_NN
fees_NN
and_PHC
development_NOMZ
milestone_NN
payments_NOMZ
receivable_JJ
from_PIN
third_JJ
parties_NN
in_PIN
the_DT
normal_JJ
course_NN
of_PIN
business_NOMZ
._.
Revenue_NN
from_PIN
product_NN
sales_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
delivery_NN
of_PIN
the_DT
product_NN
._.
Non-refundable_JJ
licence_NN
fees_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
over_IN
the_DT
term_NN
of_PIN
the_DT
licence_NN
._.
Where_RB
the_DT
Group_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
undertake_VB
research_NN
and_PHC
development_NOMZ
activities_NOMZ
and_CC
the_DT
fee_NN
is_VPRT [BEMA]
creditable_PRED
against_PIN
services_NN
provided_VBN [WZPAST]
by_PIN
the_DT
Group_NN
,_,
that_DEMO
licence_NN
fee_NN
is_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
over_IN
the_DT
period_NN
over_IN
which_WDT
the_DT
services_NN
are_VPRT [PASS]
performed_VBN
._.
Contract_NN
research_NN
fees_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
accounting_GER
period_NN
in_PIN
which_WDT [PIRE]
the_DT
related_JJ
work_NN
is_VPRT [PASS]
carried_VBN
out_PIN [STPR]
._.
Access_NN
fees_NN
and_PHC
milestones_NN
receivable_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
they_TPP3
fall_VPRT
contractually_RB
due_JJ
._.
Profit_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
long-term_JJ
contracts_NN
when_RB
the_DT
final_JJ
outcome_NN
can_POMD
be_VB [PASS]
assessed_VBN
with_PIN
reasonable_JJ
certainty_NN
by_PIN
including_VBG
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
,_,
turnover_NN
and_CC
related_JJ
costs_NN
as_IN
contract_NN
activity_NOMZ
progresses_VPRT
._.
Turnover_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
according_VBG
to_PIN
the_DT
stage_NN
reached_VBN [WZPAST]
in_PIN
the_DT
contract_NN
by_PIN
reference_NN
to_PIN
the_DT
costs_NN
incurred_VBN [WZPAST]
in_PIN
relation_NOMZ
to_PIN
total_JJ
estimated_VBN [PRIV]
expected_VBN [PRIV]
costs_NN
._.
The_DT
second_JJ
smallpox_NN
vaccine_NN
contract_NN
with_PIN
the_DT
US_FPP1
Centers_NN
for_PIN
Disease_NN
Control_NN
&_CC
Prevention_NOMZ
CDC_NN
is_VPRT [BEMA]
a_DT
fixed_VBN
fee_NN
arrangement_NOMZ
requiring_VBG [SUAV] [WZPRES]
the_DT
delivery_NN
of_PIN
products_NN
as_RB
well_RB
as_IN
a_DT
concurrent_JJ
research_NN
and_PHC
development_NOMZ
R&D_NN
program_NN
._.
This_DEMO
arrangement_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
treated_VBN
as_IN
a_DT
single_JJ
long-term_JJ
contract_NN
,_,
whose_WPS
elements_NOMZ
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
accounted_VBN
for_PIN
separately_RB
._.
Turnover_NN
and_PHC
profits_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
according_VBG
to_PIN
the_DT
stage_NN
reached_VBN [WZPAST]
in_PIN
the_DT
contract_NN
,_,
as_IN
described_VBN
above_PLACE
._.
Manufacturing_GER
costs_NN
are_VPRT [PASS]
deemed_VBN [PRIV]
to_TO
be_VB [PASS]
incurred_VBN
on_PIN
delivery_NN
of_PIN
products_NN
:_:
R&D_NN
costs_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
incurred_VBN
._.
Cost_NN
of_PIN
sales_NN
The_DT
Group_NN
has_VPRT [PEAS]
classified_VBN
costs_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
directly_RB
attributable_PRED
to_PIN
funded_JJ
research_NN
and_PHC
vaccine_NN
manufacture_NN
programs_NN
as_IN
cost_NN
of_PIN
sales_NN
._.
Certain_JJ
research_NN
and_PHC
development_NOMZ
costs_NN
were_VBD
,_,
in_PIN
prior_JJ
years_NN
,_,
classified_VBN
as_IN
R&D_NN
expenditure_NN
._.
The_DT
Directors_NN
believe_VPRT [PRIV]
that_THVC
the_DT
new_JJ
classification_NOMZ
more_EMPH
appropriately_RB
reflects_VPRT [PRIV]
the_DT
nature_NN
of_PIN
the_DT
arrangements_NOMZ
the_DT
Group_NN
has_VPRT [PEAS]
entered_VBN
into_PIN [STPR]
._.
This_DEMO
reclassification_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
applied_VBN
to_PIN
the_DT
two_CD
CDC_NN
smallpox_NN
vaccine_NN
contracts_NN
._.
The_DT
financial_JJ
information_NOMZ
for_PIN
2001_CD
and_CC
2000_CD
has_VPRT [PEAS]
been_VBN [PASS]
re-presented_VBN
so_RB
that_DEMO
cost_NN
classifications_NOMZ
are_VPRT [PASS]
shown_VBN [PRIV]
on_PIN
a_DT
comparable_JJ
basis_NN
._.
The_DT
monetary_JJ
impact_NN
of_PIN
this_DEMO
re-classification_NOMZ
in_PIN
2001_CD
and_CC
2000_CD
is_VPRT [BEMA]
5.1_CD
m_NN
and_CC
0.5_CD
m_NN
respectively_RB
,_,
which_WDT [SERE]
was_VBD [SPAU] [PASS]
previously_TIME
included_VBN
within_PIN
R&D_NN
costs_NN
._.
There_EX
is_VPRT
no_SYNE
impact_NN
on_PIN
net_JJ
profit_NN
._.
Research_NN
and_PHC
development_NOMZ
R&D_NN
costs_NN
are_VPRT [PASS]
written_VBN [PUBV]
off_PIN
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [PASS]
incurred_VBN
._.
THE_DT
INFORMATION_NOMZ
CONTAINED_VBD
IN_PIN
THIS_DEMO
COLUMN_NN
HAS_VPRT
NOT_XX0
BEEN_JJ
AUDITED_NN
._.
Government_NOMZ
grants_NN
Grants_NN
,_,
which_WDT [SERE]
are_VPRT [BEMA]
non-refundable_PRED
,_,
are_VPRT [PASS]
intended_VBN [SUAV]
to_TO
contribute_VB
towards_PIN
specific_JJ
costs_NN
and_CC
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
line_NN
with_PIN
the_DT
proportion_NOMZ
of_PIN
those_DEMO
costs_NN
incurred_VBN
and_PHC
are_VPRT [PASS]
netted_VBN
off_PIN
against_PIN
R&D_NN
costs_NN
._.
Pension_NN
costs_NN
All_QUAN
schemes_NN
are_VPRT [PASS]
defined_VBN
contribution_NOMZ
schemes_NN
and_PHC
pension_NN
contributions_NOMZ
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
in_PIN
the_DT
year_NN
to_PIN
which_WDT [PIRE]
they_TPP3
relate_VPRT
._.
Any_QUAN
difference_NN
between_PIN
amounts_NN
charged_VBN [WZPAST]
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
and_PHC
contributions_NOMZ
paid_VBN [WZPAST]
are_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
balance_NN
sheet_NN
under_IN
prepayments_NOMZ
or_CC
creditors_NN
falling_VBG [WZPRES]
due_JJ
within_PIN
one_CD
year_NN
._.
Taxation_NOMZ
Current_NN
tax_NN
,_,
including_VBG
UK_NN
corporation_NOMZ
tax_NN
and_CC
foreign_JJ
tax_NN
,_,
is_VPRT [PASS]
provided_VBN
at_PIN
amounts_NN
expected_VBN [PRIV]
to_TO
be_VB [PASS]
paid_VBN
or_CC
recovered_VBN
using_VBG
the_DT
tax_NN
rates_NN
and_PHC
laws_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
enacted_VBN
or_CC
substantially_RB
enacted_VBN
by_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
all_QUAN
deferred_VBN
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
in_PIN
accordance_NN
with_PIN
FRS_NN
19_CD
,_,
using_VBG
full_JJ
provision_NN
accounting_GER
,_,
when_RB
an_DT
event_NN
has_VPRT [PEAS]
taken_VBN
place_NN
by_PIN
the_DT
balance_NN
sheet_NN
date_NN
which_WDT [WHSUB]
gives_VPRT
rise_NN
to_PIN
an_DT
increased_VBN
or_CC
reduced_VBN
tax_NN
liability_NOMZ
in_PIN
the_DT
future_NN
._.
Deferred_JJ
tax_NN
is_VPRT [PASS]
measured_VBN
at_PIN
the_DT
average_JJ
tax_NN
rates_NN
that_TSUB
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
apply_VB
in_PIN
the_DT
periods_NN
in_PIN
which_WDT [PIRE]
the_DT
timing_NN
differences_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
reverse_VB
,_,
based_VBN [PASTP]
on_PIN
tax_NN
rates_NN
and_PHC
laws_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
enacted_VBN
or_CC
substantially_RB
enacted_VBN
by_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Deferred_JJ
tax_NN
assets_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
to_PIN
the_DT
extent_NN
that_TOBJ
they_TPP3
are_VPRT [PASS]
regarded_VBN
as_IN
recoverable_JJ
._.
Deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
not_XX0
discounted_VBN
._.
Intangible_JJ
assets_NN
goodwill_NN
Goodwill_NN
arising_VBG [WZPRES]
on_PIN
the_DT
acquisition_NOMZ
of_PIN
subsidiary_NN
undertakings_GER
,_,
representing_VBG [PRESP]
the_DT
excess_NN
of_PIN
fair_JJ
value_NN
of_PIN
the_DT
consideration_NOMZ
given_VBN
over_IN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
identified_VBN
assets_NN
and_PHC
liabilities_NOMZ
acquired_VBN
,_,
is_VPRT [PASS]
capitalized_VBN
and_PHC
written_VBN [PUBV]
off_PIN
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
its_PIT
useful_JJ
economic_JJ
life_NN
._.
The_DT
Directors_NN
are_VPRT [BEMA]
of_PIN
the_DT
opinion_NN
that_TOBJ
the_DT
useful_JJ
economic_JJ
life_NN
of_PIN
goodwill_NN
will_PRMD
not_XX0
exceed_VB
15_CD
years_NN
._.
The_DT
carrying_VBG
values_NN
of_PIN
goodwill_NN
and_CC
intangible_JJ
assets_NN
are_VPRT [BEMA]
subject_PRED
to_TO
review_VB
and_CC
any_QUAN
impairment_NOMZ
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
Tangible_JJ
fixed_JJ
assets_NN
Fixed_VBN
assets_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
original_JJ
historical_JJ
cost_NN
,_,
net_NN
of_PIN
depreciation_NOMZ
and_CC
any_QUAN
provision_NN
for_PIN
impairment_NOMZ
._.
Depreciation_NOMZ
is_VPRT [PASS]
provided_VBN
on_PIN
all_QUAN
tangible_JJ
fixed_JJ
assets_NN
at_PIN
rates_NN
calculated_VBN [PRIV]
to_TO
write_VB [PUBV]
off_PIN
the_DT
cost_NN
of_PIN
each_QUAN
asset_NN
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
its_PIT
expected_VBN [PRIV]
useful_JJ
life_NN
,_,
or_CC
the_DT
period_NN
of_PIN
the_DT
lease_NN
if_COND
shorter_JJ
,_,
to_PIN
its_PIT
residual_JJ
value_NN
based_VBN [WZPAST]
on_PIN
prices_NN
prevailing_VBG [WZPRES]
at_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
,_,
as_IN
follows_VPRT
:_:
Leasehold_VB
land_NN
and_PHC
buildings_GER
15_CD
years_NN
or_CC
term_NN
of_PIN
lease_NN
if_COND
shorter_JJ
Laboratory_NN
and_PHC
manufacturing_GER
equipment_NOMZ
4_CD
to_PIN
7_CD
years_NN
Office_NN
equipment_NOMZ
3_CD
to_PIN
5_CD
years_NN
The_DT
carrying_GER
values_NN
of_PIN
tangible_JJ
fixed_JJ
assets_NN
are_VPRT [BEMA]
subject_PRED
to_TO
review_VB
and_CC
any_QUAN
impairment_NOMZ
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
The_DT
Group_NN
does_VPRT
not_XX0
capitalize_VB
interest_NN
charges_NN
on_PIN
loans_NN
to_TO
fund_VB
the_DT
purchase_NN
of_PIN
tangible_JJ
fixed_JJ
assets_NN
._.
Investments_NOMZ
Shares_NN
in_PIN
the_DT
Company_NN
purchased_VBD
for_PIN
employee_NN
share_NN
options_NOMZ
are_VPRT [PASS]
held_VBN [PRIV]
under_IN
trust_NN
and_CC
are_VPRT [PASS]
included_VBN
as_IN
a_DT
fixed_JJ
asset_NN
investment_NOMZ
until_IN
the_DT
interest_NN
in_PIN
the_DT
shares_NN
is_VPRT [SPAU] [PASS]
unconditionally_RB
transferred_VBN
to_PIN
the_DT
employees_NN
._.
Provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
any_QUAN
permanent_JJ
impairment_NOMZ
in_PIN
the_DT
value_NN
of_PIN
the_DT
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
trust_NN
._.
The_DT
Groups_NN
other_JJ
fixed_VBN
asset_NN
investments_NOMZ
are_VPRT [PASS]
shown_VBN [PRIV]
at_PIN
cost_NN
less_JJ
any_QUAN
provision_NN
for_PIN
impairment_NOMZ
._.
Joint_NN
venture_NN
undertakings_GER
Joint_NN
ventures_NN
are_VPRT [PASS]
dealt_VBN
with_PIN
under_IN
the_DT
gross_JJ
equity_NOMZ
method_NN
._.
The_DT
Groups_NN
share_NN
of_PIN
revenues_NN
and_PHC
operating_GER
losses_NN
for_PIN
the_DT
joint_JJ
venture_NN
is_VPRT [PASS]
included_VBN
in_PIN
the_DT
Group_NN
profit_NN
and_PHC
loss_NN
account_NN
and_CC
the_DT
Groups_NN
share_NN
of_PIN
gross_JJ
assets_NN
and_PHC
liabilities_NOMZ
is_VPRT [PASS]
included_VBN
in_PIN
the_DT
Group_NN
balance_NN
sheet_NN
._.
Short-term_JJ
investments_NOMZ
Bank_NN
deposits_NN
,_,
which_WDT [SERE]
are_VPRT [BEMA]
not_XX0
repayable_PRED
on_PIN
demand_NN
,_,
are_VPRT [PASS]
treated_VBN
as_IN
short-term_JJ
investments_NOMZ
in_PIN
accordance_NN
with_PIN
FRS_NN
1_CD
,_,
Cash_NN
flow_NN
statements_NOMZ
._.
Movements_NOMZ
in_PIN
such_JJ
investments_NOMZ
are_VPRT [PASS]
included_VBN
under_IN
management_NOMZ
of_PIN
liquid_JJ
resources_NN
in_PIN
the_DT
Groups_NN
cash_NN
flow_NN
statement_NOMZ
._.
Stock_NN
,_,
excluding_VBG
long-term_JJ
contracts_NN
Stock_NN
is_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realisable_JJ
value_NN
._.
In_PIN
general_JJ
,_,
cost_NN
is_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
on_PIN
a_DT
first-in-first-out_PIN
basis_NN
and_CC
includes_VPRT
transport_NN
and_CC
handling_VBG
costs_NN
._.
Where_RB
necessary_JJ
,_,
provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
obsolete_JJ
,_,
slow-moving_JJ
and_PHC
defective_JJ
stock_NN
._.
23_CD
24_CD
NOTES_NN
TO_PIN
GROUP_NN
FINANCIAL_NN
STATEMENTS_NOMZ
31_CD
December_NN
2002_CD
Leases_NN
Assets_NN
acquired_VBD
under_IN
finance_NN
leases_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
balance_NN
sheet_NN
as_IN
tangible_JJ
fixed_JJ
assets_NN
and_CC
are_VPRT [PASS]
depreciated_VBN
over_IN
the_DT
shorter_JJ
of_PIN
the_DT
lease_NN
period_NN
or_CC
their_TPP3
useful_JJ
Turnover_NN
lives_NN
._.
The_DT
capital_NN
elements_NOMZ
of_PIN
future_JJ
lease_NN
payments_NOMZ
are_VPRT [PASS]
recorded_VBN
as_IN
liabilities_NOMZ
,_,
while_OSUB
the_DT
interest_NN
elements_NOMZ
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
over_IN
the_DT
period_NN
of_PIN
Our_FPP1
turnover_NN
represents_VPRT
product_NN
the_DT
leases_NN
to_TO
give_VB
a_DT
constant_JJ
charge_NN
on_PIN
the_DT
balance_NN
of_PIN
the_DT
capital_NN
repayments_NOMZ
outstanding_JJ
._.
The_DT
cost_NN
of_PIN
operating_VBG
leases_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
on_PIN
a_DT
sales_NN
and_PHC
revenues_NN
for_PIN
research_NN
and_CC
straight-line_JJ
basis_NN
over_IN
the_DT
lease_NN
term_NN
,_,
even_RB
if_COND
rental_JJ
payments_NOMZ
are_VPRT [PASS]
not_XX0
made_VBN
on_PIN
such_EMPH
a_NULL
basis_NN
._.
Foreign_JJ
currencies_NN
SOURCES_NN
OF_PIN
TURNOVER_NN
Transactions_NOMZ
denominated_VBD
in_PIN
foreign_JJ
currencies_NN
are_VPRT [PASS]
recorded_VBN
in_PIN
the_DT
local_JJ
currency_NN
at_PIN
actual_JJ
exchange_NN
rates_NN
as_RB
at_PIN
the_DT
date_NN
of_PIN
the_DT
transaction_NOMZ
._.
Monetary_NN
assets_NN
and_PHC
liabilities_NOMZ
denominated_VBN [WZPAST]
in_PIN
foreign_JJ
currencies_NN
are_VPRT [PASS]
translated_VBN
at_PIN
the_DT
rates_NN
ruling_VBG [SUAV] [WZPRES]
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Any_QUAN
gain_NN
or_CC
loss_NN
arising_VBG [WZPRES]
from_PIN
a_DT
change_NN
in_PIN
exchange_NN
rates_NN
subsequent_JJ
to_PIN
the_DT
date_NN
of_PIN
the_DT
transaction_NOMZ
is_VPRT [PASS]
included_VBN
as_IN
an_DT
exchange_NN
gain_NN
or_CC
loss_NN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
Assets_NN
and_PHC
liabilities_NOMZ
of_PIN
overseas_PLACE
subsidiary_NN
and_CC
joint_JJ
venture_NN
undertakings_GER
are_VPRT [PASS]
translated_VBN
into_PIN
sterling_GER
at_PIN
rates_NN
of_PIN
exchange_NN
ruling_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
The_DT
results_NN
and_PHC
cash_NN
flows_NN
of_PIN
overseas_PLACE
subsidiary_NN
and_CC
joint_JJ
venture_NN
undertakings_GER
are_VPRT [PASS]
translated_VBN
into_PIN
sterling_GER
using_VBG [WZPRES]
average_JJ
rates_NN
of_PIN
exchange_NN
._.
Exchange_NN
adjustments_NOMZ
arising_VBG [WZPRES]
when_RB
the_DT
opening_GER
net_JJ
assets_NN
and_CC
the_DT
losses_NN
for_PIN
the_DT
year_NN
retained_VBN [WZPAST]
by_PIN
overseas_PLACE
subsidiary_NN
and_CC
joint_JJ
venture_NN
undertakings_GER
are_VPRT [PASS]
translated_VBN
into_PIN
sterling_GER
are_VPRT [PASS]
taken_VBN
directly_RB
to_PIN
reserves_NN
and_CC
reported_VBN [PUBV]
in_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
._.
Where_RB
financing_GER
of_PIN
a_DT
foreign_JJ
subsidiary_NN
through_PIN
long-term_JJ
loans_NN
and_CC
deferred_VBN
trading_GER
balances_NN
is_VPRT [PASS]
intended_VBN [SUAV]
to_TO
be_VB
as_IN
permanent_JJ
as_IN
equity_NOMZ
,_,
such_JJ
loans_NN
and_CC
inter-company_JJ
balances_NN
are_VPRT [PASS]
treated_VBN
as_IN
part_NN
of_PIN
the_DT
net_JJ
investment_NOMZ
and_CC
,_,
as_IN
such_JJ
,_,
any_QUAN
exchange_NN
differences_NN
arising_VBG [WZPRES]
are_VPRT [PASS]
dealt_VBN
with_PIN
as_IN
adjustments_NOMZ
to_PIN
reserves_NN
._.
Financial_NN
instruments_NOMZ
The_DT
Group_NN
attempts_VPRT
to_TO
reduce_VB
its_PIT
foreign_JJ
currency_NN
exposure_NN
using_VBG [WZPRES]
forward_RB
planning_VBG
of_PIN
currency_NN
requirements_NOMZ
for_PIN
US_FPP1
dollars_NN
and_PHC
UK_NN
sterling_GER
,_,
and_ANDC
entering_VBG
into_PIN
spot_NN
rate_NN
currency_NN
contracts_NN
as_IN
appropriate_JJ
._.
The_DT
Group_NN
does_VPRT
not_XX0
enter_VB
into_PIN
derivative_JJ
transactions_NOMZ
._.
2000_CD
2001_CD
Employee_NN
share_NN
option_NOMZ
schemes_NN
Other_JJ
sources_NN
include_VPRT
revenues_NN
In_PIN
accordance_NN
with_PIN
Urgent_NN
Issues_NN
Task_NN
Force_NN
UITF_NN
Abstract_NN
17_CD
,_,
Employee_NN
Share_NN
Schemes_NN
UITF_NN
17_CD
,_,
the_DT
cost_NN
of_PIN
awards_NN
to_PIN
employees_NN
of_PIN
share_NN
options_NOMZ
is_VPRT [PASS]
charged_VBN
to_PIN
receivable_NN
from_PIN
Aventis_NN
Pasteur_NN
for_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
the_DT
period_NN
to_PIN
which_WDT [PIRE]
the_DT
performance_NN
relates_VPRT
,_,
based_VBN [PASTP]
on_PIN
an_DT
assessment_NOMZ
of_PIN
the_DT
probability_NOMZ
of_PIN
the_DT
performance_NN
our_FPP1
ChimeriVax-Dengue_NN
project_NN
and_PHC
criteria_NN
being_VBG [WZPRES] [PASS]
met_VBN
._.
The_DT
cost_NN
of_PIN
such_JJ
awards_NN
is_VPRT [PASS]
calculated_VBN [PRIV]
as_IN
the_DT
difference_NN
between_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
shares_NN
at_PIN
the_DT
date_NN
of_PIN
the_DT
grant_NN
and_CC
the_DT
exercise_NN
price_NN
of_PIN
the_DT
our_FPP1
H._NN
pylori_NN
joint_JJ
venture_NN
._.
Any_QUAN
liability_NOMZ
relating_VBG [WZPRES]
to_PIN
National_NN
Insurance_NN
payments_NOMZ
due_JJ
on_PIN
exercise_NN
of_PIN
options_NOMZ
that_TSUB
has_VPRT [PEAS]
not_XX0
been_VBN [PASS]
transferred_VBN
to_PIN
the_DT
employees_NN
is_VPRT [SPAU] [PASS]
also_RB
accrued_VBN
over_IN
the_DT
performance_NN
period_NN
of_PIN
the_DT
option_NOMZ
._.
2_CD
Segmental_JJ
information_NOMZ
Turnover_NN
4b_NN
The_DT
Groups_NN
turnover_NN
comprises_VPRT
product_NN
sales_NN
,_,
licence_NN
fees_NN
,_,
contract_NN
research_NN
fees_NN
,_,
royalties_NN
and_PHC
milestone_NN
payments_NOMZ
._.
One_CD
customer_NN
,_,
the_DT
CDC_NN
,_,
accounted_VBD
for_PIN
95_CD
%_NN
,_,
64_CD
%_NN
and_CC
9_CD
%_NN
of_PIN
Group_NN
turnover_NN
in_PIN
2002_CD
,_,
2001_CD
and_CC
2000_CD
respectively_RB
._.
The_DT
Directors_NN
are_VPRT [BEMA]
of_PIN
the_DT
opinion_NN
that_TOBJ
the_DT
Group_NN
has_VPRT
only_DWNT
one_CD
class_NN
of_PIN
business_NOMZ
._.
The_DT
geographical_JJ
analysis_NN
of_PIN
turnover_NN
by_PIN
origin_NN
and_PHC
destination_NOMZ
,_,
operating_VBG
profit_NN
loss_NN
and_CC
net_JJ
assets_NN
liabilities_NOMZ
and_PHC
share_NN
of_PIN
loss_NN
of_PIN
the_DT
joint_JJ
venture_NN
is_VPRT
as_IN
follows_VPRT
:_:
Europe_NN
North_NN
America_NN
2002 2001 2000 2002_CD
2001 2000 000 000_CD
000 000 000 000_CD
Turnover_NN
by_PIN
customer_NN
location_NOMZ
785_CD
73_CD
265_CD
78,931_CD
8,841_CD
5,999_CD
Turnover_NN
by_PIN
origin_NN
785_CD
73_CD
265_CD
78,931_CD
8,841_CD
5,999_CD
Profit_NN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
2,741_CD
601_CD
5,942_CD
12,319_CD
13,159_CD
5,132_CD
Net_JJ
assets_NN
liabilities_NOMZ
53,537_CD
55,805_CD
35,377_CD
7,286_CD
28,145_CD
762_CD
Share_NN
of_PIN
loss_NN
of_PIN
Joint_NN
Venture_NN
-_:
--_:
171_CD
410_CD
2,138_CD
In_PIN
2002_CD
,_,
sales_NN
to_PIN
Europe_NN
represented_VBD
1_CD
%_NN
and_PHC
sales_NN
to_PIN
North_NN
America_NN
represented_VBD
99_CD
%_NN
of_PIN
total_JJ
sales_NN
._.
The_DT
figures_NN
shown_VBN [PRIV] [WZPAST]
on_PIN
the_DT
face_NN
of_PIN
the_DT
Group_NN
profit_NN
and_PHC
loss_NN
account_NN
on_PIN
page_NN
18_CD
analyze_VPRT
the_DT
operating_GER
profit_NN
loss_NN
before_IN
finance_NN
charges_NN
and_PHC
taxation_NOMZ
._.
The_DT
net_JJ
liabilities_NOMZ
of_PIN
the_DT
joint_JJ
venture_NN
with_PIN
Aventis_NN
Pasteur_NN
of_PIN
0.2_CD
m_NN [BEMA]
2001_CD
net_JJ
assets_NN
of_PIN
0.1_CD
m_NN
,_,
see_VPRT [PRIV]
note_NN
14_CD
d_SYM
are_VPRT [PASS]
included_VBN
within_PIN
North_NN
America_NN
._.
3_CD
Administrative_JJ
costs_NN
Amortisation_NOMZ
of_PIN
goodwill_NN
2002 2001 2000_CD
This_DEMO
goodwill_NN
arose_VBD
when_RB
Acambis_NN
Inc._NN
000 000 000_CD
was_VBD [PASS]
acquired_VBN
in_PIN
1999_CD
._.
It_PIT
is_VPRT
being_VBG [PASS]
written_VBN [PUBV]
Administrative_JJ
costs_NN
3,053_CD
2,295_CD
1,745_CD
off_PIN
over_IN
15_CD
years_NN
,_,
resulting_VBG [PRESP]
in_PIN
an_DT
annual_JJ
Amortisation_NOMZ
of_PIN
goodwill_NN
1,204_CD
1,204_CD
1,204_CD
charge_NN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
of_PIN
4,257_CD
3,499_CD
2,949_CD
1.2_CD
m_NN
see_VPRT [PRIV]
note_NN
12_CD
._.
4_CD
Discontinued_VBN
operations_NOMZ
Interest_NN
element_NOMZ
of_PIN
finance_NN
leases_NN
During_PIN
2000_CD
,_,
the_DT
Group_NN
completed_VBD
the_DT
disposal_NN
of_PIN
its_PIT
interest_NN
in_PIN
its_PIT
drug_NN
discovery_NN
business_NOMZ
,_,
Mimetrix_NN
,_,
to_PIN
Medivir_NN
AB_NN
,_,
a_DT
Swedish_JJ
biotechnology_NN
company_NN
listed_VBN [WZPAST]
on_PIN
the_DT
During_PIN
2001_CD
,_,
the_DT
Group_NN
put_VBD
in_PIN
place_NN
Stockholm_NN
Stock_NN
Exchange_NN
._.
The_DT
results_NN
of_PIN
Mimetrix_NN
up_IN
to_PIN
31_CD
March_NN
2000_CD
the_DT
date_NN
from_PIN
which_WDT [PIRE]
Medivir_NN
AB_NN
assumed_VBD [PRIV]
the_DT
obligations_NOMZ
of_PIN
Mimetrixs_NN
operating_VBG [WZPRES]
activities_NOMZ
a_DT
$_$
40_CD
million_CD
c._NN
25m_JJ
lease-finance_NN
are_VPRT
as_IN
follows_VPRT
:_:
facility_NOMZ
to_TO
fund_VB
the_DT
reactivation_NOMZ
of_PIN
our_FPP1
2000_CD
manufacturing_GER
plant_NN
._.
The_DT
repayment_NOMZ
000_CD
obligations_NOMZ
for_PIN
the_DT
lease_NN
financing_GER
Turnover_NN
-_:
are_VPRT
as_IN
follows_VPRT
:_:
Research_NN
and_PHC
development_NOMZ
costs_NN
643_CD
Administrative_JJ
costs_NN
81_CD
None_INPR
in_PIN
2002_CD
:_:
Operating_GER
loss_NN
724_CD
Interest_NN
only_DWNT
in_PIN
2003_CD
:_:
and_ANDC
Capital_NN
and_PHC
interest_NN
during_PIN
2004_CD
The_DT
Mimetrix_NN
activities_NOMZ
were_VBD [BEMA]
all_QUAN
UK-based_JJ
._.
Consequently_CONJ
,_,
interest_NN
that_TSUB
accrued_VBD
5_CD
Amounts_NN
written_VBN [PUBV] [WZPAST]
off_PIN
fixed_VBN
asset_NN
investment_NOMZ
in_PIN
2002_CD
has_VPRT [PEAS]
been_VBN [PASS]
added_VBN [PUBV]
into_PIN
the_DT
During_PIN
the_DT
year_NN
,_,
the_DT
investment_NOMZ
of_PIN
shares_NN
held_VBN [PRIV] [WZPAST]
in_PIN
Medivir_NN
AB_NN
,_,
which_WDT [SERE]
were_VBD [PASS]
acquired_VBN
in_PIN
2000_CD
in_PIN
exchange_NN
for_PIN
the_DT
assets_NN
of_PIN
Mimetrix_NN
Limited_NN
,_,
were_VBD [PASS]
written_VBN [PUBV]
down_RP
to_TO
reflect_VB [PRIV]
outstanding_JJ
balance_NN
._.
the_DT
fall_NN
in_PIN
market_NN
value_NN
during_PIN
the_DT
year_NN
._.
This_DEMP
resulted_VBD
in_PIN
an_DT
exceptional_JJ
loss_NN
of_PIN
0.1_CD
m_NN [BEMA]
2001_CD
0.4_CD
m._NN
This_DEMO
adjustment_NOMZ
was_VBD [BEMA]
in_PIN
accordance_NN
with_PIN
FRS_NN
11_CD
,_,
Impairment_NOMZ
of_PIN
Fixed_NN
Assets_NN
and_PHC
Goodwill_NN
._.
6_CD
Interest_NN
payable_JJ
and_PHC
similar_JJ
charges_NN
This_DEMO
note_NN
details_NN
the_DT
interest_NN
payable_JJ
on_PIN
the_DT
Arilvax_NN
overdraft_NN
facility_NOMZ
see_VPRT [PRIV]
note_NN
18_CD
for_PIN
more_EMPH
information_NOMZ
,_,
as_RB
well_RB
as_IN
interest_NN
from_PIN
assets_NN
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
._.
2002 2001 2000 000_CD
000_CD
000_CD
On_PIN
bank_NN
overdrafts_NN
93 214 211_CD
Interest_NN
element_NOMZ
of_PIN
finance_NN
leases_NN
1,118_CD
-_:
5_CD
1,211_CD
214_CD
216_CD
7_CD
Profit_NN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
Profit_NN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
is_VPRT [PASS]
stated_VBN [PUBV]
:_:
2002 2001 2000_CD
Notes_NN
000 000 000_CD
After_IN
crediting_VBG
:_:
Grant_NN
income_NN
1,892_CD
1,142_CD
165_CD
And_CC
after_IN
charging_VBG
:_:
Amortisation_NOMZ
of_PIN
goodwill_NN
12_CD
1,204_CD
1,204_CD
1,204_CD
Depreciation_NOMZ
of_PIN
tangible_JJ
fixed_JJ
assets_NN
13_CD
owned_VBN
1,148_CD
851_CD
855_CD
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
262_SYM
-_:
73_CD
Operating_GER
lease_NN
charges_NN
26_CD
a_DT
hire_NN
of_PIN
plant_NN
and_PHC
machinery_NN
13_CD
5_CD
77_CD
other_JJ
1,379_CD
1,582_CD
1,630_CD
Auditors_NN
remuneration_JJ
audit_NN
services_NN
Company_NN
:_:
3,000_CD
77_CD
58_CD
60_CD
In_PIN
2002_CD
,_,
the_DT
Group_NN
paid_VBD
amounts_NN
to_PIN
the_DT
auditors_NN
of_PIN
0.1_CD
m_NN [BEMA]
to_PIN
Arthur_NN
Andersen_NN
2001_CD
0.1_CD
m_NN
,_,
2000_CD
0.1_CD
m_NN
and_CC
0.1_CD
m_NN [BEMA]
to_PIN
LLP_NN
in_PIN
respect_NN
of_PIN
non-audit_JJ
services_NN
primarily_RB
tax_NN
compliance_NN
and_CC
advisory_JJ
services_NN
._.
25_CD
26_CD
NOTES_NN
TO_PIN
GROUP_NN
FINANCIAL_NN
STATEMENTS_NOMZ
31_CD
December_NN
2002_CD
8_CD
Staff_NN
costs_NN
The_DT
average_JJ
monthly_JJ
number_NN
of_PIN
employees_NN
during_PIN
the_DT
year_NN
including_VBG [WZPRES]
Executive_NN
Directors_NN
was_VBD
:_:
6d_VB
Employee_NN
numbers_NN
UK_NN
US_FPP1
2002 2001 2000_CD
As_IN
shown_VBN [PRIV]
in_PIN
our_FPP1
graph_NN
below_PLACE
,_,
our_FPP1
Number_NN
Number_NN
Number_NN
Number_NN
Number_NN
average_JJ
number_NN
of_PIN
employees_NN
rose_VBD
Research_NN
and_PHC
development_NOMZ
30_CD
87_CD
117_CD
88_CD
71_CD
Manufacturing_GER
-_:
63_CD
63_CD
12_CD
-_:
significantly_RB
in_PIN
2002_CD
,_,
principally_RB
Administration_NOMZ
23_CD
39_CD
62_CD
50_CD
35_CD
as_CONJ
a_NULL
result_NULL
of_PIN
reactivating_VBG
the_DT
53 189 242 150_CD
106_CD
manufacturing_GER
facility_NOMZ
and_CC
the_DT
work_NN
on_PIN
the_DT
CDC_NN
smallpox_NN
vaccine_NN
The_DT
Group_NN
had_VBD
291_CD
employees_NN
at_PIN
31_CD
December_NN
2002 2001 178_CD
._.
The_DT
Company_NN
had_VBD
four_CD
employees_NN
,_,
all_QUAN
of_PIN
whom_WP [PIRE]
were_VBD
Directors_NN
,_,
at_PIN
31_CD
December_NN
2002_CD
2001_CD
three_CD
,_,
contracts_NN
._.
250_CD
The_DT
cost_NN
to_PIN
the_DT
Group_NN
of_PIN
paying_VBG
its_PIT
staff_NN
was_VBD
:_:
2002 2001 2000 200_CD
000 000 000_CD
Wages_NN
and_PHC
salaries_NN
11,341_CD
7,505_CD
4,862_CD
Social_NN
security_NOMZ
costs_NN
1,942_CD
1,008_CD
433_CD
150_CD
Other_JJ
pension_NN
and_CC
401K_JJ
costs_NN
see_VPRT [PRIV]
note_NN
26_CD
c_NN
447 226 235_CD
13,730_CD
8,739_CD
5,530_CD
100_CD
During_PIN
2002_CD
,_,
a_DT
third-party_JJ
company_NN
paid_VBD
a_DT
share_NN
of_PIN
the_DT
Groups_NN
administrative_JJ
costs_NN
,_,
including_VBG [PRESP]
0.3_CD
m_NN [BEMA]
2001_CD
0.3_CD
m_NN
,_,
2000_CD
0.2_CD
m_NN [BEMA]
for_PIN
staff_NN
costs_NN
._.
These_DEMO
costs_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
figures_NN
shown_VBN [PRIV]
above_PLACE
._.
Research_NN
and_CC
50_CD
development_NOMZ
9_CD
Directors_NN
remuneration_NOMZ
,_,
interests_NN
and_PHC
transactions_NOMZ
Administration_NOMZ
Full_NN
disclosure_NN
of_PIN
Directors_NN
remuneration_NOMZ
,_,
interests_NN
and_PHC
transactions_NOMZ
is_VPRT [PASS]
given_VBN
in_PIN
the_DT
auditable_JJ
part_NN
of_PIN
the_DT
remuneration_NOMZ
report_NN
._.
Aggregate_JJ
gains_NN
made_VBN [WZPAST]
by_PIN
Directors_NN
on_PIN
Manufacturing_GER
0_CD
the_DT
exercise_NN
of_PIN
share_NN
options_NOMZ
were_VBD [BEMA]
0.7_CD
m_NN [BEMA]
2001_CD
0.7_CD
m._FW
2000_CD
2001_CD
10_CD
Taxation_NOMZ
We_FPP1
estimate_VPRT [PRIV]
that_THVC
the_DT
headcount_NN
will_PRMD
Tax_NN
is_VPRT [PASS]
charged_VBN
annually_RB
,_,
on_PIN
profits_NN
made_VBN
,_,
in_PIN
the_DT
country_NN
where_RB
each_QUAN
company_NN
is_VPRT [PASS]
based_VBN
._.
increase_NN
during_PIN
2003_CD
up_IN
to_PIN
around_PLACE
325_CD
._.
Tax_NN
on_PIN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
Taxation_NOMZ
2002 2001 2000_CD
Loss-making_JJ
R&D_NN
companies_NN
000 000 000_CD
traditionally_RB
generate_VB
taxable_JJ
losses_NN
UK_NN
corporation_NOMZ
tax_NN
at_PIN
30_CD
%_NN
2001_CD
30_CD
%_NN
:_:
2000_CD
30_CD
%_NN
:_:
100_CD
--_:
Foreign_JJ
taxation_NOMZ
201_CD
-_:
-_:
which_WDT [SERE]
can_POMD
,_,
in_PIN
future_NN
,_,
be_VB [PASS]
offset_VBN
Over_IN
provision_NN
in_PIN
respect_NN
of_PIN
prior_JJ
year_NN
98_CD
131_CD
-_:
against_PIN
trading_GER
profits_NN
._.
For_PIN
as_RB
long_JJ
3_CD
131_CD
-_:
as_IN
it_PIT
remains_VPRT
uncertain_JJ
that_THAC
the_DT
Group_NN
will_PRMD
have_VB
taxable_JJ
profits_NN
against_PIN
which_WDT [PIRE]
these_DEMO
taxable_JJ
losses_NN
can_POMD
be_VB [PASS]
offset_VBN
,_,
a_DT
deferred_JJ
tax_NN
asset_NN
historic_JJ
taxable_JJ
losses_NN
is_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
in_PIN
the_DT
accounts_NN
._.
2002_CD
has_VPRT [PEAS]
seen_VBN [PRIV]
a_DT
small_JJ
tax_NN
charge_NN
due_JJ
to_PIN
state_NN
taxation_NOMZ
liability_NOMZ
arising_VBG [WZPRES]
in_PIN
the_DT
US_FPP1
which_WDT [WHSUB]
is_VPRT [SPAU] [BYPA]
largely_RB
offset_VBN
by_PIN
an_DT
R&D_NN
tax_NN
credit_NN
claimed_VBN [PUBV] [WZPAST]
in_PIN
the_DT
UK_NN
._.
Current_JJ
taxation_NOMZ
The_DT
tax_NN
assessed_VBN [WZPAST]
for_PIN
the_DT
year_NN
is_VPRT [BEMA]
different_PRED
from_PIN
the_DT
standard_JJ
rate_NN
of_PIN
corporation_NOMZ
tax_NN
in_PIN
the_DT
UK_NN
of_PIN
30_CD
%_NN
._.
The_DT
differences_NN
are_VPRT [PASS]
explained_VBN [PUBV]
below_PLACE
:_:
2002 2001 2000 000_CD
000_CD
000_CD
Profit_NN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
tax_NN
9,578_CD
12,558_CD
11,074_CD
Profit_NN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
multiplied_VBN [WZPAST]
by_PIN
the_DT
standard_JJ
rate_NN
of_PIN
corporation_NOMZ
tax_NN
in_PIN
the_DT
UK_NN
of_PIN
30_CD
%_NN
2001_CD
and_CC
2000_CD
:_:
R&D_NN
tax_NN
credit_NN
rate_NN
of_PIN
16_CD
%_NN
2,873_CD
2,009_CD
1,772_CD
Effects_NN
of_PIN
:_:
Utilisation_NOMZ
of_PIN
tax_NN
losses_NN
7,122_CD
--_:
Expenses_NN
not_XX0
deductible_JJ
for_PIN
tax_NN
purposes_NN
663_CD
10_CD
58_CD
Losses_NN
arising_VBG [WZPRES]
in_PIN
the_DT
year_NN
548_CD
1,869_CD
1,831_CD
Difference_NN
in_PIN
tax_NN
rates_NN
used_VBD
compared_VBN
to_PIN
UK_NN
standard_JJ
rate_NN
664_CD
--_:
Difference_NN
between_PIN
capital_NN
allowances_NN
and_PHC
depreciation_NOMZ
143_CD
--_:
Prior_RB
year_NN
R&D_NN
tax_NN
credit_NN
98_CD
--_:
Other_JJ
short-term_JJ
timing_NN
differences_NN
2,618_CD
1_CD
1_CD
Current_JJ
tax_NN
charge_NN
credit_NN
for_PIN
year_NN
3_CD
131_CD
-_:
Deferred_JJ
tax_NN
2002 2001 000 000_CD
Unrecognised_JJ
asset_NN
in_PIN
respect_NN
of_PIN
accelerated_JJ
capital_NN
allowances_NN
274_CD
450_CD
Unrecognised_JJ
tax_NN
losses_NN
8,535_CD
14,020_CD
Unrecognised_JJ
asset_NN
on_PIN
short-term_JJ
timing_NN
differences_NN
3,966_CD
1,515_CD
Total_JJ
unrecognised_JJ
deferred_JJ
tax_NN
asset_NN
12,775_CD
15,985_CD
11_CD
Earnings_GER
per_PIN
ordinary_JJ
share_NN
Basic_JJ
earnings_GER
per_PIN
share_NN
is_VPRT [BYPA]
calculated_VBN [PRIV]
by_PIN
dividing_VBG
the_DT
earnings_GER
attributable_JJ
to_PIN
ordinary_JJ
shareholders_NN
by_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
ordinary_JJ
shares_NN
in_PIN
issue_NN
during_PIN
the_DT
year_NN
,_,
excluding_VBG [PRESP]
those_DEMP
held_VBN [PRIV]
in_PIN
the_DT
employee_NN
share_NN
trust_NN
see_VPRT [PRIV]
note_NN
14_CD
c_NN
which_WDT [WHSUB]
are_VPRT [PASS]
treated_VBN
as_IN
canceled_VBN
until_IN
the_DT
shares_NN
vest_NN
unconditionally_RB
with_PIN
the_DT
employees_NN
._.
For_PIN
diluted_VBN
earnings_GER
per_PIN
share_NN
,_,
the_DT
weighted_JJ
average_JJ
numbers_NN
of_PIN
shares_NN
used_VBN [WZPAST]
in_PIN
the_DT
calculations_NOMZ
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
:_:
2002 2001 2000_CD
Earnings_GER
Weighted_VBN
average_JJ
Per-share_JJ
amount_NN
Earnings_GER
Weighted_VBN
average_JJ
Per-share_JJ
amount_NN
Earnings_GER
Weighted_VBN
average_JJ
Per-share_JJ
amount_NN
000_CD
number_NN
of_PIN
shares_NN
pence_NN
000_CD
number_NN
of_PIN
shares_NN
pence_NN
000_CD
number_NN
of_PIN
shares_NN
pence_NN
Basic_JJ
EPS_NN
Earnings_GER
attributable_JJ
to_PIN
ordinary_JJ
shareholders_NN
9,57596,101,507_CD
10.0_CD
12,427_CD
91,027,463_CD
13.7_CD
11,074_CD
79,638,484_CD
13.9_CD
Effect_NN
of_PIN
dilutive_JJ
securities_NOMZ
Options_NOMZ
-_:
2,875,375_CD
0.3_CD
--_:
-_:
-_:
-_:
-_:
Diluted_NN
EPS_NN
Adjusted_JJ
earnings_GER
9,57598,976,882_CD
9.7_CD
12,427_CD
91,027,463_CD
13.7_CD
11,074_CD
79,638,484_CD
13.9_CD
For_PIN
diluted_VBN
earnings_GER
per_PIN
share_NN
,_,
the_DT
weighted_JJ
average_JJ
ordinary_JJ
shares_NN
in_PIN
issue_NN
is_VPRT [PASS]
adjusted_VBN
to_TO
assume_VB [PRIV]
conversion_NN
of_PIN
all_QUAN
dilutive_JJ
potential_JJ
ordinary_JJ
shares_NN
._.
The_DT
Groups_NN
dilutive_JJ
securities_NOMZ
consist_VPRT
of_PIN
:_:
those_DEMO
share_NN
options_NOMZ
without_PIN
performance_NN
conditions_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
employees_NN
where_RB
the_DT
exercise_NN
price_NN
is_VPRT [BEMA]
less_PRED
than_PIN
the_DT
average_JJ
market_NN
price_NN
of_PIN
the_DT
Companys_NN
ordinary_JJ
shares_NN
during_PIN
the_DT
year_NN
,_,
and_ANDC
those_DEMO
share_NN
options_NOMZ
with_PIN
performance_NN
criteria_NN
and_CC
contingently_RB
issuable_JJ
shares_NN
,_,
which_WDT [SERE]
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
diluted_JJ
earnings_GER
per_PIN
share_NN
calculation_NOMZ
where_RB
the_DT
related_JJ
performance_NN
conditions_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
met_VBN
at_PIN
the_DT
year-end_NN
._.
12_CD
Goodwill_NN
This_DEMO
goodwill_NN
arose_VBD
when_RB
Acambis_NN
Inc._NN
was_VBD [PASS]
acquired_VBN
in_PIN
1999_CD
._.
It_PIT
is_VPRT
being_VBG [PASS]
written_VBN [PUBV]
off_PIN
over_IN
15_CD
years_NN
,_,
resulting_VBG [PRESP]
in_PIN
an_DT
annual_JJ
charge_NN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
2002 2001 000 000_CD
Cost_NN
at_PIN
1_CD
January_NN
and_CC
31_CD
December_NN
18,055_CD
18,055_CD
Amortisation_NOMZ
At_PIN
1_CD
January_NN
3,210_CD
2,006_CD
Charge_NN
for_PIN
the_DT
year_NN
1,204_CD
1,204_CD
At_PIN
31_CD
December_NN
4,414_CD
3,210_CD
Net_JJ
book_NN
value_NN
At_PIN
31_CD
December_NN
13,641_CD
14,845_CD
27_CD
28_CD
NOTES_NN
TO_PIN
GROUP_NN
FINANCIAL_NN
STATEMENTS_NOMZ
31_CD
December_NN
2002_CD
13_CD
Tangible_JJ
fixed_JJ
assets_NN
Physical_JJ
assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
continuing_VBG
use_NN
in_PIN
the_DT
business_NOMZ
._.
Exchange_NN
movement_NOMZ
Laboratory_NN
and_CC
During_PIN
2002_CD
,_,
the_DT
monthly_JJ
closing_GER
Short_JJ
leasehold_NN
manufacturing_VBG [WZPRES]
Office_NN
land_NN
and_PHC
buildings_GER
equipment_NOMZ
equipment_NOMZ
Total_JJ
US_FPP1
$_$
exchange_NN
rate_NN
has_VPRT [PEAS]
varied_VBN
Group_NN
000 000 000 000_CD
between_PIN
1.4555_CD
and_CC
1.6095_CD
._.
This_DEMO
Cost_NN
has_VPRT [PEAS]
given_VBN
rise_NN
to_PIN
an_DT
exchange_NN
rate_NN
At_PIN
1_CD
January_NN
2002_CD
10,111_CD
3,859_CD
869_CD
14,839_CD
movement_NOMZ
on_PIN
the_DT
assets_NN
located_VBN
Additions_NOMZ
4,963_CD
4,519_CD
1,246_CD
10,728_CD
in_PIN
the_DT
US_FPP1
,_,
which_WDT [SERE]
has_VPRT
an_DT
impact_NN
on_PIN
Disposals_NN
-_:
31 281 312_CD
both_DT
asset_NN
cost_NN
and_CC
accumulated_VBN
Exchange_NN
movement_NOMZ
1,170_CD
765_CD
126_CD
2,061_CD
depreciation_NOMZ
._.
At_PIN
31_CD
December_NN
2002_CD
13,904_CD
7,582_CD
1,708_CD
23,194_CD
Depreciation_NOMZ
At_PIN
1_CD
January_NN
2002_CD
1,274_CD
829_CD
481_CD
2,584_CD
Subsidiary_NN
undertakings_GER
Charge_NN
for_PIN
year_NN
482 651 277_CD
1,410_CD
The_DT
principal_NN
trading_GER
subsidiaries_NN
Disposals_NN
-_:
22 281 303_CD
of_PIN
the_DT
Group_NN
are_VPRT
Acambis_NN
Research_NN
Exchange_NN
movement_NOMZ
190_CD
250_CD
45_CD
485_CD
Limited_NN
and_PHC
Acambis_NN
Inc._NN
._.
The_DT
At_PIN
31_CD
December_NN
2002_CD
1,566_CD
1,208_CD
432_CD
3,206_CD
Net_JJ
book_NN
value_NN
structure_NN
of_PIN
the_DT
principal_JJ
trading_GER
At_PIN
1_CD
January_NN
2002_CD
8,837_CD
3,030_CD
388_CD
12,255_CD
subsidiaries_NN
of_PIN
the_DT
Group_NN
is_VPRT
as_IN
At_PIN
31_CD
December_NN
2002_CD
12,338_CD
6,374_CD
1,276_CD
19,988_CD
follows_VPRT
:_:
Net_JJ
book_NN
value_NN
of_PIN
assets_NN
held_VBN [PRIV]
under_IN
finance_NN
lease_NN
included_VBD
above_PLACE
:_:
At_PIN
1_CD
January_NN
2002_CD
5,220_CD
2,208_CD
-_:
7,428_CD
Acambis_NN
plc_NN
At_PIN
31_CD
December_NN
2002_CD
4,633_CD
1,923_CD
-_:
6,556_CD
The_DT
Company_NN
has_VPRT
no_SYNE
tangible_JJ
fixed_JJ
assets_NN
._.
100_CD
%_NN
100_CD
%_NN
Acambis_NN
Research_NN
Acambis_NN
Inc._NN
14_CD
Fixed_NN
asset_NN
investments_NOMZ
Limited_JJ
These_DEMP
are_VPRT
assets_NN
including_VBG [WZPRES]
shares_NN
that_TSUB
are_VPRT [PASS]
held_VBN [PRIV]
as_IN
an_DT
ongoing_JJ
investment_NOMZ
._.
Group_NN
Company_NN
2002 2001 2002 2001_CD
000 000 000 000_CD
a_DT
Subsidiary_NN
undertakings_GER
-_:
-_:
14,988_CD
14,988_CD
b_NN
Trade_NN
investments_NOMZ
303_CD
388_CD
-_:
-_:
c_NN
Investment_NOMZ
in_PIN
own_JJ
shares_NN
797_CD
1,252_CD
143_CD
598_CD
1,100_CD
1,640_CD
15,131_CD
15,586_CD
d_SYM
Joint_NN
venture_NN
206_CD
67_CD
-_:
-_:
a_DT
Subsidiary_NN
undertakings_GER
The_DT
Company_NN
,_,
Acambis_NN
plc_NN
,_,
owns_VPRT
100_CD
%_NN
of_PIN
the_DT
ordinary_JJ
share_NN
capital_NN
of_PIN
Acambis_NN
Research_NN
Limited_NN
and_PHC
Acambis_NN
Inc._NN
incorporated_VBN [WZPAST]
in_PIN
England_NN
and_PHC
Wales_NN
and_CC
the_DT
US_FPP1
4c_CD
respectively_RB
._.
The_DT
main_JJ
activity_NOMZ
of_PIN
Acambis_NN
Research_NN
Limited_NN
is_VPRT
R&D_NN
._.
The_DT
main_JJ
activities_NOMZ
of_PIN
Acambis_NN
Inc._NN
are_VPRT
R&D_NN
and_PHC
manufacturing_GER
._.
Other_JJ
companies_NN
held_VBN [PRIV] [WZPAST]
are_VPRT [BEMA]
not_XX0
significant_PRED
to_PIN
the_DT
Group_NN
._.
All_QUAN
subsidiary_NN
undertakings_GER
have_VPRT [PEAS]
been_VBN [PASS]
consolidated_VBN
._.
The_DT
cost_NN
of_PIN
the_DT
investments_NOMZ
in_PIN
the_DT
subsidiary_NN
undertakings_GER
in_PIN
the_DT
books_NN
of_PIN
the_DT
Company_NN
is_VPRT
as_IN
follows_VPRT
:_:
000_CD
Cost_NN
and_CC
net_JJ
book_NN
value_NN
at_PIN
1_CD
January_NN
and_CC
31_CD
December_NN
2002_CD
14,988_CD
THE_DT
INFORMATION_NOMZ
CONTAINED_VBD
IN_PIN
THIS_DEMO
COLUMN_NN
HAS_VPRT
NOT_XX0
BEEN_JJ
AUDITED_NN
._.
b_NN
Trade_NN
investments_NOMZ
Joint_NN
ventures_NN
The_DT
investments_NOMZ
held_VBN [PRIV] [WZPAST]
during_PIN
2002_CD
are_VPRT
shares_NN
the_DT
Group_NN
holds_VPRT [PRIV]
in_PIN
a_DT
non-related_JJ
overseas_PLACE
listed_VBN
company_NN
,_,
Medivir_NN
AB_NN
._.
The_DT
structure_NN
of_PIN
the_DT
H._NN
pylori_NN
joint_JJ
venture_NN
is_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
following_VBG
2002_CD
2001_CD
diagram_NN
:_:
000_CD
000_CD
Cost_NN
At_PIN
1_CD
January_NN
1,481_CD
1,481_CD
Acambis_NN
Aventis_NN
Pasteur_NN
At_PIN
31_CD
December_NN
1,481_CD
1,481_CD
Amounts_NN
provided_VBN
50_CD
%_NN
50_CD
%_NN
At_PIN
1_CD
January_NN
1,093_CD
670_CD
Provided_VBN
in_PIN
the_DT
year_NN
85_CD
423_CD
Pasteur_NN
MrieuxAt_NN
31_CD
December_NN
1,178_CD
1,093_CD
OraVax_NN
joint_JJ
venture_NN
Net_NN
book_NN
value_NN
At_PIN
1_CD
January_NN
388_CD
811_CD
50.1_CD
%_NN
49.9_CD
%_NN
At_PIN
31_CD
December_NN
303_CD
388_CD
Mrieux-OraVax_NN
SNC_NN
OraVax-Mrieux_NN
Co._NN
._.
The_DT
market_NN
value_NN
of_PIN
the_DT
investment_NOMZ
in_PIN
Medivir_NN
AB_NN
at_PIN
31_CD
December_NN
2002_CD
was_VBD [BEMA]
0.3_CD
m_NN [BEMA]
2001_CD
0.4_CD
m._NN
Through_PIN
the_DT
Pasteur_NN
Mrieux-OraVax_NN
c_NN
Investment_NOMZ
in_PIN
own_JJ
shares_NN
joint_JJ
venture_NN
,_,
Acambis_NN
owns_VPRT
50.1_CD
%_NN
These_DEMP
are_VPRT
shares_NN
in_PIN
Acambis_NN
plc_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [BYPA]
bought_VBN
by_PIN
an_DT
employee_NN
trust_NN
._.
The_DT
shares_NN
may_POMD
be_VB [PASS]
issued_VBN
to_PIN
certain_JJ
employees_NN
and_PHC
Directors_NN
as_IN
share_NN
options_NOMZ
or_CC
of_PIN
Mrieux-OraVax_NN
SNC_NN
,_,
a_DT
French_JJ
long-term_JJ
incentive_NN
awards_NN
are_VPRT [PASS]
exercised_VBN
._.
Provision_NN
has_VPRT [PEAS]
been_VBN [PASS]
made_VBN
for_PIN
those_DEMO
shares_NN
that_TSUB
are_VPRT [BEMA]
likely_PRED
to_TO
be_VB [PASS]
issued_VBN
._.
partnership_NN
,_,
and_ANDC
49.9_CD
%_NN
of_PIN
OraVaxMrieux_NN
Co._NN
a_DT
Massachusetts_NN
General_NN
Group_NN
Company_NN
partnership_NN
._.
Aventis_NN
Pasteur_NN
owns_VPRT
2002 2001 2002 2001_CD
000 000 000 000_CD
the_DT
remaining_VBG
balances_NN
of_PIN
the_DT
Cost_NN
two_CD
partnerships_NN
._.
At_PIN
1_CD
January_NN
1,606_CD
1,606_CD
952_CD
952_CD
Disposals_NN
287_CD
-_:
287_CD
-_:
Whilst_OSUB
Acambis_NN
and_PHC
Aventis_NN
Pasteurs_NN
At_PIN
31_CD
December_NN
1,319_CD
1,606_CD
665_CD
952_CD
interests_NN
in_PIN
each_QUAN
of_PIN
the_DT
partnerships_NN
Amounts_VPRT
provided_VBN
are_VPRT
very_AMP
slightly_DWNT
different_JJ
,_,
the_DT
At_PIN
1_CD
January_NN
354 161 354 161_CD
collaboration_NOMZ
is_VPRT [PASS]
structured_VBN
such_OSUB
that_NULL
Provided_VBN [WZPAST]
in_PIN
the_DT
year_NN
420 193 420 193_CD
all_QUAN
costs_NN
,_,
capital_NN
contributions_NOMZ
,_,
profits_NN
Release_VPRT
of_PIN
previously_TIME
provided_VBN
amounts_NN
252_CD
-_:
252_CD
-_:
and_ANDC
losses_NN
are_VPRT [PASS]
shared_VBN
equally_RB
by_PIN
At_PIN
31_CD
December_NN
522 354 522 354_CD
the_DT
parties_NN
._.
Net_JJ
book_NN
value_NN
At_PIN
1_CD
January_NN
1,252_CD
1,445_CD
598_CD
791_CD
At_PIN
31_CD
December_NN
797_CD
1,252_CD
143_CD
598_CD
At_PIN
31_CD
December_NN
2002_CD
,_,
Acambis_NN
Employees_NN
Trustees_NN
Limited_NN
held_VBD [PRIV]
589,685_CD
2001_CD
723,396_CD
ordinary_JJ
shares_NN
in_PIN
the_DT
Company_NN
with_PIN
a_DT
total_JJ
market_NN
value_NN
of_PIN
1.6_CD
m_NN [BEMA]
2001_CD
2.5_CD
m_NN [BEMA]
on_PIN
behalf_NN
of_PIN
the_DT
Acambis_NN
Employees_NN
Trust_NN
._.
All_QUAN
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
Trust_NN
have_VPRT [PEAS]
been_VBN [PASS]
allocated_VBN
to_PIN
long-term_JJ
incentive_NN
awards_NN
and_CC
a_DT
provision_NN
has_VPRT [PEAS]
been_VBN [PASS]
made_VBN
in_PIN
respect_NN
of_PIN
all_QUAN
of_PIN
these_DEMO
shares_NN
._.
All_QUAN
costs_NN
relating_VBG [WZPRES]
to_PIN
the_DT
administration_NOMZ
of_PIN
the_DT
Trust_NN
are_VPRT [PASS]
dealt_VBN
with_PIN
in_PIN
the_DT
accounts_NN
of_PIN
the_DT
Company_NN
as_IN
they_TPP3
arise_VPRT
._.
Disposals_NN
of_PIN
0.3_CD
m_NN [BEMA]
2001_CD
nil_NN
during_PIN
the_DT
year_NN
relate_VPRT
to_TO
share_VB
options_NOMZ
granted_VBN [SUAV] [WZPAST]
in_PIN
accordance_NN
with_PIN
the_DT
rules_NN
of_PIN
the_DT
Acambis_NN
Share_NN
Incentive_NN
Plan_NN
LTIP_NN
having_VBG [WZPRES] [PEAS]
vested_VBN
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
performance_NN
criteria_NN
having_VBG [WZPRES] [PEAS]
been_VBN [PASS]
met_VBN
at_PIN
the_DT
exercise_NN
date_NN
._.
During_PIN
the_DT
year_NN
,_,
a_DT
provision_NN
of_PIN
0.4_CD
m_NN [BEMA]
2001_CD
0.2_CD
m_NN [PASS]
was_VBD [PASS]
made_VBN
in_PIN
relation_NOMZ
to_TO
share_VB
options_NOMZ
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
in_PIN
accordance_NN
with_PIN
the_DT
rules_NN
of_PIN
the_DT
LTIP_NN
,_,
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
performance_NN
criteria_NN
having_VBG [WZPRES] [PEAS]
been_VBN [PASS]
met_VBN
at_PIN
31_CD
December_NN
2002_CD
._.
As_CONJ
a_NULL
result_NULL
of_PIN
certain_JJ
share_NN
options_NOMZ
becoming_VBG [WZPRES]
exercisable_JJ
during_PIN
the_DT
year_NN
,_,
this_DEMP
gave_VBD
rise_NN
to_PIN
a_DT
release_NN
of_PIN
0.3_CD
m_NN [BEMA]
2001_CD
nil_NN
being_VBG [WZPRES] [PASS]
provisions_NN
made_VBN [WZPAST]
in_PIN
previous_JJ
years_NN
see_VPRT [PRIV]
remuneration_JJ
report_NN
on_PIN
page_NN
62_CD
for_PIN
further_JJ
details_NN
._.
d_LS
Joint_NN
ventures_NN
The_DT
Group_NN
has_VPRT
an_DT
interest_NN
in_PIN
the_DT
Pasteur_NN
Mrieux-OraVax_NN
joint_JJ
venture_NN
Joint_NN
Venture_NN
,_,
whose_WPS
principal_JJ
business_NOMZ
is_VPRT
to_TO
develop_VB
,_,
manufacture_VB
,_,
market_NN
and_CC
sell_VB
immunotherapeutic_JJ
and_PHC
preventative_JJ
vaccines_NN
against_PIN
H._NN
pylori_NN
infection_NOMZ
in_PIN
humans_NN
._.
The_DT
Joint_NN
Venture_NN
represents_VPRT
a_DT
collaboration_NOMZ
between_PIN
two_CD
partnerships_NN
,_,
MrieuxOraVax_NN
SNC_NN
and_PHC
OraVax-Mrieux_NN
Co._NN
incorporated_VBN [WZPAST]
in_PIN
Delaware_NN
,_,
US_FPP1
._.
These_DEMO
partnerships_NN
were_VBD [PASS]
formed_VBN
in_PIN
March_NN
1995_CD
between_PIN
Acambis_NN
Inc._NN
and_PHC
Aventis_NN
Pasteur_NN
._.
The_DT
Joint_NN
Venture_NN
trades_VPRT
under_IN
the_DT
name_NN
of_PIN
Pasteur_NN
Mrieux-OraVax_NN
and_CC
its_PIT
accounting_GER
year-end_NN
is_VPRT [BEMA]
31_CD
December_NN
._.
The_DT
R&D_NN
budgets_NN
of_PIN
the_DT
two_CD
partnerships_NN
are_VPRT [BYPA]
established_VBN [PRIV]
by_PIN
joint_JJ
committees_NN
in_PIN
which_WDT [PIRE]
each_QUAN
of_PIN
the_DT
parties_NN
has_VPRT
an_DT
equal_JJ
participation_NOMZ
and_PHC
role_NN
._.
The_DT
parties_NN
pay_VPRT
approximately_RB
equal_JJ
shares_NN
of_PIN
the_DT
agreed_VBN [SUAV] [PUBV]
budgets_NN
._.
29_CD
30_CD
NOTES_NN
TO_PIN
GROUP_NN
FINANCIAL_NN
STATEMENTS_NOMZ
31_CD
December_NN
2002_CD
14_CD
Fixed_VBN
asset_NN
investments_NOMZ
d_LS
Joint_NN
ventures_NN
continued_VBD
Stock_NN
The_NN
following_VBG [WZPRES]
information_NOMZ
is_VPRT [PASS]
given_VBN
in_PIN
respect_NN
of_PIN
the_DT
Groups_NN
share_NN
of_PIN
the_DT
Joint_NN
Venture_NN
:_:
Stock_NN
is_VPRT [BEMA]
a_DT
new_JJ
category_NN
on_PIN
the_DT
balance_NN
sheet_NN
and_CC
consists_VPRT
solely_RB
of_PIN
2002 2001 000 000_CD
stock_NN
relating_VBG [WZPRES]
to_PIN
the_DT
production_NOMZ
of_PIN
smallpox_NN
vaccine_NN
._.
Loss_NN
before_IN
tax_NN
171_CD
410_CD
Current_JJ
assets_NN
941_CD
915_CD
Trade_NN
debtors_NN
Liabilities_NOMZ
due_JJ
within_PIN
one_CD
year_NN
1,147_CD
848_CD
Amounts_NN
owed_VBN [WZPAST]
by_PIN
the_DT
CDC_NN
under_IN
the_DT
206_CD
67_CD
two_CD
smallpox_NN
vaccine_NN
contracts_NN
are_VPRT [PASS]
included_VBN
within_PIN
trade_NN
debtors_NN
at_PIN
the_DT
Due_JJ
to_PIN
the_DT
nature_NN
of_PIN
this_DEMO
Joint_NN
Venture_NN
,_,
being_VBG [PRESP] [BEMA]
a_DT
collaboration_NOMZ
between_PIN
two_CD
partnerships_NN
,_,
the_DT
following_VBG
table_NN
provides_VPRT
an_DT
alternative_JJ
analysis_NN
of_PIN
the_DT
amounts_NN
shown_VBN [PRIV]
above_PLACE
:_:
year-end_NN
._.
2002_CD
2001_CD
Corporation_NOMZ
tax_NN
000_CD
000_CD
See_VB [PRIV]
note_NN
10_CD
on_PIN
pages_NN
26_CD
and_CC
27_CD
Share_NN
of_PIN
cumulative_JJ
amounts_NN
invested_VBN [WZPAST]
in_PIN
the_DT
partnerships_NN
18,169_CD
20,090_CD
for_PIN
details_NN
of_PIN
the_DT
corporation_NOMZ
Share_NN
of_PIN
cumulative_JJ
losses_NN
incurred_VBN [WZPAST]
by_PIN
the_DT
partnerships_NN
18,375_CD
20,023_CD
tax_NN
calculation_NOMZ
._.
206_CD
67_CD
Stock_NN
15_CD
Group_NN
Company_NN
2002 2001 2002 2001_CD
000 000 000 000_CD
Raw_NN
materials_NN
1,131_CD
-_:
-_:
-_:
Work_NN
in_PIN
progress_NN
34,934_CD
-_:
-_:
-_:
Finished_VBN
goods_NN
12,278_CD
-_:
-_:
-_:
48,343_SYM
-_:
-_:
-_:
16_CD
Debtors_NN
:_:
amounts_NN
receivable_NN
within_PIN
one_CD
year_NN
Group_NN
Company_NN
2002 2001 2002 2001_CD
000 000 000 000_CD
Trade_NN
debtors_NN
46,090_CD
5,918_CD
-_:
-_:
Other_JJ
debtors_NN
2,406_CD
285_CD
589_CD
42_CD
Corporation_NOMZ
tax_NN
198_CD
131_CD
-_:
-_:
Prepayments_NOMZ
and_CC
accrued_VBN
income_NN
5,346_CD
1,208_CD
-_:
28_CD
54,040_CD
7,542_CD
589_CD
70_CD
Debtors_NN
:_:
amounts_NN
receivable_NN
after_IN
one_CD
year_NN
17_CD
Group_NN
Company_NN
2002 2001 2002 2001_CD
000 000 000 000_CD
Amounts_NN
owed_VBN [WZPAST]
by_PIN
subsidiary_NN
undertakings_GER
-_:
-_:
71,643_CD
60,170_CD
Prepayments_NOMZ
and_CC
accrued_VBN
income_NN
4,925_CD
6,235_CD
-_:
-_:
4,925_CD
6,235_CD
71,643_CD
60,170_CD
Acambis_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
prepay_VB
insurance_NN
premiums_NN
,_,
on_PIN
behalf_NN
of_PIN
the_DT
CDC_NN
,_,
relating_VBG [PRESP]
to_PIN
the_DT
first_JJ
CDC_NN
smallpox_NN
vaccine_NN
contract_NN
,_,
secured_VBN [PASTP]
in_PIN
September_NN
2000_CD
._.
At_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
total_JJ
amount_NN
prepaid_VBN [WZPAST]
was_VBD [BEMA]
5.6_CD
m_NN [BEMA]
2001_CD
7.0_CD
m_NN
,_,
of_PIN
which_WDT [PIRE]
0.7_CD
m_NN [BEMA]
2001_CD
0.8_CD
m_NN
is_VPRT [PASS]
included_VBN
within_PIN
Debtors_NN
:_:
amounts_NN
receivable_NN
within_PIN
one_CD
year_NN
and_CC
4.9_CD
m_NN [BEMA]
2001_CD
6.2_CD
m_NN
is_VPRT [PASS]
included_VBN
within_PIN
Debtors_NN
:_:
amounts_NN
receivable_NN
after_IN
one_CD
year_NN
._.
The_DT
total_NN
of_PIN
5.6_CD
m_NN [BEMA]
2001_CD
7.0_CD
m_NN
is_VPRT [BYPA]
offset_VBN
by_PIN
an_DT
equal_JJ
amount_NN
in_PIN
creditors_NN
see_VPRT [PRIV] [THATD]
THE_DT
INFORMATION_NOMZ
CONTAINED_VBD
IN_PIN
THIS_DEMO
COLUMN_NN
notes_VPRT [PRIV]
18_CD
and_CC
19_CD
._.
Both_DT
balances_NN
will_PRMD
reduce_VB
over_IN
the_DT
term_NN
of_PIN
the_DT
insurance_NN
cover_NN
,_,
which_WDT [SERE]
was_VBD [BEMA]
up_RB
to_PIN
20_CD
years_NN
at_PIN
inception_NOMZ
in_PIN
2000_CD
._.
18_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
within_PIN
one_CD
year_NN
Group_NN
Company_NN
Trade_NN
creditors_NN
2002 2001 2002 2001_CD
This_DEMP
includes_VPRT
amounts_NN
payable_JJ
to_PIN
000 000 000 000_CD
suppliers_NN
,_,
largely_RB
for_PIN
payments_NOMZ
Overdraft_NN
facility_NOMZ
see_VPRT [PRIV]
below_PLACE
4,349_CD
4,809_CD
-_:
-_:
of_PIN
stock_NN
._.
Trade_NN
creditors_NN
54,769_CD
3,674_CD
58_CD
47_CD
Amounts_NN
owed_VBN [WZPAST]
to_PIN
Joint_NN
Venture_NN
-_:
496_CD
-_:
-_:
Accruals_NN
and_CC
deferred_JJ
income_NN
Corporation_NOMZ
tax_NN
201_CD
-_:
-_:
-_:
Deferred_JJ
income_NN
represents_VPRT
the_DT
Other_JJ
taxes_NN
and_CC
social_JJ
security_NOMZ
87_CD
69_CD
-_:
-_:
difference_NN
between_PIN
invoices_NN
Other_JJ
creditors_NN
58_CD
44_CD
49_CD
-_:
submitted_VBN [PUBV] [PASTP]
to_PIN
the_DT
CDC_NN
before_IN
the_DT
Accruals_NN
and_CC
deferred_JJ
income_NN
28,996_CD
7,511_CD
322_CD
172_CD
year-end_NN
and_CC
amounts_VPRT
recognized_VBN [PRIV]
88,460_CD
16,603_CD
429_CD
219_CD
as_IN
revenue_NN
._.
Under_IN
the_DT
terms_NN
of_PIN
the_DT
agreement_NOMZ
between_PIN
Acambis_NN
and_PHC
Evans_NN
Vaccines_NN
Limited_NN
,_,
given_VBN
certain_JJ
conditions_NOMZ
,_,
the_DT
obligation_NOMZ
under_IN
the_DT
bank_NN
overdraft_NN
facility_NOMZ
of_PIN
4.3_CD
m_NN [BEMA]
2001_CD
4.8_CD
m_NN [BEMA]
for_PIN
the_DT
costs_NN
incurred_VBN [WZPAST]
on_PIN
the_DT
Arilvax_NN
project_NN
may_POMD
be_VB [BEMA]
repayable_PRED
within_PIN
one_CD
year_NN
._.
The_DT
facility_NOMZ
is_VPRT [BYPA]
underwritten_VBN
by_PIN
PowderJect_NN
Pharmaceuticals_NN
Plc_NN
PowderJect_NN
._.
PowderJect_NN
has_VPRT [PEAS]
granted_VBN [SUAV]
to_PIN
Acambis_NN
100_CD
%_NN
of_PIN
the_DT
marketing_GER
rights_NN
to_PIN
Arilvax_NN
in_PIN
the_DT
US_FPP1
,_,
whilst_OSUB
retaining_VBG
an_DT
option_NOMZ
to_TO
buy_VB
back_RB
50_CD
%_NN
of_PIN
the_DT
profits_NN
from_PIN
the_DT
US_FPP1
sales_NN
in_PIN
return_NN
for_PIN
refunding_VBG
to_PIN
the_DT
Group_NN
the_DT
costs_NN
the_DT
Group_NN
has_VPRT [PEAS]
incurred_VBN
on_PIN
the_DT
Arilvax_NN
program_NN
._.
The_DT
overdraft_NN
facility_NOMZ
was_VBD [PASS]
renewed_VBN
in_PIN
January_NN
2003_CD
for_PIN
a_DT
further_JJ
year_NN
._.
Interest_NN
is_VPRT [PASS]
charged_VBN
as_RB
disclosed_VBN [PUBV]
within_PIN
Financial_NN
liabilities_NOMZ
in_PIN
note_NN
20_CD
._.
During_PIN
the_DT
year_NN
an_DT
exchange_NN
gain_NN
of_PIN
0.4_CD
m_NN [BEMA]
2001_CD
exchange_NN
loss_NN
of_PIN
0.1_CD
m_NN [PASS]
was_VBD [PASS]
recorded_VBN
on_PIN
the_DT
face_NN
of_PIN
the_DT
Group_NN
profit_NN
and_PHC
loss_NN
account_NN
,_,
resulting_VBG [PRESP]
from_PIN
the_DT
revaluation_NOMZ
of_PIN
this_DEMO
US_FPP1
dollar-denominated_JJ
facility_NOMZ
._.
19_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
after_IN
one_CD
year_NN
Group_NN
Company_NN
2002 2001 2002 2001_CD
000 000 000 000_CD
Obligations_NOMZ
under_IN
finance_NN
leases_NN
13,972_CD
14,299_CD
-_:
-_:
Accruals_NN
and_CC
deferred_JJ
income_NN
4,925_CD
6,235_CD
-_:
-_:
18,897_CD
20,534_CD
-_:
-_:
The_DT
amount_NN
in_PIN
accruals_NN
and_CC
deferred_JJ
income_NN
relates_VPRT
to_PIN
the_DT
insurance_NN
premiums_NN
,_,
payable_JJ
on_PIN
behalf_NN
of_PIN
the_DT
CDC_NN
,_,
relating_VBG [PRESP]
to_PIN
the_DT
first_JJ
CDC_NN
smallpox_NN
vaccine_NN
contract_NN
,_,
the_DT
equivalent_JJ
figure_NN
being_VBG [WZPRES] [PASS]
included_VBN
in_PIN
Debtors_NN
,_,
as_IN
referred_VBN
to_PIN
in_PIN
note_NN
17_CD
above_PLACE
._.
In_PIN
December_NN
2001_CD
,_,
the_DT
Group_NN
committed_VBD
to_PIN
a_DT
finance_NN
lease_NN
,_,
repayable_JJ
within_PIN
five_CD
years_NN
,_,
relating_VBG [PRESP]
to_PIN
the_DT
purchase_NN
and_PHC
sale-and-leaseback_NN
of_PIN
capital_NN
assets_NN
within_PIN
the_DT
manufacturing_GER
plant_NN
._.
Further_JJ
details_NN
regarding_VBG [WZPRES]
this_DEMO
finance_NN
lease_NN
facility_NOMZ
are_VPRT [PASS]
given_VBN
within_PIN
Financial_NN
liabilities_NOMZ
in_PIN
note_NN
20_CD
._.
20_CD
Financial_NN
instruments_NOMZ
11_CD
The_DT
Groups_NN
financial_JJ
instruments_NOMZ
comprise_VPRT
primarily_RB
cash_NN
and_CC
liquid_JJ
resources_NN
,_,
a_DT
long-term_JJ
finance_NN
lease_NN
,_,
an_DT
overdraft_NN
facility_NOMZ
and_CC
various_JJ
items_NN
,_,
such_JJ
as_IN
trade_NN
debtors_NN
and_PHC
trade_NN
creditors_NN
,_,
that_DEMP
arise_VB
directly_RB
from_PIN
its_PIT
operations_NOMZ
._.
The_DT
main_JJ
purpose_NN
of_PIN
these_DEMO
financial_JJ
instruments_NOMZ
is_VPRT
to_TO
provide_VB
working_JJ
capital_NN
for_PIN
the_DT
Groups_NN
operations_NOMZ
._.
The_DT
Group_NN
holds_VPRT [PRIV]
funds_NN
in_PIN
both_DT
US_FPP1
dollars_NN
and_PHC
sterling_GER
._.
The_DT
Groups_NN
current_JJ
policy_NN
is_VPRT
to_TO
hold_VB [PRIV]
surplus_NN
funds_NN
in_PIN
sterling_GER
over_IN
the_DT
long_JJ
term_NN
,_,
which_WDT [SERE]
currently_RB
achieves_VPRT
a_DT
higher_JJ
interest_NN
rate_NN
return_NN
,_,
whilst_OSUB
also_RB
mitigating_VBG
exchange_NN
rate_NN
exposure_NN
._.
The_DT
main_JJ
risks_NN
arising_VBG [WZPRES]
from_PIN
the_DT
Groups_NN
financial_JJ
instruments_NOMZ
are_VPRT
interest_NN
rate_NN
risk_NN
,_,
liquidity_NOMZ
risk_NN
and_CC
foreign_JJ
currency_NN
risk_NN
._.
The_DT
Board_NN
reviews_NN
and_CC
agrees_VPRT [SUAV] [PUBV]
policies_NN
for_PIN
managing_VBG
each_QUAN
of_PIN
these_DEMO
risks_NN
._.
These_DEMO
policies_NN
have_VPRT [PEAS]
remained_VBN
unchanged_JJ
since_OSUB
the_DT
beginning_GER
of_PIN
2000_CD
._.
All_QUAN
of_PIN
the_DT
Groups_NN
short-term_JJ
debtors_NN
and_PHC
creditors_NN
are_VPRT [PASS]
excluded_VBN
from_PIN
these_DEMO
disclosures_NN
,_,
other_JJ
than_PIN
currency_NN
risk_NN
disclosures_NN
._.
Interest_NN
rate_NN
risk_NN
The_DT
Group_NN
finances_VPRT
its_PIT
operations_NOMZ
predominantly_RB
through_PIN
cash_NN
,_,
liquid_JJ
resources_NN
and_PHC
lease_NN
financing_GER
._.
It_PIT
is_VPRT [BEMA]
the_DT
Groups_NN
policy_NN
to_TO
invest_VB
surplus_NN
cash_NN
in_PIN
money_NN
market_NN
funds_NN
,_,
managed_VBN [PASTP]
by_PIN
professional_JJ
money_NN
managers_NN
._.
The_DT
performance_NN
of_PIN
the_DT
funds_NN
invested_VBN [WZPAST]
is_VPRT [BYPA]
reviewed_VBN
by_PIN
the_DT
Board_NN
on_PIN
a_DT
regular_JJ
basis_NN
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
competitive_JJ
rates_NN
of_PIN
return_NN
are_VPRT
being_VBG [PASS]
achieved_VBN
._.
The_DT
Board_NN
reviews_VPRT
regularly_RB
the_DT
financing_GER
facilities_NOMZ
available_JJ
to_PIN
the_DT
Group_NN
to_TO
ensure_VB [SUAV] [PRIV]
competitive_JJ
rates_NN
of_PIN
interest_NN
are_VPRT
being_VBG [PASS]
obtained_VBN
._.
Liquidity_NOMZ
risk_NN
The_NN
Board_NN
monitors_VPRT
the_DT
level_NN
of_PIN
cash_NN
and_CC
liquid_JJ
resources_NN
on_PIN
a_DT
regular_JJ
basis_NN
,_,
and_ANDC
management_NOMZ
on_PIN
a_DT
daily_JJ
basis_NN
,_,
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
the_DT
Group_NN
has_VPRT
sufficient_JJ
liquid_NN
funds_NN
THE_DT
INFORMATION_NOMZ
CONTAINED_VBD
IN_PIN
THIS_DEMO
COLUMN_NN
to_TO
enable_VB
it_PIT
to_TO
continue_VB
as_IN
a_DT
going_VBG
concern_NN
._.
This_DEMP
is_VPRT [PASS]
achieved_VBN
through_PIN
the_DT
production_NOMZ
and_PHC
review_NN
of_PIN
cash_NN
forecasts_NN
,_,
including_VBG
sensitivity_NOMZ
analyses_NN
._.
The_DT
Groups_NN
liquid_JJ
HAS_VPRT
NOT_XX0
BEEN_JJ
AUDITED_NN
._.
31_CD
resources_NN
are_VPRT [PASS]
managed_VBN
on_PIN
a_DT
discretionary_JJ
basis_NN
by_PIN
a_DT
third_JJ
party_NN
within_PIN
strict_JJ
parameters_NN
,_,
which_WDT [SERE]
have_VPRT [PEAS]
been_VBN [BYPA]
set_VBN
by_PIN
the_DT
Board_NN
._.
32_CD
NOTES_NN
TO_PIN
GROUP_NN
FINANCIAL_NN
STATEMENTS_NOMZ
31_CD
December_NN
2002_CD
20_CD
Financial_NN
instruments_NOMZ
continued_VBD
Foreign_JJ
currency_NN
risk_NN
The_DT
Group_NN
has_VPRT
one_CD
principal_NN
subsidiary_NN
that_TSUB
operates_VPRT
and_PHC
trades_VPRT
overseas_PLACE
Acambis_NN
Inc._NN
._.
It_PIT
operates_VPRT
in_PIN
the_DT
US_FPP1
and_CC
its_PIT
revenues_NN
,_,
expenses_NN
and_PHC
financing_GER
are_VPRT [PASS]
denominated_VBN
principally_RB
in_PIN
US_FPP1
dollars_NN
._.
The_DT
Group_NN
has_VPRT
a_DT
US_FPP1
dollar-denominated_JJ
overdraft_NN
facility_NOMZ
,_,
as_IN
described_VBN
in_PIN
note_NN
18_CD
,_,
which_WDT [SERE]
is_VPRT [PASS]
held_VBN [PRIV]
in_PIN
the_DT
UK_NN
and_CC
is_VPRT [BEMA]
subject_PRED
to_TO
exchange_VB
rate_NN
movements_NOMZ
._.
These_DEMP
are_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
incurred_VBN
._.
In_CONJ
addition_NULL
,_,
the_DT
Group_NN
has_VPRT
other_JJ
current_JJ
assets_NN
and_PHC
liabilities_NOMZ
denominated_VBN [WZPAST]
in_PIN
foreign_JJ
currencies_NN
,_,
which_WDT [SERE]
the_DT
Board_NN
does_VPRT
not_XX0
consider_VB [PRIV]
to_TO
be_VB [BEMA]
significant_PRED
._.
The_DT
tables_NN
below_PLACE
show_VPRT [PRIV]
the_DT
extent_NN
to_PIN
which_WDT [PIRE]
Group_NN
companies_NN
have_VPRT
monetary_JJ
assets_NN
and_PHC
liabilities_NOMZ
in_PIN
currencies_NN
other_JJ
than_PIN
their_TPP3
local_JJ
currency_NN
._.
Net_JJ
foreign_JJ
currency_NN
monetary_JJ
assets_NN
liabilities_NOMZ
2001_CD
Sterling_GER
US_FPP1
dollar_NN
Euros_NN
Total_NN
000 000 000 000_CD
Functional_JJ
currency_NN
of_PIN
Group_NN
operation_NOMZ
:_:
Sterling_GER
-28,782_SYM
-_:
28,782_CD
US_FPP1
dollars_NN
--_:
-_:
-_:
-28,782_SYM
-_:
28,782_CD
2002_CD
Sterling_GER
US_FPP1
dollar_NN
Euros_NN
Total_NN
000 000 000 000_CD
Functional_JJ
currency_NN
of_PIN
Group_NN
operation_NOMZ
:_:
Sterling_GER
-27,399_CD
755_CD
28,154_CD
US_FPP1
dollars_NN
--_:
-_:
-_:
-27,399_CD
755_CD
28,154_CD
Financial_JJ
assets_NN
The_DT
Group_NN
had_VBD
cash_NN
and_CC
liquid_JJ
resources_NN
of_PIN
11.8_CD
m_NN [BEMA]
at_PIN
31_CD
December_NN
2002_CD
2001_CD
22.2_CD
m._NN
The_DT
majority_NOMZ
of_PIN
these_DEMO
resources_NN
are_VPRT [PASS]
invested_VBN
in_PIN
managed_VBN
funds_NN
,_,
denominated_VBN [PASTP]
in_PIN
sterling_GER
and_PHC
US_FPP1
dollars_NN
,_,
and_ANDC
are_VPRT [BEMA]
available_PRED
for_PIN
use_NN
with_PIN
a_DT
days_NN
notice_NN
._.
During_PIN
2002_CD
,_,
these_DEMO
funds_NN
achieved_VBD
weighted_JJ
average_JJ
returns_NN
of_PIN
4.1_CD
%_NN
2001_CD
5.4_CD
%_NN
for_PIN
funds_NN
invested_VBN [WZPAST]
in_PIN
UK_NN
sterling_GER
,_,
and_ANDC
1.9_CD
%_NN
2001_CD
4.7_CD
%_NN
for_PIN
funds_NN
invested_VBN [WZPAST]
in_PIN
US_FPP1
dollars_NN
._.
The_DT
Group_NN
also_RB
holds_VPRT [PRIV]
shares_NN
in_PIN
Medivir_NN
AB_NN
see_VPRT [PRIV]
note_NN
14_CD
b._NN
This_DEMO
investment_NOMZ
does_VPRT
not_XX0
subject_JJ
the_DT
Group_NN
to_PIN
interest_NN
rate_NN
risk_NN
as_IN
it_PIT
has_VPRT
no_SYNE
maturity_NOMZ
date_NN
._.
Financial_NN
liabilities_NOMZ
The_DT
Groups_NN
overdraft_NN
facility_NOMZ
,_,
which_WDT [SERE]
is_VPRT [PASS]
denominated_VBN
in_PIN
US_FPP1
dollars_NN
and_CC
is_VPRT [BYPA]
underwritten_VBN
by_PIN
PowderJect_NN
,_,
is_VPRT [PASS]
explained_VBN [PUBV]
in_PIN
note_NN
18_CD
._.
At_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
Group_NN
had_VBD [SPAU] [PEAS]
fully_AMP
utilised_VBN
the_DT
overdraft_NN
facility_NOMZ
2001_CD
fully_AMP
utilised_VBN
._.
Interest_NN
on_PIN
the_DT
facility_NOMZ
is_VPRT [PASS]
charged_VBN
at_PIN
0.35_CD
%_NN
per_PIN
annum_NN
above_PLACE
the_DT
bank-lending_JJ
rate_NN
for_PIN
US_FPP1
dollars_NN
._.
During_PIN
2002_CD
,_,
the_DT
weighted_JJ
average_JJ
interest_NN
payable_JJ
on_PIN
the_DT
facility_NOMZ
was_VBD [BEMA]
2.0_CD
%_NN
2001_CD
4.5_CD
%_NN
._.
The_DT
only_DWNT
other_JJ
financial_JJ
liability_NOMZ
of_PIN
the_DT
Group_NN
at_PIN
31_CD
December_NN
2002_CD
was_VBD [BEMA]
a_DT
long-term_JJ
lease-finance_NN
facility_NOMZ
,_,
which_WDT [SERE]
matures_VPRT
within_PIN
four_CD
years_NN
._.
This_DEMP
$_$
40m_CD
c._NN
25m_JJ
leasefinance_NN
facility_NOMZ
,_,
arranged_VBN [SUAV] [PASTP]
through_PIN
Baxter_NN
International_NN
,_,
Inc._NN
._.
Baxter_NN
,_,
was_VBD [BYPA]
approved_VBN
by_PIN
shareholders_NN
in_PIN
December_NN
2001_CD
._.
The_DT
Group_NN
secured_VBN
financing_GER
of_PIN
$_$
10m_CD
c._NN
6.8_CD
m_NN [BEMA]
for_PIN
the_DT
sale-and-leaseback_NN
of_PIN
the_DT
land_NN
and_PHC
shell_NN
of_PIN
the_DT
manufacturing_GER
plant_NN
,_,
and_ANDC
up_RB
to_TO
$_$
25m_CD
c._NN
17m_CD
to_TO
lease-finance_VB
the_DT
capital_NN
expenditure_NN
items_NN
purchased_VBD
to_TO
reactivate_VB
the_DT
manufacturing_GER
plant_NN
._.
In_PIN
December_NN
2001_CD
,_,
the_DT
Group_NN
received_VBD
$_$
18.6_CD
m_NN
c._NN
12.8_CD
m_NN
,_,
which_WDT [SERE]
represented_VBD
$_$
8.6_CD
m_NN
c._NN
6.0_CD
m_NN [BEMA]
in_PIN
respect_NN
of_PIN
capital_NN
expenditure_NN
already_RB
incurred_VBN
throughout_PIN
2001_CD
,_,
plus_PIN
$_$
10m_CD
c._NN
6.8_CD
m_NN
representing_VBG [WZPRES]
the_DT
net_JJ
proceeds_NN
from_PIN
sale-and-leaseback_NN
of_PIN
the_DT
land_NN
and_PHC
shell_NN
of_PIN
the_DT
building_GER
._.
To_TO
facilitate_VB
this_DEMO
transaction_NOMZ
,_,
the_DT
land_NN
and_PHC
shell_NN
were_VBD [PASS]
purchased_VBN
for_PIN
$_$
2.3_CD
m_NN
c._NN
1.5_CD
m._FW
This_DEMO
amount_NN
is_VPRT [PASS]
included_VBN
in_PIN
the_DT
outstanding_JJ
facility_NOMZ
._.
During_PIN
2002_CD
,_,
no_SYNE
further_JJ
draw_NN
downs_NN
were_VBD [PASS]
made_VBN
from_PIN
the_DT
facility_NOMZ
,_,
although_CONC
interest_NN
of_PIN
$_$
1.7_CD
m_NN [BEMA]
1.1_CD
m_NN [PASS]
accrued_VBN [WZPAST]
during_PIN
the_DT
year_NN
and_CC
has_VPRT [PEAS]
converted_VBN
into_PIN
the_DT
capital_NN
balance_NN
owing_NN
on_PIN
the_DT
facility_NOMZ
._.
The_DT
financing_GER
has_VPRT [PEAS]
been_VBN [PASS]
reflected_VBN [PRIV]
in_PIN
the_DT
financial_JJ
statements_NOMZ
as_IN
a_DT
long-term_JJ
creditor_NN
._.
During_PIN
2002_CD
,_,
interest_NN
was_VBD [PASS]
charged_VBN
to_PIN
the_DT
facility_NOMZ
at_PIN
3_CD
%_NN
above_PLACE
the_DT
prime_JJ
rate_NN
of_PIN
Banc_NN
One_CD
Corporation_NOMZ
,_,
a_DT
USbased_JJ
bank_NN
,_,
resulting_VBG [PRESP]
in_PIN
an_DT
interest_NN
charge_NN
of_PIN
1.1_CD
m_NN [BEMA]
2001_CD
0.03_CD
m_NN
being_VBG [WZPRES] [PASS]
added_VBN [PUBV]
to_PIN
the_DT
facility_NOMZ
._.
From_PIN
January_NN
2003_CD
,_,
the_DT
interest_NN
percentage_NN
payable_JJ
in_PIN
respect_NN
of_PIN
the_DT
facility_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
fixed_VBN
at_PIN
6.25_CD
%_NN
until_IN
the_DT
end_NN
of_PIN
the_DT
life_NN
of_PIN
the_DT
lease_NN
._.
The_DT
repayment_NOMZ
schedule_NN
for_PIN
the_DT
lease_NN
financing_GER
requires_VPRT [SUAV]
that_THVC
no_SYNE
interest_NN
or_CC
capital_NN
were_VBD [BEMA]
repayable_PRED
during_PIN
2002_CD
,_,
interest_NN
only_DWNT
need_MD
be_VB [PASS]
repaid_VBN
in_PIN
2003_CD
and_CC
capital_NN
and_PHC
interest_NN
are_VPRT [BEMA]
repayable_PRED
over_IN
2004_CD
to_PIN
2006_CD
._.
The_DT
Group_NN
has_VPRT
an_DT
option_NOMZ
to_TO
repurchase_VB
all_QUAN
of_PIN
the_DT
facilitys_NN
assets_NN
from_PIN
the_DT
end_NN
of_PIN
2003_CD
,_,
and_ANDC
on_PIN
each_QUAN
anniversary_NN
thereafter_RB
,_,
for_PIN
the_DT
capital_NN
balance_NN
outstanding_JJ
at_PIN
that_DEMO
time_NN
,_,
plus_PIN
any_QUAN
accrued_VBN
but_CC
unpaid_JJ
interest_NN
due_JJ
at_PIN
the_DT
time_NN
,_,
plus_PIN
a_DT
make-whole_JJ
payment_NOMZ
discounted_VBN [WZPAST]
to_PIN
present_JJ
value_NN
equal_JJ
to_PIN
the_DT
projected_VBN
future_JJ
interest_NN
stream_NN
payable_JJ
to_PIN
the_DT
end_NN
of_PIN
the_DT
lease_NN
term_NN
._.
At_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
balance_NN
on_PIN
this_DEMO
facility_NOMZ
was_VBD
$_$
22.5_CD
m_NN [BEMA]
14.0_CD
m_NN
,_,
resulting_VBG [PRESP]
in_PIN
$_$
17.5_CD
m_NN
c._NN
10.9_CD
m_NN
not_XX0
being_VBG [PASS]
used_VBN
at_PIN
that_DEMO
time_NN
2001_CD
$_$
19.2_CD
m._FW
The_DT
facility_NOMZ
is_VPRT
Profile_NN
of_PIN
Groups_NN
financial_JJ
denominated_VBN
in_PIN
US_FPP1
dollars_NN
._.
liabilities_NOMZ
-_:
finance_NN
lease_NN
This_DEMP
relates_VPRT
to_PIN
the_DT
financing_GER
put_VBN [WZPAST]
in_PIN
Profile_NN
of_PIN
the_DT
Groups_NN
financial_JJ
liabilities_NOMZ
place_VPRT
for_PIN
our_FPP1
manufacturing_GER
plant_NN
The_DT
maturity_NOMZ
profile_NN
of_PIN
the_DT
overdraft_NN
facility_NOMZ
,_,
together_RB
with_PIN
the_DT
future_JJ
minimum_NN
finance_NN
lease_NN
obligations_NOMZ
net_NN
of_PIN
finance_NN
charges_NN
to_PIN
which_WDT [PIRE]
the_DT
Group_NN
is_VPRT [PASS]
committed_VBN
are_VPRT [BEMA]
in_PIN
2001_CD
._.
We_FPP1
have_VPRT
an_DT
option_NOMZ
to_PIN
as_IN
follows_VPRT
:_:
repurchase_VBD
the_DT
plant_NN
and_CC
all_QUAN
of_PIN
its_PIT
assets_NN
in_PIN
December_NN
2003_CD
on_PIN
Overdraft_NN
faciity_NOMZ
Finance_NN
lease_NN
2002_CD
Overdraft_NN
faciity_NOMZ
Finance_NN
lease_NN
2001_CD
the_DT
second_JJ
anniversary_NN
of_PIN
the_DT
000 000 000 000_CD
000_CD
000_CD
establishment_NOMZ
of_PIN
the_DT
agreement_NOMZ
,_,
Within_PIN
one_CD
and_CC
two_CD
years_NN
4,349_CD
4,428_CD
8,777_CD
4,809_CD
-_:
4,809_CD
and_CC
on_PIN
each_QUAN
anniversary_NN
thereafter_RB
,_,
Between_PIN
two_CD
and_CC
five_CD
years_NN
-9,544_CD
9,544_CD
-14,299_CD
14,299_CD
for_PIN
the_DT
outstanding_JJ
capital_NN
balance_NN
._.
4,349_CD
13,972_CD
18,321_CD
4,809_CD
14,299_CD
19,108_CD
Share_NN
option_NOMZ
schemes_NN
Fair_NN
values_NN
of_PIN
financial_JJ
assets_NN
and_CC
financial_JJ
liabilities_NOMZ
We_FPP1
recognize_VPRT [PRIV]
that_THVC
our_FPP1
people_NN
are_VPRT [BEMA]
In_PIN
the_DT
opinion_NN
of_PIN
the_DT
Directors_NN
,_,
there_EX
is_VPRT
no_SYNE
material_NN
difference_NN
between_PIN
the_DT
book_NN
values_NN
and_CC
fair_JJ
values_NN
of_PIN
the_DT
Groups_NN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
as_IN
at_PIN
31_CD
December_NN
one_CD
of_PIN
our_FPP1
most_EMPH
important_JJ
assets_NN
2002_CD
._.
Fair_NN
values_NN
have_VPRT [PEAS]
been_VBN [BYPA]
calculated_VBN [PRIV]
by_PIN
discounting_VBG
cash_NN
flows_NN
at_PIN
prevailing_VBG
interest_NN
rates_NN
._.
and_ANDC
encourage_VB
all_QUAN
employees_NN
to_TO
share_VB
in_PIN
the_DT
growth_NN
of_PIN
the_DT
Group_NN
by_PIN
21_CD
Called-up_JJ
share_NN
capital_NN
Year_NN
ending_VBG [WZPRES]
31_CD
December_NN
2002_CD
Year_NN
ending_VBG [WZPRES]
31_CD
December_NN
2001_CD
offering_GER
share_NN
options_NOMZ
to_PIN
every_QUAN
Number_NN
000_CD
Number_NN
000_CD
employee_NN
._.
The_DT
subscription_NOMZ
is_VPRT [BEMA]
payable_PRED
in_PIN
instalments_NOMZ
between_PIN
December_NN
2000_CD
and_CC
,_,
at_PIN
the_DT
latest_JJ
,_,
June_NN
2003_CD
._.
The_DT
subscription_NOMZ
price_NN
in_PIN
2002_CD
was_VBD [BEMA]
1.40_CD
2001_CD
1.30_CD
per_PIN
ordinary_JJ
share_NN
._.
As_IN
described_VBN
within_PIN
Post_NN
balance_NN
sheet_NN
events_NN
on_PIN
page_NN
37_CD
,_,
on_PIN
27_CD
March_NN
2003_CD
,_,
Baxter_NN
accelerated_VBD
its_PIT
fourth_JJ
and_PHC
final_JJ
subscription_NOMZ
,_,
taking_VBG [PRESP]
its_PIT
shareholding_GER
to_PIN
20.6_CD
%_NN
._.
Share_NN
option_NOMZ
schemes_NN
The_DT
Group_NN
operates_VPRT
several_QUAN
share_NN
option_NOMZ
schemes_NN
._.
Notes_NN
1_CD
The_DT
Peptide_NN
Therapeutics_NN
Group_NN
plc_NN
1994_CD
Unapproved_NN
Share_NN
Option_NOMZ
Scheme_NN
._.
2_CD
Parallel_JJ
options_NOMZ
under_IN
the_DT
1995_CD
Scheme_NN
existed_VBD
over_IN
14,015_CD
of_PIN
the_DT
options_NOMZ
outstanding_JJ
at_PIN
31_CD
December_NN
2002_CD
._.
Option_NOMZ
holders_NN
may_POMD
elect_VB
to_TO
exercise_VB
either_DT
option_NOMZ
,_,
at_PIN
which_WDT [PIRE]
time_NN
the_DT
alternative_NN
option_NOMZ
lapses_NN
._.
The_DT
Group_NN
operates_VPRT
an_DT
Inland_NN
Revenue-approved_JJ
Save-As-You-Earn_NN
SAYE_NN
scheme_NN
in_PIN
the_DT
UK_NN
and_CC
has_VPRT [PEAS]
taken_VBN
advantage_NN
of_PIN
the_DT
exemption_NOMZ
given_VBN [WZPAST]
in_PIN
UITF_NN
17_CD
from_PIN
recognizing_VBG [PRIV]
a_DT
charge_NN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
for_PIN
the_DT
discount_NN
on_PIN
those_DEMO
options_NOMZ
._.
At_PIN
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
to_TO
be_VB [PASS]
held_VBN [PRIV]
on_PIN
13_CD
May_POMD
2003_CD
,_,
the_DT
Directors_NN
will_PRMD
seek_VB
the_DT
authority_NOMZ
of_PIN
shareholders_NN
to_TO
introduce_VB
a_DT
new_JJ
all-employee_JJ
share_NN
plan_NN
for_PIN
US-based_JJ
employees_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
similar_PRED
to_PIN
the_DT
SAYE_NN
scheme_NN
in_PIN
the_DT
UK_NN
._.
22_CD
Reserves_NN
2002 2001 2000_CD
Share_NN
premium_NN
account_NN
Share_NN
premium_NN
Profit_NN
and_PHC
loss_NN
Share_NN
premium_NN
Profit_NN
and_PHC
loss_NN
Share_NN
premium_NN
Profit_NN
and_PHC
loss_NN
account_NN
account_NN
account_NN
account_NN
account_NN
account_NN
Acambis_NN
ordinary_JJ
shares_NN
have_VPRT
a_DT
Group_NN
reserves_NN
000 000 000 000_CD
000_CD
000_CD
nominal_JJ
value_NN
of_PIN
10p_CD
._.
When_RB
new_JJ
At_PIN
1_CD
January_NN
80,598_CD
62,246_CD
76,776_CD
49,505_CD
67,456_CD
37,614_CD
shares_NN
are_VPRT [PASS]
issued_VBN
,_,
either_CC
through_PIN
Issue_NN
of_PIN
new_JJ
shares_NN
7,147_CD
-_:
3,822_SYM
-_:
9,320_CD
-_:
fundraisings_GER
,_,
share_NN
option_NOMZ
exercises_VPRT
Exchange_NN
adjustments_NOMZ
-_:
1,276_SYM
-_:
314_CD
-_:
817_CD
or_CC
corporate_JJ
transactions_NOMZ
such_JJ
as_IN
Retained_JJ
profit_NN
loss_NN
for_PIN
the_DT
year_NN
-9,575_CD
-_:
12,427_SYM
-_:
11,074_CD
the_DT
subscription_NOMZ
agreement_NOMZ
with_PIN
At_PIN
31_CD
December_NN
87,745_CD
51,395_CD
80,598_CD
62,246_CD
76,776_CD
49,505_CD
Baxter_NN
,_,
the_DT
price_NN
paid_VBN [WZPAST]
for_PIN
the_DT
shares_NN
2002 2001 2000_CD
in_PIN
excess_NN
of_PIN
the_DT
10p_JJ
nominal_JJ
value_NN
is_VPRT
Share_NN
premium_NN
Profit_NN
and_PHC
loss_NN
Share_NN
premium_NN
Profit_NN
and_PHC
loss_NN
Share_NN
premium_NN
Profit_NN
and_PHC
loss_NN
recognized_VBN [PRIV]
as_IN
share_NN
premium_NN
._.
account_NN
account_NN
account_NN
account_NN
account_NN
account_NN
Company_NN
reserves_NN
000 000 000 000_CD
000_CD
000_CD
At_PIN
1_CD
January_NN
80,464_CD
4,719_CD
76,642_CD
99_CD
67,322_CD
132_CD
Issue_NN
of_PIN
new_JJ
shares_NN
7,147_CD
-_:
3,822_SYM
-_:
9,320_CD
-_:
Exchange_NN
adjustments_NOMZ
-_:
1,459_SYM
-_:
-_:
-_:
-_:
Retained_VBN
loss_NN
profit_NN
for_PIN
the_DT
year_NN
-_:
1,621_CD
-_:
4,620_SYM
-_:
33_CD
At_PIN
31_CD
December_NN
87,611_CD
1,639_CD
80,464_CD
4,719_CD
76,642_CD
99_CD
23_CD
Reconciliation_NOMZ
of_PIN
movements_NOMZ
in_PIN
Group_NN
shareholders_NN
funds_NN
2002 2001 000 000_CD
Retained_VBN
profit_NN
loss_NN
for_PIN
the_DT
period_NN
9,575_CD
12,427_CD
Gain_NN
loss_NN
on_PIN
foreign_JJ
currency_NN
exchange_NN
1,276_CD
314_CD
New_NN
share_NN
capital_NN
subscribed_VBN
7,740_CD
4,262_CD
Net_JJ
increase_NN
decrease_NN
in_PIN
shareholders_NN
funds_NN
18,591_CD
8,479_CD
Opening_GER
shareholders_NN
funds_NN
27,660_CD
36,139_CD
Closing_GER
shareholders_NN
funds_NN
46,251_CD
27,660_CD
24_CD
Reconciliation_NOMZ
of_PIN
the_DT
operating_GER
profit_NN
loss_NN
to_PIN
net_JJ
cash_NN
outflow_NN
from_PIN
operating_VBG
activities_NOMZ
2002 2001 2000 000_CD
000_CD
000_CD
Operating_GER
profit_NN
loss_NN
9,911_CD
12,242_CD
9,397_CD
Depreciation_NOMZ
and_PHC
amortisation_NOMZ
2,614_CD
1,942_CD
2,132_CD
Increase_VPRT
in_PIN
stock_NN
52,631_CD
--_:
Increase_VB
in_PIN
debtors_NN
50,602_CD
3,685_CD
8,558_CD
Increase_VPRT
in_PIN
creditors_NN
81,798_CD
5,685_CD
6,607_CD
Loss_NN
on_PIN
sale_NN
of_PIN
tangible_JJ
fixed_JJ
assets_NN
9_CD
-_:
6_CD
Exchange_NN
differences_NN
arising_VBG [WZPRES]
on_PIN
inter-company_JJ
balances_NN
1,274_CD
499_CD
691_CD
Other_JJ
1,445_CD
840_CD
694_CD
Net_JJ
cash_NN
outflow_NN
from_PIN
operating_VBG
activities_NOMZ
6,182_CD
7,959_CD
9,207_CD
In_PIN
2001_CD
and_CC
2002_CD
,_,
all_QUAN
cash_NN
flows_VPRT
arose_VBD
from_PIN
continuing_VBG
operating_GER
activities_NOMZ
._.
35_CD
36_CD
NOTES_NN
TO_PIN
GROUP_NN
FINANCIAL_NN
STATEMENTS_NOMZ
31_CD
December_NN
2002_CD
25_CD
Analysis_NN
and_PHC
reconciliation_NOMZ
of_PIN
net_JJ
funds_NN
debt_NN
Net_JJ
debt_NN
1_CD
January_NN
2001_CD
Cash_NN
flow_NN
Non-cash_JJ
movements_NOMZ
Exchange_NN
movement_NOMZ
31_CD
December_NN
2001 000 000 000_CD
000_CD
000_CD
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
major_JJ
working_JJ
capital_NN
requirements_NOMZ
for_PIN
the_DT
second_JJ
Cash_NN
1,179_CD
20,910_CD
-_:
4_CD
22,093_CD
CDC_NN
smallpox_NN
vaccine_NN
contract_NN
,_,
cash_NN
Liquid_NN
resources_NN
19,938_CD
19,834_CD
-_:
16_CD
120_CD
Overdraft_NN
facility_NOMZ
4,686_CD
-_:
-_:
124_CD
4,810_CD
and_CC
liquid_JJ
resources_NN
at_PIN
the_DT
year-end_JJ
1,076_CD
of_PIN
11.8_CD
million_CD
was_VBD [BEMA]
less_PRED
than_PIN
our_FPP1
Finance_NN
lease_NN
13_CD
12,725_CD
1,546_CD
15_CD
14,299_CD
obligations_NOMZ
under_IN
the_DT
finance_NN
lease_NN
Net_JJ
funds_NN
16,418_CD
11,649_CD
1,546_CD
119_CD
3,104_CD
and_CC
overdraft_NN
facilities_NOMZ
._.
However_CONJ
,_,
this_DEMP
was_VBD [BEMA]
simply_RB
the_DT
result_NN
of_PIN
timing_VBG
1_CD
January_NN
2002_CD
Cash_NN
flow_NN
Non-cash_JJ
movements_NOMZ
Exchange_NN
movement_NOMZ
31_CD
December_NN
2002_CD
differences_NN
in_PIN
payments_NOMZ
._.
Two_CD
days_NN
000 000 000 000_CD
000_CD
following_VBG
the_DT
2002_CD
year-end_NN
our_FPP1
Cash_NN
22,093_CD
9,179_CD
-_:
1,242_CD
11,672_CD
cash_NN
was_VBD [BEMA]
such_OSUB
that_NULL
net_JJ
funds_NN
of_PIN
the_DT
Liquid_NN
resources_NN
120_CD
5_LS
-_:
10_CD
105_CD
Group_NN
were_VBD
once_TIME
again_TIME
positive_JJ
._.
Overdraft_NN
facility_NOMZ
4,810_CD
-_:
-_:
461_CD
4,349_CD
9,184_CD
Finance_NN
lease_NN
14,299_CD
-_:
1,118_CD
1,445_CD
13,972_CD
Net_JJ
debt_NN
3,104_CD
9,184_CD
1,118_CD
654_CD
6,544_CD
Liquid_NN
resources_NN
at_PIN
31_CD
December_NN
2002_CD
of_PIN
0.1_CD
m_NN
represents_VPRT
amounts_NN
held_VBN [PRIV] [WZPAST]
by_PIN
Acambis_NN
Inc._NN
as_IN
a_DT
deposit_NN
against_PIN
property_NN
rentals_NN
._.
2002 2001 2000 000_CD
000_CD
000_CD
Decrease_NN
increase_NN
in_PIN
cash_NN
9,179_CD
20,910_CD
351_CD
Decrease_NN
increase_NN
in_PIN
liquid_JJ
resources_NN
5_CD
19,834_CD
1,894_CD
Decrease_NN
increase_NN
in_PIN
cash_NN
and_CC
liquid_JJ
resources_NN
9,184_CD
1,076_CD
1,543_CD
Net_JJ
cash_NN
outflow_NN
from_PIN
lease_NN
financing_GER
-_:
13_CD
29_CD
Proceeds_NN
from_PIN
new_JJ
finance_NN
lease_NN
-_:
12,738_CD
-_:
Net_JJ
increase_NN
in_PIN
overdraft_NN
facility_NOMZ
-_:
-_:
2,502_CD
Change_NN
in_PIN
net_JJ
debt_NN
funds_NN
arising_VBG [WZPRES]
from_PIN
cash_NN
flows_NN
9,184_CD
11,649_CD
930_CD
Non-cash_JJ
element_NOMZ
of_PIN
finance_NN
lease_NN
1,118_CD
1,546_CD
-_:
Exchange_NN
adjustments_NOMZ
654_CD
119_CD
59_CD
Movement_NOMZ
in_PIN
net_JJ
debt_NN
funds_NN
9,648_CD
13,314_CD
989_CD
Net_JJ
funds_NN
at_PIN
1_CD
January_NN
3,104_CD
16,418_CD
17,407_CD
Net_JJ
debt_NN
funds_NN
at_PIN
31_CD
December_NN
6,544_CD
3,104_CD
16,418_CD
26_CD
Financial_NN
commitments_NOMZ
a_DT
Lease_NN
commitments_NOMZ
The_DT
minimum_JJ
annual_JJ
rentals_NN
payable_JJ
by_PIN
the_DT
Group_NN
under_IN
non-cancellable_JJ
operating_GER
leases_NN
are_VPRT
as_IN
follows_VPRT
:_:
Land_NN
and_PHC
buildings_GER
Equipment_NOMZ
2002 2001 2002 2001_CD
000 000 000 000_CD
Operating_GER
leases_NN
which_WDT [WHSUB]
expire_VPRT
:_:
Within_PIN
one_CD
year_NN
31_CD
-_:
13_CD
-_:
Within_PIN
two_CD
to_PIN
five_CD
years_NN
1,640_CD
962_CD
-_:
6_CD
After_IN
more_EMPH
than_PIN
five_CD
years_NN
-_:
520_CD
-_:
-_:
1,671_CD
1,482_CD
13_CD
6_CD
At_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
Company_NN
had_VBD
no_SYNE
operating_GER
leases_VPRT
2001_CD
nil_NN
._.
In_PIN
March_NN
2000_CD
,_,
the_DT
Group_NN
entered_VBD
into_PIN
a_DT
sub-lease_NN
with_PIN
Medivir_NN
UK_NN
Limited_NN
in_PIN
respect_NN
of_PIN
50_CD
%_NN
of_PIN
the_DT
facility_NOMZ
at_PIN
Peterhouse_NN
Technology_NN
Park_NN
in_PIN
the_DT
UK_NN
._.
The_DT
sub-lease_NN
expires_VPRT
in_PIN
September_NN
2003_CD
,_,
and_ANDC
provides_VPRT
that_DEMO
Medivir_NN
UK_NN
Limited_NN
will_PRMD
pay_VB
Acambis_NN
0.3_CD
m_FW [BEMA]
per_PIN
annum_NN
in_PIN
operating_VBG
lease_NN
rentals_NN
relating_VBG [WZPRES]
to_PIN
land_NN
and_PHC
buildings_GER
._.
In_PIN
September_NN
1999_CD
,_,
the_DT
Group_NN
entered_VBD
a_DT
further_JJ
sub-lease_NN
with_PIN
Millennium_NN
Pharmaceuticals_NN
,_,
Inc._NN
in_PIN
respect_NN
of_PIN
25_CD
%_NN
of_PIN
the_DT
facility_NOMZ
at_PIN
38_CD
Sidney_NN
Street_NN
in_PIN
Cambridge_NN
,_,
Massachusetts_NN
,_,
USA_NN
._.
This_DEMO
sub-lease_NN
expired_VBD
in_PIN
December_NN
2002_CD
at_PIN
which_WDT [PIRE]
point_NN
Acambis_NN
re-occupied_VBD
all_QUAN
of_PIN
this_DEMO
space_NN
._.
b_NN
Capital_NN
commitments_NOMZ
At_PIN
the_DT
end_NN
of_PIN
the_DT
year_NN
,_,
capital_NN
commitments_NOMZ
contracted_VBD
but_CC
not_XX0
provided_VBN
for_PIN
were_VBD [BEMA]
0.1_CD
m_NN [BEMA]
2001_CD
6.4_CD
m._NN
c_NN
Pension_NN
arrangements_NOMZ
The_DT
Group_NN
provides_VPRT
pension_NN
benefits_NN
to_PIN
all_QUAN
full-time_JJ
employees_NN
on_PIN
a_DT
defined_VBN
contribution_NOMZ
basis_NN
._.
The_DT
Company_NN
operates_VPRT
a_DT
self-administered_JJ
,_,
Inland_NN
Revenue-approved_JJ
pension_NN
scheme_NN
for_PIN
UK_NN
Executive_NN
Directors_NN
._.
Other_JJ
employees_NN
may_POMD
operate_VB
private_JJ
personal_JJ
pension_NN
schemes_NN
._.
In_PIN
the_DT
US_FPP1
the_DT
Group_NN
offers_VPRT
a_DT
401k_JJ
Savings_GER
and_PHC
Retirement_NOMZ
Plan_NN
for_PIN
all_QUAN
employees_NN
,_,
including_VBG
Executive_NN
Directors_NN
._.
The_DT
Group_NN
pension_NN
cost_NN
including_VBG [WZPRES]
401k_JJ
costs_NN
for_PIN
the_DT
year_NN
was_VBD [BEMA]
0.5_CD
m_NN [BEMA]
2001_CD
0.2_CD
m._NN
At_PIN
the_DT
year-end_NN
,_,
the_DT
Group_NN
owed_VBD
0.2_CD
m_NN [BEMA]
2001_CD
0.01_CD
m_NN [BEMA]
to_PIN
the_DT
pension_NN
schemes_NN
._.
This_DEMO
amount_NN
is_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
balance_NN
sheet_NN
under_IN
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
within_PIN
one_CD
year_NN
._.
27_CD
Related_VBN
party_NN
transactions_NOMZ
7b_VPRT
Under_IN
the_DT
provisions_NN
of_PIN
FRS_NN
8_CD
,_,
Related_NN
Party_NN
Disclosures_NN
,_,
it_PIT
is_VPRT [BEMA]
not_XX0
necessary_PRED
to_TO
disclose_VB [PUBV]
related_JJ
party_NN
transactions_NOMZ
between_PIN
the_DT
Company_NN
,_,
Acambis_NN
Research_NN
Limited_NN
and_PHC
Acambis_NN
Inc._NN
because_CAUS
they_TPP3
are_VPRT [PASS]
eliminated_VBN
on_PIN
preparation_NOMZ
of_PIN
the_DT
Groups_NN
financial_JJ
statements_NOMZ
._.
As_IN
described_VBN
in_PIN
note_NN
14_CD
d_LS
,_,
the_DT
Group_NN
has_VPRT
an_DT
interest_NN
in_PIN
the_DT
Joint_NN
Venture_NN
._.
Since_OSUB
May_POMD
1999_CD
,_,
Acambis_NN
has_VPRT [PEAS]
performed_VBN
a_DT
pre-agreed_JJ
work_NN
program_NN
on_PIN
behalf_NN
of_PIN
the_DT
Joint_NN
Venture_NN
._.
Costs_NN
incurred_VBN [WZPAST]
by_PIN
the_DT
Group_NN
on_PIN
behalf_NN
of_PIN
the_DT
Joint_NN
Venture_NN
and_CC
corresponding_JJ
turnover_NN
received_VBN [WZPAST]
from_PIN
the_DT
Joint_NN
Venture_NN
have_VPRT [PEAS]
been_VBN [PASS]
included_VBN
in_PIN
the_DT
Groups_NN
financial_JJ
statements_NOMZ
._.
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
,_,
the_DT
Group_NN
has_VPRT [PEAS]
included_VBN
turnover_NN
of_PIN
0.3_CD
m_NN [BEMA]
2001_CD
0.5_CD
m_NN [BEMA]
in_PIN
respect_NN
of_PIN
costs_NN
incurred_VBN [WZPAST]
in_PIN
performing_VBG
services_NN
for_PIN
the_DT
Joint_NN
Venture_NN
within_PIN
its_PIT
Group_NN
financial_JJ
statements_NOMZ
._.
50_CD
%_NN
of_PIN
the_DT
loss_NN
incurred_VBN [WZPAST]
by_PIN
Pasteur_NN
Mrieux-OraVax_NN
in_PIN
2002_CD
,_,
amounting_VBG [PRESP]
to_PIN
0.2_CD
m_NN [BEMA]
2001_CD
0.4_CD
m_NN
,_,
is_VPRT [PASS]
shown_VBN [PRIV]
on_PIN
the_DT
face_NN
of_PIN
the_DT
Group_NN
profit_NN
and_PHC
loss_NN
account_NN
on_PIN
page_NN
18_CD
._.
At_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
amounts_NN
the_DT
Group_NN
owed_VBD
to_PIN
the_DT
Joint_NN
Venture_NN
amounted_VBD
to_TO
nil_VB
2001_CD
0.5_CD
m._NN
Amounts_NN
owed_VBN [WZPAST]
by_PIN
the_DT
Joint_NN
Venture_NN
to_PIN
the_DT
Group_NN
at_PIN
31_CD
December_NN
2002_CD
were_VBD [BEMA]
nil_PRED
2001_CD
nil_NN
._.
In_PIN
2002_CD
,_,
the_DT
Group_NN
took_VBD
the_DT
view_NN
that_DEMP
,_,
taking_VBG [PRESP]
into_PIN
account_NN
the_DT
increase_NN
in_PIN
its_PIT
shareholding_GER
in_PIN
Acambis_NN
and_CC
the_DT
presence_NN
of_PIN
a_DT
representative_NN
from_PIN
Baxter_NN
on_PIN
the_DT
Board_NN
,_,
Baxters_NN
influence_NN
on_PIN
Acambis_NN
became_VBD
significant_JJ
,_,
and_ANDC
therefore_CONJ
Baxter_NN
is_VPRT [BEMA]
a_DT
related_JJ
party_NN
._.
Baxters_NN
subscriptions_NOMZ
in_PIN
the_DT
shares_NN
of_PIN
the_DT
Company_NN
are_VPRT [PASS]
set_VBN
out_PIN
in_PIN
note_NN
C_NN
on_PIN
page_NN
21_CD
,_,
and_ANDC
the_DT
Groups_NN
long-term_JJ
lease-finance_NN
facility_NOMZ
with_PIN
Baxter_NN
is_VPRT [PASS]
described_VBN
within_PIN
Financial_NN
liabilities_NOMZ
in_PIN
note_NN
20_CD
._.
The_DT
Group_NN
made_VBD
sales_NN
to_PIN
Baxter_NN
of_PIN
0.7_CD
m_NN [BEMA]
in_PIN
2002_CD
2001_CD
nil_NN
,_,
of_PIN
which_WDT [PIRE]
0.7_CD
m_NN [BEMA]
2001_CD
nil_NN
was_VBD [BEMA]
unpaid_PRED
at_PIN
the_DT
year-end_NN
,_,
and_ANDC
made_VBD
purchases_NN
of_PIN
goods_NN
and_PHC
services_NN
from_PIN
Baxter_NN
of_PIN
45.7_CD
m_NN [BEMA]
2001_CD
nil_NN
,_,
of_PIN
which_WDT [PIRE]
42.7_CD
m_NN [BEMA]
2001_CD
nil_NN
was_VBD [BEMA]
unpaid_PRED
at_PIN
the_DT
year-end_NN
._.
28_CD
Post_NN
balance_NN
sheet_NN
events_NN
Under_IN
a_DT
prior_JJ
agreement_NOMZ
with_PIN
BTG_NN
International_NN
Limited_NN
BTG_NN
,_,
Acambis_NN
was_VBD [PASS]
required_VBN [SUAV]
to_TO
pay_VB
to_PIN
BTG_NN
an_DT
annual_JJ
turnover_NN
tax_NN
of_PIN
2_CD
%_NN
of_PIN
the_DT
Groups_NN
gross_JJ
turnover_NN
on_PIN
an_DT
ongoing_JJ
basis_NN
._.
Following_VBG [PRESP]
a_DT
decision_NN
by_PIN
the_DT
High_NN
Court_NN
of_PIN
Justice_NN
Queens_NN
Bench_NN
Division_NN
in_PIN
the_DT
UK_NN
in_PIN
February_NN
2003_CD
,_,
it_PIT
was_VBD [PASS]
confirmed_VBN [PUBV] [THATD]
that_DEMP
this_DEMO
turnover_NN
tax_NN
covers_VPRT
all_QUAN
subsidiaries_NN
of_PIN
the_DT
Company_NN
._.
This_DEMO
decision_NN
has_VPRT
no_SYNE
effect_NN
on_PIN
the_DT
financial_JJ
statements_NOMZ
of_PIN
the_DT
Group_NN
._.
On_PIN
27_CD
March_NN
2003_CD
,_,
Baxter_NN
International_NN
,_,
Inc._NN
accelerated_VBD
its_PIT
fourth_JJ
and_PHC
final_JJ
subscription_NOMZ
of_PIN
equity_NOMZ
shares_NN
from_PIN
the_DT
original_JJ
subscription_NOMZ
date_NN
of_PIN
no_DT
later_TIME
than_PIN
1_CD
June_NN
2003_CD
._.
These_DEMO
shares_NN
were_VBD [PASS]
traded_VBN
from_PIN
27_CD
March_NN
2003_CD
._.
This_DEMO
subscription_NOMZ
of_PIN
4.6_CD
million_CD
shares_NN
at_PIN
a_DT
subscription_NOMZ
amount_NN
of_PIN
7.0_CD
m_NN [PASS]
increased_VBD
Baxters_NN
shareholding_GER
in_PIN
the_DT
Company_NN
to_PIN
20.6_CD
%_NN
._.
37_CD
38_CD
NOTES_NN
TO_PIN
GROUP_NN
FINANCIAL_NN
STATEMENTS_NOMZ
31_CD
December_NN
2002_CD
29_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
Summary_NN
of_PIN
significant_JJ
differences_NN
between_PIN
UK_NN
GAAP_NN
followed_VBD
by_PIN
the_DT
Group_NN
and_PHC
US_FPP1
GAAP_NN
Compensation_NOMZ
costs_VPRT
under_IN
variable_JJ
The_DT
Groups_NN
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
under_IN
UK_NN
GAAP_NN
,_,
which_WDT [SERE]
differs_VPRT
in_PIN
certain_JJ
respects_NN
from_PIN
US_FPP1
GAAP_NN
._.
The_DT
principal_JJ
differences_NN
between_PIN
the_DT
Groups_NN
plan_VPRT
accounting_VBG
for_PIN
stock_NN
options_NOMZ
accounting_GER
policies_NN
under_IN
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
and_ANDC
SAYE_NN
plan_NN
discount_NN
Under_IN
US_FPP1
GAAP_NN
,_,
a_DT
company_NN
is_VPRT
Revenue_NN
recognition_NOMZ
required_VBN [SUAV]
to_TO
put_VB
a_DT
charge_NN
through_PIN
its_PIT
Revenues_NN
represent_VPRT
sales_NN
and_PHC
income_NN
derived_VBN [WZPAST]
from_PIN
product_NN
sales_NN
,_,
licence_NN
fees_NN
,_,
contract_NN
research_NN
fees_NN
and_PHC
development_NOMZ
milestone_NN
payments_NOMZ
._.
Under_IN
UK_NN
GAAP_NN
,_,
these_DEMO
profit_NN
and_PHC
loss_NN
account_NN
for_PIN
share_NN
revenues_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
using_VBG
the_DT
accounting_GER
policies_NN
as_IN
set_VBN
out_PIN
in_PIN
note_NN
1_CD
._.
The_DT
Directors_NN
have_VPRT [PEAS]
selected_VBN
the_DT
accounting_GER
policies_NN
they_TPP3
believe_VPRT [PRIV]
to_TO
be_VB [BEMA]
the_DT
most_EMPH
appropriate_JJ
options_NOMZ
not_XX0
yet_RB
exercised_VBN
but_CC
that_DEMO
in_PIN
the_DT
circumstances_NN
,_,
as_IN
required_VBN [SUAV]
by_PIN
FRS_NN
18_CD
Accounting_GER
Policies_NN
._.
In_PIN
making_VBG
this_DEMO
judgment_NOMZ
,_,
they_TPP3
have_VPRT [PEAS]
taken_VBN
into_PIN
account_NN
recent_JJ
publications_NOMZ
by_PIN
the_DT
Accounting_GER
are_VPRT [BEMA]
likely_PRED
to_TO
be_VB [PASS]
exercised_VBN
._.
The_DT
Standards_NN
Board_NN
ASB_NN
,_,
specifically_RB
the_DT
discussion_NN
paper_NN
entitled_VBN
Revenue_NN
Recognition_NOMZ
and_CC
the_DT
proposed_VBN [SUAV]
additional_JJ
application_NOMZ
note_NN
to_PIN
FRS_NN
5_CD
,_,
Substance_NN
of_PIN
charge_NN
is_VPRT [PASS]
calculated_VBN [PRIV]
as_IN
the_DT
Transactions_NOMZ
._.
difference_NN
between_PIN
the_DT
market_NN
value_NN
of_PIN
the_DT
shares_NN
at_PIN
the_DT
year-end_NN
For_PIN
US_FPP1
purposes_NN
,_,
the_DT
Group_NN
adopted_VBD
Staff_NN
Accounting_GER
Bulletin_NN
SAB_NN
101_CD
with_PIN
effect_NN
from_PIN
1_CD
January_NN
2000_CD
._.
and_ANDC
the_DT
exercise_NN
price_NN
._.
Licence_NN
fees_NN
Prior_RB
to_PIN
2001_CD
,_,
under_IN
UK_NN
GAAP_NN
,_,
certain_JJ
licence_NN
fees_NN
were_VBD [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
paid_VBN
,_,
where_RB
such_JJ
payments_NOMZ
were_VBD [BEMA]
not_XX0
refundable_PRED
._.
Following_VBG [PRESP]
the_DT
Groups_NN
adoption_NOMZ
of_PIN
SAB101_CD
under_IN
US_FPP1
GAAP_NN
,_,
where_RB
licence_NN
fees_NN
are_VPRT [BEMA]
not_XX0
refundable_PRED
and_CC
are_VPRT [BEMA]
not_XX0
creditable_PRED
against_PIN
associated_VBN
R&D_NN
activities_NOMZ
,_,
these_DEMO
fees_NN
are_VPRT [PASS]
considered_VBN [PRIV]
inseparable_JJ
from_PIN
the_DT
associated_VBN
R&D_NN
effort_NN
._.
As_IN
such_JJ
,_,
those_DEMO
licence_NN
fees_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
over_IN
the_DT
period_NN
of_PIN
the_DT
licence_NN
term_NN
or_CC
over_IN
the_DT
period_NN
of_PIN
the_DT
R&D_NN
agreement_NOMZ
._.
Multiple_JJ
element_NOMZ
arrangements_NOMZ
In_PIN
November_NN
2001_CD
,_,
Acambis_NN
was_VBD [PASS]
awarded_VBN
a_DT
second_JJ
contract_NN
by_PIN
the_DT
CDC_NN
._.
This_DEMO
contract_NN
is_VPRT [PASS]
divided_VBN
into_PIN
two_CD
principal_JJ
components_NN
:_:
to_TO
manufacture_VB
155_CD
million_CD
doses_NN
of_PIN
smallpox_NN
vaccine_NN
:_:
and_ANDC
to_TO
take_VB
the_DT
vaccine_NN
through_PIN
clinical_JJ
trials_NN
to_PIN
US_FPP1
Food_NN
and_PHC
Drug_NN
Administration_NOMZ
FDA_NN
licensure_NN
._.
Under_IN
UK_NN
GAAP_NN
,_,
this_DEMO
contract_NN
has_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
single-element_JJ
arrangement_NOMZ
._.
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
Group_NN
treats_VPRT
this_DEMO
contract_NN
as_IN
a_DT
multiple_JJ
element_NOMZ
arrangement_NOMZ
resulting_VBG [WZPRES]
in_PIN
a_DT
different_JJ
allocation_NOMZ
of_PIN
revenue_NN
compared_VBN [WZPAST]
to_PIN
the_DT
UK_NN
GAAP_NN
treatment_NOMZ
._.
The_DT
Group_NN
has_VPRT [PEAS]
determined_VBN [SUAV] [PRIV]
the_DT
fair_JJ
value_NN
of_PIN
the_DT
development_NOMZ
and_PHC
manufacturing_GER
portions_NOMZ
of_PIN
the_DT
contract_NN
and_CC
has_VPRT [PEAS]
allocated_VBN
the_DT
total_JJ
contract_NN
value_NN
to_PIN
the_DT
development_NOMZ
and_PHC
manufacturing_GER
using_VBG [WZPRES]
the_DT
relative_JJ
fair_JJ
value_NN
method_NN
as_IN
prescribed_VBN
by_PIN
Emerging_VBG
Issues_NN
Task_NN
Force_NN
EITF_NN
Issue_NN
No._NN
._.
00-21_CD
,_,
Accounting_GER
for_PIN
Revenue_NN
Arrangements_NOMZ
with_PIN
Multiple_NN
Deliverables_NN
._.
The_DT
development_NOMZ
portion_NOMZ
of_PIN
the_DT
contract_NN
consists_VPRT
of_PIN
the_DT
completion_NOMZ
of_PIN
Phase_NN
I_FPP1
II_NN
clinical_JJ
trials_NN
,_,
completion_NOMZ
of_PIN
Phase_NN
III_NN
clinical_JJ
trials_NN
including_VBG [WZPRES]
completion_NOMZ
and_PHC
submission_NN
of_PIN
a_DT
Biologics_NN
Licenses_NN
Application_NOMZ
with_PIN
the_DT
FDA_NN
and_PHC
post_NN
FDA_NN
approval_NN
activities_NOMZ
._.
The_DT
manufacturing_GER
portion_NOMZ
consists_VPRT
of_PIN
the_DT
manufacture_NN
and_PHC
delivery_NN
of_PIN
smallpox_NN
vaccine_NN
to_PIN
the_DT
CDC_NN
._.
The_DT
Group_NN
recognizes_VPRT [PRIV]
revenue_NN
for_PIN
each_QUAN
significant_JJ
development_NOMZ
activity_NOMZ
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
the_DT
expected_VBN [PRIV]
duration_NOMZ
of_PIN
each_QUAN
respective_JJ
activity_NOMZ
unrelated_JJ
to_PIN
the_DT
costs_NN
incurred_VBN
over_IN
that_DEMO
period_NN
:_:
this_DEMP
contrasts_VPRT
with_PIN
the_DT
UK_NN
GAAP_NN
treatment_NOMZ
,_,
where_RB
revenues_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
costs_NN
are_VPRT [PASS]
incurred_VBN
,_,
using_VBG [PRESP]
the_DT
principles_NN
of_PIN
long-term_JJ
contract_NN
accounting_GER
._.
The_DT
Group_NN
recognizes_VPRT [PRIV]
revenue_NN
on_PIN
the_DT
manufacturing_GER
portion_NOMZ
of_PIN
the_DT
contract_NN
as_IN
smallpox_NN
vaccine_NN
is_VPRT [PASS]
delivered_VBN
to_PIN
the_DT
CDC_NN
and_CC
all_QUAN
risks_NN
and_PHC
rewards_NN
of_PIN
ownership_NN
have_VPRT [PEAS]
transferred_VBN
to_PIN
the_DT
CDC_NN
._.
Costs_NN
associated_VBN [WZPAST]
with_PIN
expected_VBN [PRIV]
re-labelling_GER
to_TO
be_VB [PASS]
undertaken_VBN
in_PIN
the_DT
future_NN
are_VPRT
being_VBG [PASS]
accrued_VBN
as_IN
smallpox_NN
vaccine_NN
is_VPRT [PASS]
delivered_VBN
to_PIN
the_DT
CDC_NN
._.
Costs_NN
and_PHC
revenue_NN
associated_VBN [WZPAST]
with_PIN
providing_VBG
storage_NN
or_CC
vaccine_NN
disposal_NN
services_NN
are_VPRT [SPAU] [PASS]
only_DWNT
included_VBN
when_RB
,_,
and_ANDC
if_COND
,_,
it_PIT
is_VPRT [PASS]
deemed_VBN [PRIV]
probable_JJ
that_THAC
such_JJ
services_NN
will_PRMD
be_VB [PASS]
performed_VBN
._.
Compensation_NOMZ
costs_NN
under_IN
variable_JJ
plan_NN
accounting_GER
for_PIN
stock_NN
options_NOMZ
and_PHC
SAYE_NN
plan_NN
discount_NN
Acambis_NN
has_VPRT [PEAS]
granted_VBN [SUAV]
stock_NN
options_NOMZ
to_PIN
employees_NN
that_TSUB
will_PRMD
vest_NN
upon_PIN
the_DT
attainment_NOMZ
of_PIN
certain_JJ
targets_NN
._.
Under_IN
UK_NN
GAAP_NN
,_,
there_EX
is_VPRT
no_SYNE
accounting_GER
for_PIN
these_DEMO
grants_NN
after_IN
the_DT
initial_JJ
grant_NN
date_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
APB_NN
Opinion_NN
No._NN
._.
25_CD
,_,
Accounting_GER
for_PIN
Stock_NN
Issued_NN
to_PIN
Employees_NN
APB25_NN
,_,
the_DT
Company_NN
would_PRMD
be_VB [PASS]
required_VBN [SUAV]
to_TO
follow_VB
variable_JJ
plan_NN
accounting_GER
for_PIN
these_DEMO
grants_NN
and_PHC
measure_NN
compensation_NOMZ
expense_NN
as_IN
the_DT
difference_NN
between_PIN
the_DT
exercise_NN
price_NN
and_CC
the_DT
fair_JJ
market_NN
value_NN
of_PIN
the_DT
stock_NN
during_PIN
each_QUAN
accounting_GER
period_NN
over_IN
the_DT
vesting_JJ
period_NN
of_PIN
the_DT
options_NOMZ
._.
Increases_NN
in_PIN
fair_JJ
market_NN
value_NN
of_PIN
the_DT
stock_NN
would_PRMD
result_VB
in_PIN
a_DT
charge_NN
to_PIN
operations_NOMZ
and_CC
decreases_VPRT
in_PIN
the_DT
fair_JJ
market_NN
value_NN
of_PIN
the_DT
stock_NN
would_PRMD
result_VB
in_PIN
a_DT
credit_NN
to_PIN
operations_NOMZ
,_,
subject_JJ
to_PIN
the_DT
cumulative_JJ
amount_NN
previously_TIME
expensed_VBN
._.
Under_IN
UK_NN
GAAP_NN
,_,
Acambis_NN
has_VPRT [PEAS]
taken_VBN
advantage_NN
of_PIN
the_DT
exemption_NOMZ
provided_VBN [WZPAST]
by_PIN
UITF_NN
17_CD
,_,
not_XX0
to_TO
recognize_VB [PRIV]
any_QUAN
compensation_NOMZ
charge_NN
in_PIN
respect_NN
of_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
SAYE_NN
plans_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
in_PIN
accounting_GER
for_PIN
new_JJ
offers_NN
made_VBD
since_OSUB
24_CD
January_NN
2002_CD
,_,
Acambis_NN
would_PRMD
follow_VB
the_DT
requirements_NOMZ
of_PIN
pronouncement_NOMZ
EITF_NN
00-23_CD
Issues_NN
relating_VBG [WZPRES]
to_PIN
the_DT
Accounting_GER
for_PIN
Stock_NN
Compensation_NOMZ
under_IN
APB25_NN
and_PHC
FIN44_NN
Financial_NN
Accounting_GER
Standards_NN
Board_NN
Interpretation_NOMZ
Number_NN
FIN_NN
44_CD
,_,
Accounting_GER
for_PIN
Certain_NN
Transactions_NOMZ
Involving_GER
Stock_NN
Compensation_NOMZ
,_,
FIN44_CD
which_WDT
does_VPRT
not_XX0
permit_VB
such_PDT
an_DT
exemption_NOMZ
in_PIN
respect_NN
of_PIN
plans_NN
with_PIN
certain_JJ
characteristics_NN
._.
The_DT
compensation_NOMZ
charge_NN
under_IN
US_FPP1
GAAP_NN
in_PIN
respect_NN
of_PIN
such_JJ
plans_NN
would_PRMD
be_VB [PASS]
calculated_VBN [PRIV]
as_IN
the_DT
difference_NN
between_PIN
the_DT
market_NN
price_NN
of_PIN
the_DT
shares_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
and_CC
the_DT
exercise_NN
price_NN
of_PIN
the_DT
option_NOMZ
and_CC
would_PRMD
be_VB [PASS]
recorded_VBN
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
the_DT
savings_GER
period_NN
._.
The_DT
table_NN
below_PLACE
shows_NN
the_DT
additional_JJ
charge_NN
or_CC
credit_NN
that_TSUB
would_PRMD
have_VB [PEAS]
been_VBN [PASS]
made_VBN
to_PIN
the_DT
Group_NN
profit_NN
and_PHC
loss_NN
account_NN
under_IN
US_FPP1
GAAP_NN
._.
Year_NN
ended_VBD
31_CD
December_NN
2002 2001 2000 000_CD
000_CD
000_CD
Charged_VBN
to_PIN
the_DT
Group_NN
profit_NN
and_PHC
loss_NN
account_NN
1,212_CD
5,210_CD
312_CD
Provision_NN
against_PIN
own_JJ
shares_NN
held_VBD [PRIV]
Under_IN
UK_NN
GAAP_NN
,_,
own_JJ
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
Acambis_NN
Employees_NN
Trustees_NN
Limited_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
as_IN
fixed_JJ
asset_NN
investments_NOMZ
and_PHC
provisions_NN
made_VBN [WZPAST]
against_PIN
these_DEMO
investments_NOMZ
to_TO
reduce_VB
them_TPP3
to_PIN
the_DT
recoverable_JJ
amount_NN
are_VPRT [PASS]
charged_VBN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
own_JJ
shares_NN
are_VPRT [PASS]
recorded_VBN
at_PIN
cost_NN
,_,
are_VPRT [PASS]
not_XX0
reviewed_VBN
for_PIN
impairment_NOMZ
and_CC
are_VPRT [PASS]
accounted_VBN
for_PIN
within_PIN
shareholders_NN
equity_NOMZ
._.
Purchase_NN
price_NN
accounting_GER
for_PIN
in-process_JJ
R&D_NN
and_PHC
goodwill_NN
amortisation_NOMZ
During_PIN
1999_CD
,_,
Acambis_NN
acquired_VBD
Acambis_NN
Inc._NN
._.
Under_IN
both_DT
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
,_,
goodwill_NN
is_VPRT [PASS]
identified_VBN
as_IN
being_VBG [BEMA]
the_DT
amount_NN
that_TOBJ
the_DT
fair_JJ
value_NN
of_PIN
the_DT
consideration_NOMZ
exceeds_VPRT
the_DT
fair_JJ
value_NN
of_PIN
assets_NN
acquired_VBN
._.
However_CONJ
,_,
under_IN
UK_NN
GAAP_NN
no_SYNE
value_NN
is_VPRT [PASS]
attributed_VBN
to_PIN
in-process_JJ
R&D_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
not_XX0
the_DT
case_NN
under_IN
US_FPP1
GAAP_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
in_PIN
accordance_NN
with_PIN
APB_NN
Opinion_NN
No._NN
._.
17_CD
,_,
Intangible_NN
Assets_NN
,_,
in-process_JJ
R&D_NN
is_VPRT [SPAU] [PASS]
separately_RB
identified_VBN
and_PHC
analyzed_VBN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
fair_JJ
market_NN
value_NN
at_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
._.
In-process_JJ
R&D_NN
is_VPRT [PASS]
identified_VBN
in_PIN
accordance_NN
with_PIN
the_DT
definition_NOMZ
within_PIN
Statement_NOMZ
of_PIN
Financial_NN
Accounting_GER
Standard_NN
SFAS_NN
No._NN
._.
2_CD
,_,
Accounting_GER
for_PIN
Research_NN
and_PHC
Development_NOMZ
Costs_NN
._.
Following_VBG
identification_NOMZ
of_PIN
qualifying_VBG
R&D_NN
projects_NN
,_,
their_TPP3
value_NN
was_VBD [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
estimating_VBG [PRIV]
the_DT
costs_NN
to_TO
develop_VB
the_DT
purchased_VBN
in-process_NN
R&D_NN
into_PIN
commercially_RB
viable_JJ
products_NN
,_,
estimating_VBG [PRIV] [PRESP]
the_DT
resulting_VBG
net_JJ
cash_NN
flows_VPRT
from_PIN
the_DT
projects_NN
and_CC
discounting_VBG
the_DT
net_JJ
cash_NN
flows_VPRT
to_PIN
their_TPP3
present_JJ
value_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
valuation_NOMZ
of_PIN
in-process_JJ
R&D_NN
under_IN
US_FPP1
GAAP_NN
,_,
the_DT
fair_JJ
value_NN
of_PIN
assets_NN
acquired_VBN [WZPAST]
is_VPRT [BEMA]
different_PRED
from_PIN
that_DEMP
calculated_VBN [PRIV]
under_IN
UK_NN
GAAP_NN
,_,
resulting_VBG [PRESP]
in_PIN
differing_VBG
values_NN
of_PIN
goodwill_NN
._.
The_DT
table_NN
below_PLACE
shows_NN
the_DT
difference_NN
in_PIN
the_DT
goodwill_NN
calculation_NOMZ
and_CC
the_DT
associated_VBN
amortisation_NOMZ
charge_NN
in_PIN
the_DT
Group_NN
profit_NN
and_PHC
loss_NN
account_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
in-process_JJ
R&D_NN
is_VPRT [PASS]
written_VBN [PUBV]
off_PIN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
when_RB
incurred_VBN
._.
Under_IN
UK_NN
GAAP_NN
,_,
Acambis_NN
amortises_VPRT
goodwill_NN
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
an_DT
estimate_NN
of_PIN
the_DT
time_NN
the_DT
Group_NN
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
benefit_VB
from_PIN
it_PIT
._.
Until_IN
1_CD
January_NN
2002_CD
,_,
this_DEMP
was_VBD
also_RB
Acambis_NN
accounting_GER
policy_NN
under_IN
US_FPP1
GAAP_NN
._.
Following_VBG [PRESP]
the_DT
provisions_NN
of_PIN
SFAS_NN
142_CD
,_,
Goodwill_NN
and_CC
Other_JJ
Intangible_NN
Assets_NN
SFAS_NN
142_CD
,_,
the_DT
carrying_VBG
value_NN
of_PIN
goodwill_NN
in_PIN
US_FPP1
GAAP_NN
was_VBD [PASS]
frozen_VBN
and_PHC
became_VBD
subject_JJ
to_PIN
annual_JJ
impairment_NOMZ
reviews_NN
._.
The_DT
transitional_JJ
impairment_NOMZ
review_NN
carried_VBD
out_PIN
on_PIN
adoption_NOMZ
of_PIN
SFAS_NN
142_CD
did_VBD
not_XX0
reveal_VB [PRIV]
any_QUAN
indication_NOMZ
of_PIN
impairment_NOMZ
._.
Year_NN
ended_VBD
31_CD
December_NN
2002_CD
Year_NN
ended_VBD
31_CD
December_NN
2001_CD
UK_NN
GAAP_NN
US_FPP1
GAAP_NN
UK_NN
GAAP_NN
US_FPP1
GAAP_NN
000 000 000 000_CD
Goodwill_NN
on_PIN
acquisition_NOMZ
included_VBD
on_PIN
balance_NN
sheet_NN
cost_NN
18,055_CD
6,155_CD
18,055_CD
6,155_CD
Amortisation_NOMZ
brought_VBD
forward_RB
3,210_CD
1,094_CD
2,006_CD
684_CD
Amortisation_NOMZ
charged_VBD
to_PIN
Group_NN
profit_NN
and_PHC
loss_NN
account_NN
for_PIN
the_DT
year_NN
1,204_CD
-_:
1,204_CD
410_CD
Goodwill_NN
net_JJ
book_NN
value_NN
13,641_CD
5,061_CD
14,845_CD
5,061_CD
Capitalisation_NOMZ
of_PIN
interest_NN
Under_IN
UK_NN
GAAP_NN
,_,
Acambis_NN
accounting_GER
policy_NN
is_VPRT
that_DEMO
interest_NN
is_VPRT [PASS]
not_XX0
capitalized_VBN
._.
US_FPP1
GAAP_NN
would_PRMD
require_VB [SUAV] [THATD]
interest_NN
incurred_VBN
as_IN
part_NN
of_PIN
the_DT
cost_NN
of_PIN
constructing_VBG
fixed_JJ
assets_NN
to_TO
be_VB [PASS]
capitalized_VBN
and_PHC
amortised_VBN
over_IN
the_DT
life_NN
of_PIN
the_DT
asset_NN
._.
39_CD
40_CD
NOTES_NN
TO_PIN
GROUP_NN
FINANCIAL_NN
STATEMENTS_NOMZ
31_CD
December_NN
2002_CD
29_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
Reconciliation_NOMZ
of_PIN
net_JJ
loss_NN
from_PIN
UK_NN
GAAP_NN
to_PIN
US_FPP1
GAAP_NN
Based_VBD
on_PIN
the_DT
differences_NN
detailed_VBN
above_PLACE
,_,
the_DT
following_VBG
table_NN
shows_VPRT [PRIV]
the_DT
reconciliation_NOMZ
of_PIN
the_DT
Groups_NN
net_JJ
loss_NN
for_PIN
the_DT
past_JJ
three_CD
years_NN
:_:
Year_NN
ended_VBD
31_CD
December_NN
2002 2001 2000 000_CD
000_CD
000_CD
Net_JJ
profit_NN
loss_NN
as_IN
reported_VBN [PUBV]
under_IN
UK_NN
GAAP_NN
9,575_CD
12,427_CD
11,074_CD
Adjustments_NOMZ
for_PIN
:_:
Revenue_NN
recognition_NOMZ
24,124_CD
1,995_CD
570_CD
Compensation_NOMZ
costs_NN
credit_NN
under_IN
variable_JJ
plan_NN
accounting_GER
for_PIN
stock_NN
options_NOMZ
and_PHC
SAYE_NN
plan_NN
discount_NN
1,212_CD
5,210_CD
312_CD
Provision_NN
against_PIN
own_JJ
shares_NN
held_VBD [PRIV]
420_CD
--_:
Amortisation_NOMZ
charge_NN
for_PIN
goodwill_NN
1,204_CD
794_CD
794_CD
Capitalisation_NOMZ
of_PIN
interest_NN
560_CD
-_:
-_:
Net_JJ
loss_NN
as_IN
reported_VBN [PUBV]
under_IN
US_FPP1
GAAP_NN
before_IN
cumulative_JJ
effect_NN
of_PIN
accounting_GER
change_NN
13,577_CD
14,848_CD
11,162_CD
Cumulative_JJ
effect_NN
of_PIN
accounting_GER
change_NN
:_:
revenue_NN
recognition_NOMZ
-_:
-_:
2,572_CD
Net_JJ
loss_NN
as_IN
reported_VBN [PUBV]
under_IN
US_FPP1
GAAP_NN
after_IN
cumulative_JJ
effect_NN
of_PIN
accounting_GER
change_NN
13,577_CD
14,848_CD
13,734_CD
Loss_NN
per_PIN
share_NN
under_IN
US_FPP1
GAAP_NN
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
Group_NN
would_PRMD
compute_VB
loss_NN
per_PIN
share_NN
under_IN
SFAS_NN
No._NN
._.
Under_IN
SFAS_NN
128_CD
,_,
basic_JJ
net_JJ
loss_NN
per_PIN
ordinary_JJ
share_NN
is_VPRT [BEMA]
computed_PRED
using_VBG
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
of_PIN
common_JJ
stock_NN
outstanding_JJ
during_PIN
the_DT
period_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
diluted_VBD
net_JJ
loss_NN
per_PIN
ordinary_JJ
share_NN
for_PIN
Acambis_NN
is_VPRT [BEMA]
the_DT
same_JJ
as_IN
basic_JJ
net_JJ
loss_NN
per_PIN
ordinary_JJ
share_NN
,_,
as_IN
the_DT
effects_NN
of_PIN
the_DT
Companys_NN
potential_JJ
ordinary_JJ
share_NN
equivalents_NN
are_VPRT [BEMA]
anti-dilutive_PRED
._.
Under_IN
UK_NN
GAAP_NN
the_DT
basis_NN
of_PIN
calculation_NOMZ
is_VPRT [BEMA]
the_DT
same_JJ
._.
Because_CAUS
the_DT
Group_NN
has_VPRT [PEAS]
recorded_VBN
a_DT
net_JJ
profit_NN
under_IN
UK_NN
GAAP_NN
,_,
certain_JJ
securities_NOMZ
which_WDT [WHSUB]
are_VPRT [BEMA]
dilutive_PRED
under_IN
UK_NN
GAAP_NN
are_VPRT [BEMA]
anti-dilutive_PRED
under_IN
US_FPP1
GAAP_NN
._.
The_DT
net_JJ
loss_NN
per_PIN
share_NN
under_IN
US_FPP1
GAAP_NN
is_VPRT [PASS]
presented_VBN
below_PLACE
:_:
Year_NN
ended_VBD
31_CD
December_NN
2002 2001 2000 000_CD
000_CD
000_CD
Basic_JJ
loss_NN
per_PIN
ordinary_JJ
share_NN
in_PIN
pence_NN
before_IN
cumulative_JJ
effect_NN
of_PIN
accounting_GER
change_NN
14.1_CD
16.3_CD
14.0_CD
Basic_JJ
loss_NN
per_PIN
share_NN
in_PIN
pence_NN
of_PIN
cumulative_JJ
effect_NN
of_PIN
accounting_GER
change_NN
-_:
-_:
3.2_CD
Basic_JJ
loss_NN
per_PIN
share_NN
in_PIN
pence_NN
14.1_CD
16.3_CD
17.2_CD
Shares_NN
used_VBN [WZPAST]
in_PIN
computing_VBG
basic_JJ
loss_NN
per_PIN
ordinary_JJ
share_NN
96,101,507_CD
91,027,463_CD
79,638,484_CD
Diluted_JJ
loss_NN
per_PIN
ordinary_JJ
share_NN
in_PIN
pence_NN
14.1_CD
16.3_CD
17.2_CD
Shares_NN
used_VBN [WZPAST]
in_PIN
computing_VBG
diluted_JJ
loss_NN
per_PIN
ordinary_JJ
share_NN
96,101,507_CD
91,027,463_CD
79,638,484_CD
Anti-dilutive_JJ
securities_NOMZ
,_,
not_XX0
included_VBN
above_PLACE
3,100,226_CD
2,294,366_CD
1,565,251_CD
Anti-dilutive_JJ
securities_NOMZ
represent_VPRT
stock_NN
options_NOMZ
outstanding_JJ
,_,
which_WDT [SERE]
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
included_VBN
in_PIN
the_DT
calculation_NOMZ
of_PIN
loss_NN
per_PIN
ordinary_JJ
share_NN
as_IN
the_DT
impact_NN
of_PIN
including_VBG
such_JJ
shares_NN
in_PIN
the_DT
calculation_NOMZ
of_PIN
loss_NN
per_PIN
share_NN
would_PRMD
be_VB [BEMA]
anti-dilutive_PRED
._.
Income_NN
and_PHC
expense_NN
transactions_NOMZ
with_PIN
the_DT
same_JJ
party_NN
In_PIN
accordance_NN
with_PIN
EITF_NN
Issue_NN
02-16_CD
,_,
Accounting_GER
by_PIN
a_DT
Reseller_NN
for_PIN
Cash_NN
Consideration_NOMZ
Received_VBD
from_PIN
a_DT
Vendor_NN
,_,
certain_JJ
transactions_NOMZ
with_PIN
the_DT
same_JJ
party_NN
,_,
which_WDT [SERE]
are_VPRT [PASS]
shown_VBN [PRIV]
gross_JJ
under_IN
UK_NN
GAAP_NN
,_,
are_VPRT [PASS]
netted_VBN
under_IN
US_FPP1
GAAP_NN
._.
These_DEMO
adjustments_NOMZ
have_VPRT
no_SYNE
impact_NN
on_PIN
net_JJ
income_NN
._.
The_DT
individual_JJ
line_NN
items_NN
affected_VBN [WZPAST]
are_VPRT
cost_NN
of_PIN
sales_NN
which_WDT [WHOBJ]
under_IN
US_FPP1
GAAP_NN
in_PIN
2002_CD
is_VPRT [BEMA]
48.0_CD
m_NN
and_PHC
R&D_NN
costs_NN
included_VBD
within_PIN
operating_GER
expenses_NN
2002_CD
21.5_CD
m._NN
Discontinued_VBN
operations_NOMZ
As_IN
discussed_VBN
in_PIN
note_NN
4_CD
,_,
the_DT
Group_NN
completed_VBD
the_DT
disposal_NN
of_PIN
its_PIT
interest_NN
in_PIN
its_PIT
drug_NN
discovery_NN
business_NOMZ
,_,
Mimetrix_NN
,_,
during_PIN
2000_CD
._.
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
operating_GER
results_NN
of_PIN
discontinued_VBN
operations_NOMZ
should_NEMD
be_VB [PASS]
reported_VBN [PUBV]
separately_RB
in_PIN
a_DT
single_JJ
caption_NOMZ
after_IN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
,_,
net_NN
of_PIN
income_NN
tax_NN
effects_NN
,_,
for_PIN
all_QUAN
periods_NN
presented_VBN
._.
This_DEMO
presentation_NOMZ
difference_NN
has_VPRT
no_SYNE
impact_NN
on_PIN
the_DT
net_JJ
loss_NN
for_PIN
the_DT
periods_NN
presented_VBN
._.
Reconciliation_NOMZ
of_PIN
shareholders_NN
equity_NOMZ
from_PIN
UK_NN
GAAP_NN
to_PIN
US_FPP1
GAAP_NN
As_IN
at_PIN
31_CD
December_NN
2002 2001 2000 000_CD
000_CD
000_CD
Shareholders_NN
equity_NOMZ
as_IN
reported_VBN [PUBV]
under_IN
UK_NN
GAAP_NN
46,251_CD
27,660_CD
36,139_CD
Goodwill_NN
8,580_CD
9,784_CD
10,578_CD
Revenue_NN
recognition_NOMZ
cumulative_JJ
25,272_CD
1,147_CD
3,142_CD
Capitalisation_NOMZ
of_PIN
interest_NN
560_CD
--_:
Reclassification_NOMZ
of_PIN
net_JJ
book_NN
value_NN
of_PIN
investment_NOMZ
in_PIN
Group_NN
shares_NN
797_CD
1,252_CD
1,445_CD
Shareholders_NN
equity_NOMZ
as_IN
reported_VBN [PUBV]
under_IN
US_FPP1
GAAP_NN
12,162_CD
15,477_CD
20,974_CD
Group_NN
statement_NOMZ
of_PIN
cash_NN
flows_VPRT
The_DT
Group_NN
statement_NOMZ
of_PIN
cash_NN
flows_NN
prepared_VBN
under_IN
UK_NN
GAAP_NN
presents_VPRT
substantially_RB
the_DT
same_JJ
information_NOMZ
as_IN
that_DEMP
required_VBN [SUAV]
under_IN
US_FPP1
GAAP_NN
by_PIN
SFAS_NN
No._NN
._.
These_DEMO
standards_NN
differ_VPRT
,_,
however_CONJ
,_,
with_PIN
regard_NN
to_PIN
classification_NOMZ
of_PIN
items_NN
within_PIN
the_DT
statements_NOMZ
and_CC
the_DT
definition_NOMZ
of_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
._.
Under_IN
UK_NN
GAAP_NN
,_,
cash_NN
comprises_VPRT
only_DWNT
cash_NN
in_PIN
hand_NN
and_PHC
deposits_NN
repayable_JJ
on_PIN
demand_NN
._.
Deposits_NN
are_VPRT [BEMA]
repayable_PRED
on_PIN
demand_NN
if_COND
they_TPP3
can_POMD
be_VB [PASS]
withdrawn_VBN
at_PIN
any_QUAN
time_NN
without_PIN
notice_NN
and_CC
without_PIN
penalty_NN
or_CC
if_COND
a_DT
maturity_NOMZ
or_CC
period_NN
of_PIN
notice_NN
of_PIN
not_XX0
more_EMPH
than_PIN
24_CD
hours_NN
or_CC
one_CD
working_VBG
day_NN
has_VPRT [PEAS]
been_VBN [PASS]
agreed_VBN [SUAV] [PUBV]
._.
Under_IN
US_FPP1
GAAP_NN
,_,
cash_NN
equivalents_NN
are_VPRT [BEMA]
short-term_JJ
highly_AMP
liquid_JJ
investments_NOMZ
,_,
with_PIN
a_DT
maturity_NOMZ
of_PIN
three_CD
months_NN
or_CC
less_JJ
at_PIN
inception_NOMZ
,_,
that_DEMP
are_VPRT [BEMA]
readily_RB
convertible_PRED
to_PIN
known_JJ
amounts_NN
of_PIN
cash_NN
and_CC
present_JJ
insignificant_JJ
risk_NN
of_PIN
changes_NN
in_PIN
value_NN
because_CAUS
of_PIN
changes_NN
in_PIN
interest_NN
rates_NN
._.
Under_IN
UK_NN
GAAP_NN
,_,
cash_NN
flows_NN
are_VPRT [PASS]
presented_VBN
separately_RB
for_PIN
operating_VBG
activities_NOMZ
,_,
returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
,_,
taxation_NOMZ
,_,
capital_NN
expenditure_NN
and_CC
financial_JJ
investment_NOMZ
,_,
management_NOMZ
of_PIN
liquid_JJ
resources_NN
and_PHC
financing_GER
activities_NOMZ
._.
US_FPP1
GAAP_NN
requires_VPRT [SUAV]
only_DWNT
three_CD
categories_NN
of_PIN
cash_NN
flow_NN
activity_NOMZ
to_TO
be_VB [PASS]
reported_VBN [PUBV]
:_:
operating_GER
,_,
investing_VBG
and_PHC
financing_VBG
._.
Cash_NN
flows_VPRT
from_PIN
taxation_NOMZ
and_PHC
returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
under_IN
UK_NN
GAAP_NN
would_PRMD
,_,
with_PIN
the_DT
exception_NOMZ
of_PIN
dividends_NN
paid_VBN
,_,
be_VB [PASS]
shown_VBN [PRIV]
under_IN
operating_VBG
activities_NOMZ
under_IN
US_FPP1
GAAP_NN
._.
The_DT
payment_NOMZ
of_PIN
dividends_NN
and_CC
the_DT
payment_NOMZ
to_TO
acquire_VB
own_JJ
shares_NN
treasury_NN
stock_NN
would_PRMD
be_VB [PASS]
included_VBN
as_IN
a_DT
financing_GER
activity_NOMZ
under_IN
US_FPP1
GAAP_NN
._.
Management_NOMZ
of_PIN
liquid_JJ
resources_NN
under_IN
UK_NN
GAAP_NN
would_PRMD
be_VB [PASS]
included_VBN
as_IN
cash_NN
and_PHC
cash_NN
equivalents_NN
under_IN
US_FPP1
GAAP_NN
to_PIN
the_DT
extent_NN
that_TOBJ
the_DT
amounts_NN
involved_VBN
have_VPRT
a_DT
maturity_NOMZ
of_PIN
less_JJ
than_PIN
three_CD
months_NN
and_CC
are_VPRT [BEMA]
convertible_PRED
into_PIN
known_JJ
amounts_NN
of_PIN
cash_NN
._.
Summary_JJ
statements_NOMZ
of_PIN
cash_NN
flow_NN
presented_VBN
under_IN
US_FPP1
GAAP_NN
are_VPRT [PASS]
given_VBN
below_PLACE
:_:
Year_NN
ended_VBD
31_CD
December_NN
2002 2001 2000 000_CD
000_CD
000_CD
Net_JJ
cash_NN
used_VBN [WZPAST]
in_PIN
operating_VBG
activities_NOMZ
5,459_CD
6,968_CD
8,782_CD
Net_JJ
cash_NN
used_VBN [WZPAST]
in_PIN
investing_VBG
activities_NOMZ
11,460_CD
5,803_CD
4,488_CD
Net_JJ
cash_NN
provided_VBN [WZPAST]
by_PIN
used_VBN
in_PIN
financing_GER
activities_NOMZ
7,740_CD
16,987_CD
12,819_CD
Effect_NN
of_PIN
foreign_JJ
exchange_NN
on_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
1,242_CD
--_:
Decrease_NN
increase_NN
in_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
10,421_CD
15,822_CD
451_CD
Opening_GER
cash_NN
and_PHC
cash_NN
equivalents_NN
22,093_CD
6,271_CD
6,722_CD
Closing_GER
cash_NN
and_PHC
cash_NN
equivalents_NN
11,672_CD
22,093_CD
6,271_CD
Statement_NOMZ
of_PIN
other_JJ
comprehensive_JJ
income_NN
2002 2001 2000 000_CD
000_CD
000_CD
Net_JJ
loss_NN
13,577_CD
14,848_CD
13,734_CD
Other_JJ
comprehensive_JJ
income_NN
:_:
foreign_JJ
currency_NN
translation_NOMZ
adjustment_NOMZ
net_NN
of_PIN
tax_NN
1,276_CD
314_CD
817_CD
Total_JJ
comprehensive_JJ
income_NN
12,301_CD
15,162_CD
14,551_CD
41_CD
42_CD
NOTES_NN
TO_PIN
GROUP_NN
FINANCIAL_NN
STATEMENTS_NOMZ
31_CD
December_NN
2002_CD
29_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
Recently_TIME
issued_VBN
pronouncements_NOMZ
In_PIN
June_NN
2002_CD
,_,
the_DT
Financial_NN
Accounting_GER
Standards_NN
Board_NN
FASB_NN
issued_VBD
SFAS_NN
No._NN
._.
146_CD
,_,
Accounting_GER
for_PIN
costs_NN
associated_VBN [WZPAST]
with_PIN
exit_NN
or_CC
disposal_NN
activities_NOMZ
SFAS_NN
146_CD
._.
SFAS_NN
Further_JJ
information_NOMZ
required_VBN [SUAV]
146_CD
addresses_NN
financial_JJ
accounting_GER
and_CC
reporting_VBG [PUBV]
for_PIN
costs_NN
associated_VBN [WZPAST]
with_PIN
exit_NN
or_CC
disposal_NN
activities_NOMZ
and_PHC
nullifies_NN
EITF_NN
94-3_CD
,_,
Liability_NOMZ
recognition_NOMZ
for_PIN
certain_JJ
employee_NN
by_PIN
Form_NN
20-F_JJ
termination_NOMZ
benefits_NN
and_CC
other_JJ
costs_NN
to_PIN
exit_NN
an_DT
activity_NOMZ
including_VBG [WZPRES]
certain_JJ
costs_NN
incurred_VBN [WZPAST]
in_PIN
a_DT
restructuring_GER
._.
SFAS_NN
146_CD
requires_VPRT [SUAV]
that_THVC
a_DT
liability_NOMZ
for_PIN
a_DT
cost_NN
associated_VBN [WZPAST]
with_PIN
This_DEMO
section_NOMZ
contains_VPRT
the_DT
an_DT
exit_NN
or_CC
disposal_NN
activity_NOMZ
be_VB [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
the_DT
liability_NOMZ
is_VPRT [PASS]
incurred_VBN
._.
Under_IN
EITF_NN
94-3_CD
,_,
a_DT
liability_NOMZ
for_PIN
an_DT
exit_NN
cost_NN
was_VBD [PASS]
recognized_VBN [PRIV]
at_PIN
the_DT
date_NN
of_PIN
the_DT
commitment_NOMZ
to_PIN
an_DT
information_NOMZ
that_TOBJ
the_DT
US_FPP1
Securities_NOMZ
exit_NN
plan_NN
._.
SFAS_NN
146_CD
states_NN
that_TOBJ
a_DT
commitment_NOMZ
to_PIN
a_DT
plan_NN
,_,
by_PIN
itself_PIT
,_,
does_VPRT
not_XX0
create_VB
an_DT
obligation_NOMZ
that_TSUB
meets_VPRT
the_DT
definition_NOMZ
of_PIN
a_DT
liability_NOMZ
._.
Therefore_CONJ
,_,
SFAS_NN
146_CD
eliminates_VPRT
the_DT
and_CC
Exchange_NN
Commission_NN
requires_VPRT [SUAV]
definition_NOMZ
and_PHC
requirement_NOMZ
for_PIN
recognition_NOMZ
of_PIN
exit_NN
costs_NN
in_PIN
EITF_NN
94-3_CD
._.
It_PIT
also_RB
established_VBD [PRIV]
that_THVC
fair_JJ
value_NN
is_VPRT [BEMA]
the_DT
objective_NN
for_PIN
initial_JJ
measurement_NOMZ
of_PIN
the_DT
liability_NOMZ
._.
SFAS_NN
146_CD
is_VPRT [BEMA]
in_PIN
a_DT
Form_NN
20-F_NN
that_TSUB
does_VPRT
not_XX0
appear_VB [SMP]
to_TO
be_VB [PASS]
applied_VBN
prospectively_RB
to_PIN
exit_NN
or_CC
disposal_NN
activities_NOMZ
initiated_VBN
after_IN
31_CD
December_NN
2002_CD
._.
Management_NOMZ
does_VPRT
not_XX0
expect_VB [PRIV]
the_DT
adoption_NOMZ
of_PIN
SFAS_NN
146_CD
to_TO
have_VB
a_DT
material_NN
elsewhere_RB
in_PIN
our_FPP1
Annual_JJ
Report_NN
._.
effect_NN
on_PIN
its_PIT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
In_PIN
November_NN
2002_CD
,_,
the_DT
FASB_NN
issued_VBD
FASB_NN
Interpretation_NOMZ
Number_NN
FIN_NN
No._NN
._.
45_CD
,_,
Guarantors_NN
accounting_GER
and_PHC
disclosure_NN
requirements_NOMZ
for_PIN
guarantees_NN
,_,
including_VBG
indirect_JJ
guarantees_NN
of_PIN
indebtedness_NOMZ
of_PIN
others_NN
FIN_NN
45_CD
._.
FIN_NN
45_CD
requires_VPRT [SUAV]
the_DT
guarantor_NN
to_TO
recognize_VB [PRIV]
,_,
at_PIN
the_DT
inception_NOMZ
of_PIN
a_DT
guarantee_NN
,_,
a_DT
liability_NOMZ
for_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
obligation_NOMZ
undertaken_VBN [WZPAST]
in_PIN
issuing_VBG
the_DT
guarantee_NN
._.
It_PIT
also_RB
elaborates_VPRT
on_PIN
the_DT
disclosure_NN
to_TO
be_VB [BYPA]
made_VBN
by_PIN
a_DT
guarantor_NN
in_PIN
its_PIT
financial_JJ
statements_NOMZ
about_IN
its_PIT
obligation_NOMZ
under_IN
certain_JJ
guarantees_NN
that_TOBJ
it_PIT
has_VPRT [PEAS]
issued_VBN
and_CC
to_TO
be_VB [PASS]
made_VBN
in_PIN
regard_NN
of_PIN
product_NN
warranties_NN
._.
The_DT
initial_JJ
recognition_NOMZ
and_PHC
movement_NOMZ
provisions_NN
of_PIN
this_DEMO
interpretation_NOMZ
are_VPRT [BEMA]
applicable_PRED
on_PIN
a_DT
prospective_JJ
basis_NN
to_PIN
guarantees_NN
issued_VBN
or_CC
modified_VBN
after_IN
31_CD
December_NN
2002_CD
,_,
while_OSUB
the_DT
provisions_NN
of_PIN
the_DT
disclosure_NN
requirements_NOMZ
are_VPRT [BEMA]
effective_PRED
for_PIN
financial_JJ
statements_NOMZ
of_PIN
interim_JJ
or_CC
annual_JJ
periods_NN
ending_VBG [WZPRES]
after_IN
15_CD
December_NN
2002_CD
._.
Management_NOMZ
does_VPRT
not_XX0
expect_VB [PRIV]
the_DT
adoption_NOMZ
of_PIN
FIN_NN
45_CD
to_TO
have_VB
a_DT
material_NN
effect_NN
on_PIN
its_PIT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
In_PIN
November_NN
2002_CD
,_,
the_DT
EITF_NN
reached_VBD
a_DT
consensus_NN
on_PIN
Accounting_GER
for_PIN
revenue_NN
arrangements_NOMZ
with_PIN
multiple_JJ
deliverables_NN
Issue_NN
00-21_CD
._.
This_DEMO
addresses_NN
certain_JJ
aspects_NN
of_PIN
the_DT
accounting_GER
by_PIN
a_DT
vendor_NN
for_PIN
arrangements_NOMZ
under_IN
which_WDT
it_PIT
will_PRMD
perform_VB
multiple_JJ
revenue-generating_JJ
activities_NOMZ
._.
Specifically_RB
,_,
Issue_NN
00-21_CD
addresses_NN
how_RB
to_TO
determine_VB [SUAV] [PRIV]
whether_IN [WHCL]
an_DT
arrangement_NOMZ
involving_VBG [WZPRES]
multiple_JJ
deliverables_NN
contains_VPRT
more_EMPH
than_PIN
one_CD
unit_NN
of_PIN
accounting_GER
and_ANDC
how_RB
arrangement_NOMZ
consideration_NOMZ
should_NEMD
be_VB [PASS]
measured_VBN
and_PHC
allocated_VBN
to_PIN
the_DT
separate_JJ
units_NN
of_PIN
accounting_GER
in_PIN
the_DT
arrangement_NOMZ
._.
The_DT
provisions_NN
of_PIN
Issue_NN
00-21_CD
are_VPRT [BEMA]
effective_PRED
for_PIN
revenue_NN
arrangements_NOMZ
entered_VBD
into_PIN
in_PIN
fiscal_JJ
periods_NN
beginning_VBG [WZPRES]
after_IN
15_CD
June_NN
2003_CD
,_,
with_PIN
early_TIME
application_NOMZ
permitted_VBD
._.
Management_NOMZ
have_VPRT [PEAS]
applied_VBN
the_DT
provisions_NN
of_PIN
EITF_NN
00-21_CD
to_TO
existing_VBG
multiple_JJ
element_NOMZ
arrangements_NOMZ
._.
In_PIN
January_NN
2003_CD
,_,
the_DT
FASB_NN
issued_VBD
FIN_NN
No._NN
._.
46_CD
,_,
Consolidation_NOMZ
of_PIN
variable_JJ
interest_NN
entities_NOMZ
FIN_NN
46_CD
._.
FIN_NN
46_CD
clarifies_VPRT
the_DT
application_NOMZ
of_PIN
Accounting_GER
Research_NN
Bulletin_NN
No._NN
._.
51_CD
,_,
Consolidated_NN
financial_JJ
statements_NOMZ
,_,
to_PIN
certain_JJ
entities_NOMZ
in_PIN
which_WDT [PIRE]
equity_NOMZ
investors_NN
do_VPRT
not_XX0
have_VB
the_DT
characteristics_NN
of_PIN
a_DT
controlling_VBG
financial_JJ
interest_NN
or_CC
do_VB
not_XX0
have_VB
sufficient_JJ
equity_NOMZ
at_PIN
risk_NN
for_PIN
the_DT
entity_NOMZ
to_TO
finance_VB
its_PIT
activities_NOMZ
without_PIN
additional_JJ
subordinated_JJ
financial_JJ
support_NN
from_PIN
other_JJ
parties_NN
._.
FIN_NN
46_CD
applies_VPRT
immediately_TIME
to_PIN
variable_JJ
interest_NN
entities_NOMZ
created_VBN
after_IN
31_CD
January_NN
2003_CD
,_,
and_ANDC
to_PIN
variable_JJ
interest_NN
entities_NOMZ
in_PIN
which_WDT [PIRE]
an_DT
enterprise_NN
obtains_VPRT
an_DT
interest_NN
after_IN
that_DEMO
date_NN
._.
It_PIT
applies_VPRT
in_PIN
the_DT
first_JJ
fiscal_JJ
year_NN
or_CC
interim_JJ
period_NN
beginning_VBG [WZPRES]
after_IN
15_CD
June_NN
2003_CD
,_,
to_PIN
variable_JJ
interest_NN
entities_NOMZ
in_PIN
which_WDT [PIRE]
an_DT
enterprise_NN
holds_VPRT [PRIV]
a_DT
variable_JJ
interest_NN
that_TOBJ
it_PIT
acquired_VBD
before_IN
1_CD
February_NN
2003_CD
._.
FIN_NN
46_CD
applies_VPRT
to_PIN
public_JJ
enterprises_NN
as_IN
of_PIN
the_DT
beginning_GER
of_PIN
the_DT
applicable_JJ
interim_NN
or_CC
annual_JJ
period_NN
._.
Management_NOMZ
does_VPRT
not_XX0
expect_VB [PRIV]
the_DT
adoption_NOMZ
of_PIN
FIN_NN
46_CD
to_TO
have_VB
a_DT
material_NN
effect_NN
on_PIN
its_PIT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
FURTHER_JJ
INFORMATION_NOMZ
REQUIRED_NN
BY_PIN
FORM_NN
20-F_JJ
unaudited_JJ
Managements_NOMZ
discussion_NN
and_PHC
analysis_NN
of_PIN
financial_JJ
condition_NOMZ
and_PHC
results_NN
of_PIN
operations_NOMZ
4b_VPRT
Overview_NN
The_DT
financial_JJ
statements_NOMZ
contained_VBD
within_PIN
this_DEMO
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_NN
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
UK_NN
GAAP_NN
._.
A_DT
reconciliation_NOMZ
to_PIN
US_FPP1
GAAP_NN
is_VPRT [PASS]
set_VBN
out_PIN
in_PIN
note_NN
29_CD
to_PIN
the_DT
financial_JJ
statements_NOMZ
._.
The_DT
principal_JJ
differences_NN
between_PIN
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
accounting_GER
arise_VB
on_PIN
revenue_NN
recognition_NOMZ
timing_NN
differences_NN
which_WDT [WHSUB]
has_VPRT [PEAS]
resulted_VBN
in_PIN
lower_JJ
revenue_NN
being_VBG [WZPRES] [PASS]
recorded_VBN
under_IN
US_FPP1
GAAP_NN
in_PIN
2002_CD
which_WDT
will_PRMD
reverse_VB
in_PIN
2003_CD
and_CC
2004_CD
,_,
accounting_VBG [PRESP]
for_PIN
stock_NN
options_NOMZ
and_CC
the_DT
treatment_NOMZ
of_PIN
goodwill_NN
._.
These_DEMO
differences_NN
are_VPRT [PASS]
described_VBN
within_PIN
note_NN
29_CD
to_PIN
the_DT
financial_JJ
statements_NOMZ
._.
Critical_JJ
accounting_GER
policies_NN
The_DT
preparation_NOMZ
of_PIN
our_FPP1
financial_JJ
statements_NOMZ
requires_VPRT [SUAV]
us_FPP1
to_TO
make_VB
estimates_NN
and_PHC
judgments_NOMZ
that_TSUB
affect_VPRT
the_DT
reported_VBN [PUBV]
amount_NN
of_PIN
net_JJ
assets_NN
at_PIN
the_DT
date_NN
of_PIN
our_FPP1
financial_JJ
statements_NOMZ
and_CC
the_DT
reported_VBN [PUBV]
amounts_NN
of_PIN
revenues_NN
and_PHC
expenses_NN
during_PIN
the_DT
period_NN
._.
Critical_JJ
accounting_GER
policies_NN
are_VPRT [BEMA]
those_DEMO
that_DEMP
have_VPRT
a_DT
significant_JJ
impact_NN
on_PIN
the_DT
Group_NN
's_POS
results_NN
and_CC
require_VB [SUAV]
the_DT
most_EMPH
difficult_JJ
,_,
subjective_JJ
or_CC
complex_JJ
judgments_NOMZ
by_PIN
management_NOMZ
._.
For_PIN
a_DT
full_JJ
description_NOMZ
of_PIN
our_FPP1
accounting_GER
policies_NN
please_VB
refer_VPRT
to_TO
note_VB [PRIV]
1_CD
._.
Our_FPP1
critical_JJ
accounting_GER
policies_NN
include_VPRT
the_DT
following_GER
:_:
Revenue_NN
recognition_NOMZ
Revenue_NN
on_PIN
long-term_JJ
contracts_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
according_VBG
to_PIN
estimates_NN
by_PIN
management_NOMZ
of_PIN
the_DT
progress_NN
of_PIN
the_DT
contract_NN
and_CC
the_DT
estimated_VBN [PRIV]
total_NN
costs_NN
._.
This_DEMP
requires_VPRT [SUAV]
that_THVC
the_DT
extent_NN
of_PIN
progress_NN
towards_PIN
completion_NOMZ
of_PIN
contracts_NN
may_POMD
be_VB [PASS]
estimated_VBN [PRIV]
with_PIN
reasonable_JJ
certainty_NN
._.
Revisions_NN
in_PIN
these_DEMO
estimates_NN
may_POMD
cause_VB
the_DT
Group_NN
's_POS
revenues_NN
to_TO
fluctuate_VB
from_PIN
period_NN
to_PIN
period_NN
._.
The_DT
Group_NN
's_POS
US_FPP1
GAAP_NN
revenue_NN
recognition_NOMZ
accounting_GER
policy_NN
for_PIN
multiple_JJ
element_NOMZ
arrangements_NOMZ
,_,
which_WDT [SERE]
is_VPRT [PASS]
described_VBN
more_EMPH
fully_AMP
on_PIN
page_NN
38_CD
,_,
requires_VPRT [SUAV]
the_DT
determination_NOMZ
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
individual_JJ
elements_NOMZ
of_PIN
multiple_JJ
element_NOMZ
arrangements_NOMZ
and_CC
the_DT
allocation_NOMZ
of_PIN
the_DT
total_JJ
contract_NN
value_NN
amongst_PIN
the_DT
elements_NOMZ
identified_VBD
using_VBG
the_DT
relative_JJ
fair_JJ
value_NN
method_NN
._.
Under_IN
the_DT
Group_NN
's_POS
UK_NN
GAAP_NN
accounting_GER
policy_NN
,_,
contracts_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
as_IN
long-term_JJ
contracts_NN
and_CC
are_VPRT [BEMA]
only_DWNT
segmented_PRED
into_PIN
multiple_JJ
elements_NOMZ
where_RB
the_DT
Group_NN
is_VPRT [BEMA]
capable_PRED
of_PIN
attributing_VBG
a_DT
reliable_JJ
fair_JJ
value_NN
to_PIN
each_QUAN
element_NOMZ
by_PIN
reference_NN
to_PIN
individual_JJ
transactions_NOMZ
which_WDT [WHSUB]
might_POMD
be_VB [BEMA]
the_DT
case_NN
,_,
for_CONJ
instance_NULL
,_,
where_RB
separate_JJ
tenders_NN
were_VBD [PASS]
submitted_VBN [PUBV]
for_PIN
each_QUAN
element_NOMZ
._.
The_DT
Group_NN
therefore_CONJ
makes_VPRT
significant_JJ
judgments_NOMZ
in_PIN
determining_VBG [SUAV] [PRIV]
whether_IN [WHCL]
a_DT
particular_JJ
multiple_JJ
element_NOMZ
arrangement_NOMZ
is_VPRT [BEMA]
capable_PRED
of_PIN
segmentation_NOMZ
under_IN
the_DT
requirements_NOMZ
of_PIN
US_FPP1
GAAP_NN
and_CC
following_VBG
best_JJ
practice_NN
under_IN
UK_NN
GAAP_NN
._.
Where_RB
,_,
under_IN
US_FPP1
GAAP_NN
,_,
segmentation_NOMZ
is_VPRT [PASS]
required_VBN [SUAV]
,_,
significant_JJ
assumptions_NOMZ
are_VPRT [PASS]
made_VBN
in_PIN
selecting_VBG
appropriate_JJ
similar_JJ
contracts_NN
to_TO
provide_VB
evidence_NN
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
individual_JJ
elements_NOMZ
._.
Changes_NN
in_PIN
estimates_NN
of_PIN
fair_JJ
value_NN
of_PIN
elements_NOMZ
in_PIN
an_DT
arrangement_NOMZ
would_PRMD
have_VB
a_DT
significant_JJ
impact_NN
on_PIN
the_DT
timing_NN
of_PIN
revenue_NN
recognition_NOMZ
._.
Differences_NN
in_PIN
revenue_NN
recognition_NOMZ
policies_NN
under_IN
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
give_VPRT
rise_NN
to_PIN
a_DT
significant_JJ
reconciling_GER
adjustment_NOMZ
._.
The_DT
size_NN
and_PHC
direction_NOMZ
of_PIN
this_DEMO
reconciling_GER
amount_NN
in_PIN
the_DT
reconciliation_NOMZ
of_PIN
UK_NN
to_PIN
US_FPP1
GAAP_NN
net_JJ
income_NN
will_PRMD
vary_VB
considerably_RB
from_PIN
period_NN
to_PIN
period_NN
based_VBN [WZPAST]
on_PIN
the_DT
nature_NN
of_PIN
contract_NN
activity_NOMZ
in_PIN
the_DT
period_NN
._.
Deferred_JJ
tax_NN
The_DT
Group_NN
has_VPRT
significant_JJ
brought_VBN
forward_RB
operating_VBG
losses_NN
in_PIN
a_DT
particular_JJ
tax_NN
jurisdiction_NOMZ
,_,
against_PIN
which_WDT [PIRE]
,_,
at_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
Group_NN
has_VPRT [PEAS]
maintained_VBN [PUBV]
a_DT
full_JJ
valuation_NOMZ
allowance_NN
._.
In_PIN
determining_VBG [SUAV] [PRIV]
the_DT
appropriateness_NOMZ
of_PIN
this_DEMO
valuation_NOMZ
allowance_NN
,_,
estimates_NN
are_VPRT [PASS]
made_VBN
of_PIN
the_DT
Group_NN
's_POS
ability_NOMZ
to_TO
use_VB
these_DEMO
losses_NN
,_,
based_VBN [PASTP]
on_PIN
the_DT
estimated_VBN [PRIV]
taxable_JJ
profit_NN
or_CC
loss_NN
in_PIN
that_DEMO
jurisdiction_NOMZ
,_,
which_WDT [SERE]
include_VPRT
estimates_NN
of_PIN
future_JJ
revenues_NN
and_PHC
costs_NN
,_,
as_RB
well_RB
as_IN
the_DT
jurisdiction_NOMZ
in_PIN
which_WDT [PIRE]
they_TPP3
will_PRMD
arise_VB
._.
Revisions_NN
in_PIN
these_DEMO
estimates_NN
may_POMD
cause_VB
the_DT
valuation_NOMZ
allowance_NN
recorded_VBN
and_CC
the_DT
Group_NN
's_POS
tax_NN
charge_NN
to_TO
fluctuate_VB
from_PIN
period_NN
to_PIN
period_NN
._.
Valuation_NOMZ
of_PIN
long-lived_JJ
assets_NN
and_PHC
goodwill_NN
Depreciation_NOMZ
and_PHC
amortisation_NOMZ
rates_NN
are_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
based_VBN
on_PIN
management_NOMZ
estimates_NN
of_PIN
the_DT
expected_VBN [PRIV]
useful_JJ
economic_JJ
lives_NN
of_PIN
the_DT
assets_NN
concerned_VBN
._.
The_DT
most_EMPH
appropriate_JJ
life_NN
is_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
separately_RB
for_PIN
each_QUAN
asset_NN
on_PIN
acquisition_NOMZ
,_,
subject_JJ
to_TO
prescribed_VBN
ranges_NN
of_PIN
asset_NN
lives_NN
,_,
as_IN
disclosed_VBN [PUBV]
in_PIN
note_NN
1_CD
to_PIN
the_DT
financial_JJ
statements_NOMZ
._.
Changes_NN
to_PIN
the_DT
useful_JJ
lives_NN
selected_VBN
could_POMD
have_VB
a_DT
material_NN
impact_NN
on_PIN
the_DT
Group_NN
's_POS
net_JJ
profit_NN
._.
The_DT
Group_NN
assesses_VPRT
the_DT
carrying_VBG
value_NN
of_PIN
long-lived_JJ
assets_NN
and_PHC
goodwill_NN
whenever_RB
events_NN
or_CC
changes_NN
in_PIN
circumstances_NN
indicate_VPRT [PRIV]
that_THVC
such_JJ
carrying_VBG
value_NN
may_POMD
not_XX0
be_VB [BEMA]
recoverable_PRED
._.
When_RB
we_FPP1
determine_VPRT [SUAV] [PRIV]
that_THVC
the_DT
carrying_VBG
value_NN
of_PIN
long-lived_JJ
assets_NN
and_PHC
goodwill_NN
may_POMD
not_XX0
be_VB [BEMA]
recoverable_PRED
,_,
we_FPP1
measure_VPRT
any_QUAN
impairment_NOMZ
based_VBN [WZPAST]
on_PIN
a_DT
projected_VBN
discounted_JJ
cash_NN
flow_NN
method_NN
using_VBG [WZPRES]
a_DT
discount_NN
rate_NN
determined_VBN [SUAV] [PRIV] [WZPAST]
by_PIN
our_FPP1
management_NOMZ
to_TO
be_VB [BEMA]
commensurate_PRED
with_PIN
the_DT
risk_NN
inherent_JJ
in_PIN
our_FPP1
current_JJ
business_NOMZ
model_NN
._.
This_DEMO
review_NN
is_VPRT [PASS]
based_VBN
upon_PIN
our_FPP1
projections_NOMZ
of_PIN
anticipated_JJ
timing_NN
and_PHC
amount_NN
of_PIN
future_JJ
cash_NN
flows_NN
and_CC
appropriate_JJ
discount_NN
rates_NN
._.
While_OSUB
we_FPP1
believe_VPRT [PRIV]
that_THVC
our_FPP1
assumptions_NOMZ
are_VPRT [BEMA]
appropriate_PRED
,_,
such_JJ
estimates_NN
and_PHC
assumptions_NOMZ
could_POMD
differ_VB
materially_RB
from_PIN
actual_JJ
results_NN
and_CC
accordingly_RB
result_VB
in_PIN
a_DT
material_NN
impact_NN
on_PIN
the_DT
carrying_VBG
value_NN
of_PIN
long-lived_JJ
assets_NN
and_PHC
goodwill_NN
._.
5a_JJ
Results_NN
of_PIN
operations_NOMZ
5d_VBD
The_DT
information_NOMZ
contained_VBD
within_PIN
the_DT
financial_JJ
review_NN
on_PIN
pages_NN
14_CD
and_CC
15_CD
covers_VPRT
the_DT
results_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
prepared_VBN
under_IN
UK_NN
GAAP_NN
compared_VBD
to_PIN
the_DT
prior_JJ
year_NN
ended_VBD
31_CD
December_NN
2001_CD
._.
The_DT
following_VBG
information_NOMZ
compares_VPRT
the_DT
results_NN
under_IN
UK_NN
GAAP_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2001_CD
to_PIN
the_DT
prior_JJ
year_NN
ended_VBD
31_CD
December_NN
2000_CD
,_,
and_ANDC
the_DT
Groups_NN
financial_JJ
position_NOMZ
at_PIN
31_CD
December_NN
2002_CD
and_CC
2001_CD
._.
2001_CD
year_NN
versus_PIN
2000_CD
year_NN
The_DT
financial_JJ
results_NN
for_PIN
the_DT
year_NN
2000_CD
include_VPRT
data_NN
for_PIN
the_DT
three-month_JJ
period_NN
ended_VBD
31_CD
March_NN
2000_CD
for_PIN
the_DT
discontinued_VBN
operation_NOMZ
of_PIN
Mimetrix_NN
Limited_NN
._.
Turnover_NN
for_PIN
the_DT
year_NN
2001_CD
was_VBD [BEMA]
8.9_CD
m_NN [BEMA]
2000_CD
6.3_CD
m_NN
,_,
which_WDT [SERE]
comprised_VBD
R&D_NN
funding_VBG [WZPRES]
primarily_RB
from_PIN
ongoing_JJ
contracts_NN
with_PIN
the_DT
CDC_NN
and_PHC
Aventis_NN
Pasteur_NN
._.
The_DT
increase_NN
in_PIN
revenues_NN
reflects_VPRT [PRIV]
a_DT
full_JJ
year_NN
of_PIN
revenue_NN
receivable_NN
from_PIN
the_DT
first_JJ
contract_NN
with_PIN
the_DT
CDC_NN
in_PIN
2001_CD
compared_VBN
to_TO
only_DWNT
three_CD
months_NN
in_PIN
2000_CD
._.
5c_JJ
Expenditure_NN
on_PIN
R&D_NN
increased_VBD
in_PIN
2001_CD
to_PIN
17.7_CD
m_NN [BEMA]
2000_CD
12.7_CD
m._FW
There_EX
was_VBD
an_DT
increase_NN
in_PIN
the_DT
number_NN
of_PIN
product_NN
programs_NN
,_,
each_QUAN
of_PIN
which_WDT [PIRE]
has_VPRT [PEAS]
continued_VBN
to_TO
advance_VB
towards_PIN
the_DT
next_JJ
stage_NN
of_PIN
development_NOMZ
and_CC
or_CC
clinical_JJ
trials_NN
._.
Our_FPP1
share_NN
of_PIN
the_DT
expenditure_NN
on_PIN
the_DT
H._NN
pylori_NN
joint_JJ
venture_NN
with_PIN
Aventis_NN
Pasteur_NN
was_VBD [BEMA]
lower_PRED
in_PIN
2001_CD
at_PIN
0.4_CD
m_NN [BEMA]
2000_CD
2.1_CD
m_NN
,_,
as_IN
expenditure_NN
on_PIN
the_DT
project_NN
was_VBD [SPAU] [PASS]
largely_RB
restricted_VBN
to_TO
continuing_VBG
a_DT
number_NN
of_PIN
small_JJ
clinical_JJ
trials_NN
._.
43_CD
44_CD
FURTHER_NN
INFORMATION_NOMZ
REQUIRED_NN
BY_PIN
FORM_NN
20-F_JJ
unaudited_JJ
Results_NN
of_PIN
operations_NOMZ
continued_VBD
Administrative_JJ
costs_NN
increased_VBN [WZPAST]
during_PIN
2001_CD
to_PIN
3.5_CD
m_NN [BEMA]
2000_CD
2.9_CD
m_NN
,_,
primarily_RB
as_CONJ
a_NULL
result_NULL
of_PIN
expansion_NN
of_PIN
the_DT
Companys_NN
activities_NOMZ
,_,
in_CONJ
particular_NULL
the_DT
reactivation_NOMZ
of_PIN
the_DT
manufacturing_GER
facility_NOMZ
._.
Administrative_JJ
costs_NN
include_VPRT
1.2_CD
m_JJ [BEMA]
2000_CD
1.2_CD
m_NN [BEMA]
of_PIN
amortisation_NOMZ
of_PIN
the_DT
goodwill_NN
which_WDT [WHSUB]
arose_VBD
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
of_PIN
Acambis_NN
Inc._NN
in_PIN
1999_CD
._.
Interest_NN
receivable_NN
decreased_VBD
marginally_RB
to_PIN
0.9_CD
m_NN [BEMA]
in_PIN
2001_CD
2000_CD
1.0_CD
m_NN
,_,
primarily_RB
as_CONJ
a_NULL
result_NULL
of_PIN
lower_JJ
rates_NN
of_PIN
interest_NN
available_JJ
in_PIN
the_DT
period_NN
._.
Interest_NN
payable_JJ
of_PIN
0.2_CD
m_NN [BEMA]
2000_CD
0.2_CD
m_NN
,_,
relating_VBG [PRESP]
entirely_AMP
to_PIN
the_DT
Arilvax_NN
overdraft_NN
facility_NOMZ
,_,
remained_VBD
constant_JJ
._.
During_PIN
2001_CD
,_,
an_DT
exchange_NN
loss_NN
of_PIN
0.1_CD
m_NN [BEMA]
2000_CD
0.3_CD
m_NN [PASS]
arose_VBD
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
revaluation_NOMZ
of_PIN
the_DT
amount_NN
outstanding_JJ
under_IN
the_DT
US_FPP1
dollar-denominated_JJ
Arilvax_NN
facility_NOMZ
._.
In_PIN
accordance_NN
with_PIN
FRS_NN
11_CD
,_,
Impairment_NOMZ
of_PIN
Fixed_NN
Assets_NN
and_PHC
Goodwill_NN
,_,
during_PIN
2001_CD
the_DT
Group_NN
recorded_VBD
an_DT
exceptional_JJ
loss_NN
of_PIN
0.4_CD
m_NN [BEMA]
2000_CD
0.7_CD
m_NN
relating_VBG [WZPRES]
to_PIN
the_DT
impairment_NOMZ
write-down_NN
of_PIN
the_DT
investment_NOMZ
held_VBN [PRIV] [WZPAST]
in_PIN
Medivir_NN
AB_NN
,_,
which_WDT [SERE]
the_DT
Group_NN
acquired_VBD
on_PIN
the_DT
sale_NN
of_PIN
the_DT
Mimetrix_NN
business_NOMZ
in_PIN
2000_CD
._.
During_PIN
2001_CD
,_,
the_DT
Group_NN
elected_VBD
to_TO
claim_VB [PUBV]
an_DT
R&D_NN
tax_NN
credit_NN
of_PIN
0.1_CD
m_NN [BEMA]
2000_CD
nil_NN
in_PIN
relation_NOMZ
to_TO
qualifying_VBG
R&D_NN
expenditure_NN
in_PIN
the_DT
UK_NN
._.
The_DT
net_JJ
loss_NN
for_PIN
the_DT
year_NN
increased_VBD
to_PIN
12.4_CD
m_NN [BEMA]
2000_CD
11.1_CD
m_NN
,_,
primarily_RB
as_CONJ
a_NULL
result_NULL
of_PIN
increased_VBN
R&D_NN
and_CC
operating_VBG
costs_NN
at_PIN
the_DT
new_JJ
Massachusetts_NN
manufacturing_GER
facility_NOMZ
,_,
both_DT
of_PIN
which_WDT [PIRE]
were_VBD [SPAU] [BYPA]
largely_RB
offset_VBN
by_PIN
increased_VBN
turnover_NN
._.
Liquidity_NOMZ
and_PHC
capital_NN
resources_NN
4b_VPRT
5b_JJ
The_DT
Group_NN
had_VBD
aggregate_JJ
cash_NN
and_CC
liquid_JJ
resources_NN
of_PIN
11.8_CD
m_NN [BEMA]
at_PIN
31_CD
December_NN
2002_CD
2001_CD
22.2_CD
m_NN
,_,
a_DT
decrease_NN
of_PIN
10.4_CD
m_NN
since_OSUB
the_DT
start_NN
of_PIN
the_DT
year_NN
2001_CD
increase_NN
of_PIN
1.1_CD
m._FW
During_PIN
the_DT
year_NN
,_,
Acambis_NN
received_VBD
7.7_CD
m_NN [BEMA]
2001_CD
4.3_CD
m_NN [BEMA]
from_PIN
the_DT
issue_NN
of_PIN
new_JJ
shares_NN
,_,
primarily_RB
being_VBG [BEMA]
attributable_PRED
to_PIN
the_DT
net_JJ
proceeds_NN
receivable_NN
from_PIN
the_DT
third_JJ
equity_NOMZ
subscription_NOMZ
for_PIN
new_JJ
shares_NN
by_PIN
Baxter_NN
._.
Cash_NN
used_VBN [WZPAST]
by_PIN
operations_NOMZ
during_PIN
the_DT
year_NN
,_,
principally_RB
to_TO
support_VB
R&D_NN
,_,
was_VBD [BEMA]
6.2_CD
m_NN [BEMA]
2001_CD
8.0_CD
m._NN
During_PIN
2002_CD
,_,
Acambis_NN
made_VBD
additions_NOMZ
of_PIN
short_JJ
leasehold_JJ
land_NN
and_PHC
buildings_GER
of_PIN
5.0_CD
m_NN [BEMA]
2001_CD
6.9_CD
m_NN
,_,
2000_CD
0.2_CD
m_NN
,_,
acquired_VBD
4.5_CD
m_NN [BEMA]
of_PIN
laboratory_NN
and_PHC
manufacturing_GER
equipment_NOMZ
2001_CD
2.7_CD
m_NN
,_,
2000_CD
0.1_CD
m_NN
and_CC
1.2_CD
m_NN [BEMA]
of_PIN
office_NN
equipment_NOMZ
2001_CD
0.4_CD
m_NN
,_,
2000_CD
0.1_CD
m._NN
Additions_NOMZ
in_PIN
2002_CD
and_CC
2001_CD
were_VBD [BEMA]
primarily_RB
in_PIN
relation_NOMZ
to_PIN
the_DT
reactivation_NOMZ
of_PIN
our_FPP1
manufacturing_GER
facility_NOMZ
._.
From_PIN
incorporation_NOMZ
through_PIN
to_PIN
31_CD
December_NN
2002_CD
,_,
Acambis_NN
has_VPRT [PEAS]
financed_VBN
its_PIT
operations_NOMZ
primarily_RB
from_PIN
equity_NOMZ
issuances_NN
totalling_VBG [WZPRES]
85.3_CD
m_NN
,_,
licence_NN
fees_NN
and_PHC
milestone_NN
payments_NOMZ
totalling_VBG [WZPRES]
3.1_CD
m_NN
,_,
R&D_NN
contract_NN
fees_NN
and_PHC
sales_NN
of_PIN
product_NN
totalling_VBG [WZPRES]
101.6_CD
m_NN
and_PHC
government_NOMZ
grants_NN
totalling_VBG [WZPRES]
3.9_CD
m._FW
At_PIN
31_CD
December_NN
2002_CD
,_,
Acambis_NN
held_VBD [PRIV]
investments_NOMZ
in_PIN
Medivir_NN
AB_NN
market_NN
value_NN
at_PIN
31_CD
December_NN
2002_CD
of_PIN
0.3_CD
m_NN
,_,
2001_CD
0.4_CD
m_NN
and_CC
in_PIN
Acambis_NN
ordinary_JJ
shares_NN
through_PIN
Acambis_NN
Employee_NN
Share_NN
Ownership_NN
Trust_NN
market_NN
value_NN
at_PIN
31_CD
December_NN
2002_CD
of_PIN
1.6_CD
m_NN
,_,
2001_CD
2.5_CD
m._FW
Under_IN
the_DT
terms_NN
of_PIN
the_DT
strategic_JJ
alliance_NN
set_VBN
up_RP
with_PIN
Baxter_NN
in_PIN
2000_CD
,_,
the_DT
Group_NN
has_VPRT [PEAS]
received_VBN
cash_NN
of_PIN
7.0_CD
m_NN [BEMA]
in_PIN
2002_CD
2001_CD
3.5_CD
m_NN
,_,
2000_CD
10.4_CD
m_NN [BEMA]
in_PIN
exchange_NN
for_PIN
new_JJ
shares_NN
in_PIN
Acambis_NN
._.
On_PIN
27_CD
March_NN
2003_CD
,_,
the_DT
Group_NN
issued_VBD
4.6_CD
million_CD
new_JJ
shares_NN
in_PIN
relation_NOMZ
to_PIN
the_DT
final_JJ
subscription_NOMZ
to_PIN
Baxter_NN
._.
At_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
balance_NN
on_PIN
the_DT
Arilvax_NN
overdraft_NN
facility_NOMZ
was_VBD [BEMA]
4.3_CD
m_NN
$_$
7.0_CD
m_NN [BEMA]
2001_CD
4.8_CD
m_NN
,_,
2000_CD
4.7_CD
m._NN
At_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
Group_NN
did_VBD
not_XX0
have_VB
any_QUAN
undrawn_JJ
borrowing_GER
facilities_NOMZ
in_PIN
respect_NN
of_PIN
this_DEMO
overdraft_NN
facility_NOMZ
2001_CD
nil_NN
,_,
2000_CD
nil_NN
._.
Given_VBN
certain_JJ
circumstances_NN
,_,
this_DEMO
facility_NOMZ
which_WDT [WHSUB]
is_VPRT [SPAU] [PASS]
fully_AMP
described_VBN
in_PIN
note_NN
d_SYM
on_PIN
page_NN
46_CD
,_,
Evans_NN
Vaccines_NN
agreement_NOMZ
,_,
may_POMD
be_VB [BEMA]
repayable_PRED
within_PIN
one_CD
year_NN
._.
In_PIN
December_NN
2001_CD
,_,
the_DT
Group_NN
secured_VBN
lease_NN
financing_GER
for_PIN
up_RB
to_TO
$_$
40m_CD
c._NN
28m_CD
with_PIN
Baxter_NN
in_PIN
respect_NN
of_PIN
Acambis_NN
manufacturing_VBG [WZPRES]
facility_NOMZ
._.
At_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
Group_NN
had_VBD
an_DT
outstanding_JJ
liability_NOMZ
of_PIN
14.0_CD
m_NN
$_$
22.5_CD
m_NN
under_IN
this_DEMO
financing_GER
facility_NOMZ
2001_CD
14.3_CD
m_NN
,_,
2000_CD
nil_NN
._.
At_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
Group_NN
had_VBD
$_$
17.5_CD
m_NN
c._NN
10.9_CD
m_NN [BEMA]
undrawn_JJ
borrowing_GER
facilities_NOMZ
in_PIN
respect_NN
of_PIN
this_DEMO
financing_GER
facility_NOMZ
2001_CD
13.2_CD
m_NN
,_,
2000_CD
nil_NN
._.
The_DT
repayment_NOMZ
terms_NN
of_PIN
this_DEMO
facility_NOMZ
are_VPRT [PASS]
described_VBN
in_PIN
note_NN
18_CD
._.
The_DT
Group_NN
does_VPRT
not_XX0
have_VB
any_QUAN
other_JJ
financial_JJ
liabilities_NOMZ
._.
Since_OSUB
inception_NOMZ
,_,
Acambis_NN
cash_NN
expenditures_NN
have_VPRT [PEAS]
exceeded_VBN
revenues_NN
on_PIN
an_DT
annualised_JJ
basis_NN
._.
Acambis_NN
future_JJ
capital_NN
requirements_NOMZ
will_PRMD
depend_VB
on_PIN
many_QUAN
factors_NN
,_,
including_VBG
,_,
but_CC
not_XX0
limited_VBN
to_TO
,_,
the_DT
expenditure_NN
required_VBN [SUAV]
to_TO
maintain_VB [PUBV]
the_DT
manufacturing_GER
facility_NOMZ
,_,
the_DT
progress_NN
of_PIN
R&D_NN
programs_NN
,_,
pre-clinical_JJ
and_PHC
clinical_JJ
testing_GER
,_,
the_DT
time_NN
and_PHC
costs_NN
involved_VBN [WZPAST]
in_PIN
obtaining_VBG
regulatory_JJ
approvals_NN
,_,
the_DT
cost_NN
of_PIN
filing_NN
,_,
prosecuting_VBG
and_PHC
enforcing_VBG
any_QUAN
patent_NN
claims_NN
and_CC
other_JJ
intellectual_JJ
property_NN
rights_NN
,_,
competing_VBG
technological_JJ
and_CC
market_NN
developments_NOMZ
,_,
changes_NN
in_PIN
Acambis_NN
existing_VBG [WZPRES]
research_NN
relationships_NN
,_,
the_DT
ability_NOMZ
of_PIN
Acambis_NN
to_TO
establish_VB [PRIV]
collaborative_JJ
arrangements_NOMZ
,_,
receipt_NN
of_PIN
any_QUAN
licence_NN
fees_NN
and_PHC
royalties_NN
and_CC
the_DT
acquisition_NOMZ
of_PIN
additional_JJ
facilities_NOMZ
and_PHC
capital_NN
expenditure_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
$_$
40m_CD
c._NN
28m_JJ
lease-financing_GER
facility_NOMZ
secured_VBN [WZPAST]
in_PIN
December_NN
2001_CD
and_CC
the_DT
award_NN
of_PIN
the_DT
second_JJ
US_FPP1
Government_NOMZ
smallpox_NN
vaccine_NN
contract_NN
in_PIN
November_NN
2001_CD
,_,
Acambis_NN
believes_VPRT [PRIV]
that_THVC
there_EX
will_PRMD
be_VB
sufficient_JJ
cash_NN
to_TO
fund_VB
its_PIT
operations_NOMZ
through_PIN
2003_CD
._.
Changes_NN
in_PIN
R&D_NN
plans_NN
or_CC
other_JJ
events_NN
affecting_VBG [WZPRES]
Acambis_NN
operations_NOMZ
,_,
however_CONJ
,_,
may_POMD
result_VB
in_PIN
accelerated_VBN
or_CC
unexpected_JJ
expenditures_NN
._.
If_COND
additional_JJ
funds_NN
are_VPRT [BYPA]
raised_VBN
by_PIN
issuing_VBG
equity_NOMZ
securities_NOMZ
,_,
dilution_NOMZ
to_TO
existing_VBG
shareholders_NN
may_POMD
result_VB
and_CC
future_JJ
investors_NN
may_POMD
be_VB [PASS]
granted_VBN [SUAV]
rights_NN
superior_JJ
to_PIN
those_DEMO
of_PIN
existing_VBG
shareholders_NN
._.
5c_JJ
Collaboration_NOMZ
agreements_NOMZ
10c_VPRT
a_DT
US_FPP1
CDC_NN
agreements_NOMZ
The_DT
Group_NN
has_VPRT [PEAS]
been_VBN [PASS]
awarded_VBN
two_CD
distinct_JJ
contracts_NN
Contract_NN
1_CD
and_CC
Contract_NN
2_CD
by_PIN
the_DT
CDC_NN
to_TO
develop_VB
and_PHC
manufacture_VB
smallpox_NN
vaccines_NN
for_PIN
the_DT
purposes_NN
of_PIN
countering_VBG
the_DT
threat_NN
of_PIN
bioterrorism_NN
._.
Contract_NN
1_CD
This_DEMO
contract_NN
was_VBD [PASS]
awarded_VBN
in_PIN
September_NN
2000_CD
,_,
and_ANDC
incorporates_VPRT
two_CD
elements_NOMZ
._.
First_RB
,_,
to_TO
develop_VB
a_DT
new_JJ
smallpox_NN
vaccine_NN
and_CC
,_,
second_JJ
,_,
to_TO
produce_VB
and_PHC
maintain_VB [PUBV]
a_DT
stockpile_NN
of_PIN
vaccine_NN
doses_NN
._.
At_PIN
the_DT
time_NN
of_PIN
the_DT
initial_JJ
award_NN
,_,
the_DT
estimated_VBN [PRIV]
value_NN
of_PIN
the_DT
20-year_JJ
contract_NN
was_VBD
$_$
343m_CD
._.
This_DEMO
value_NN
made_VBD
certain_JJ
assumptions_NOMZ
concerning_VBG [WZPRES]
price_NN
per_PIN
dose_NN
,_,
the_DT
shelf-life_NN
of_PIN
the_DT
vaccine_NN
and_CC
that_THVC
a_DT
40_CD
milliondose_JJ
stockpile_NN
of_PIN
the_DT
vaccine_NN
would_PRMD
be_VB [PASS]
produced_VBN
and_PHC
maintained_VBN [PUBV]
for_PIN
20_CD
years_NN
._.
Following_VBG [PRESP]
the_DT
terrorist_JJ
events_NN
of_PIN
11_CD
September_NN
2001_CD
,_,
the_DT
CDC_NN
issued_VBD
a_DT
change_NN
order_NN
,_,
increasing_VBG [PRESP]
the_DT
number_NN
of_PIN
doses_NN
to_TO
be_VB [PASS]
delivered_VBN
from_PIN
40_CD
million_CD
to_PIN
54_CD
million_CD
._.
The_DT
Group_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
sustain_VB
a_DT
production_NOMZ
capability_NOMZ
throughout_PIN
the_DT
20-year_JJ
life_NN
of_PIN
the_DT
contract_NN
,_,
both_DT
to_TO
replace_VB
outdated_JJ
doses_NN
and_CC
to_TO
be_VB [BEMA]
able_PRED
to_TO
respond_VB
to_TO
increased_VBN
demand_NN
as_IN
required_VBN [SUAV]
._.
The_DT
exclusive_JJ
commercial_JJ
rights_NN
to_PIN
the_DT
smallpox_NN
vaccine_NN
developed_VBN
under_IN
this_DEMO
contract_NN
with_PIN
the_DT
CDC_NN
are_VPRT [BYPA]
retained_VBN
by_PIN
Acambis_NN
._.
During_PIN
2002_CD
,_,
the_DT
Group_NN
recorded_VBD
turnover_NN
of_PIN
17.7_CD
m_NN [BEMA]
2001_CD
5.7_CD
m_NN
,_,
2000_CD
0.6_CD
m_NN [BEMA]
for_PIN
R&D_NN
costs_NN
incurred_VBN [WZPAST]
by_PIN
the_DT
Group_NN
and_CC
funded_VBN
by_PIN
the_DT
CDC_NN
._.
Contract_NN
2_CD
In_PIN
November_NN
2001_CD
,_,
Acambis_NN
was_VBD [PASS]
awarded_VBN
a_DT
second_JJ
contract_NN
by_PIN
the_DT
CDC_NN
to_TO
develop_VB
,_,
manufacture_VB
,_,
deliver_VB
and_PHC
store_VB
155_CD
million_CD
doses_NN
of_PIN
smallpox_NN
vaccine_NN
._.
The_DT
value_NN
of_PIN
this_DEMO
contract_NN
,_,
which_WDT [SERE]
carries_VPRT
a_DT
fixed_JJ
price_NN
,_,
is_VPRT
$_$
428m_CD
c._NN
270m_NN
._.
Contract_NN
2_CD
is_VPRT [PASS]
divided_VBN
into_PIN
two_CD
principal_JJ
components_NN
:_:
funding_GER
to_TO
take_VB
the_DT
vaccine_NN
through_PIN
clinical_JJ
trials_NN
to_PIN
US_FPP1
FDA_NN
licensure_NN
:_:
and_ANDC
manufacture_NN
of_PIN
the_DT
vaccine_NN
._.
The_DT
funding_GER
for_PIN
the_DT
R&D_NN
element_NOMZ
will_PRMD
be_VB [PASS]
received_VBN
over_IN
2002_CD
and_CC
2003_CD
,_,
whereas_OSUB
the_DT
funding_GER
for_PIN
the_DT
manufacture_NN
will_PRMD
be_VB [PASS]
received_VBN
on_PIN
delivery_NN
of_PIN
the_DT
vaccine_NN
,_,
which_WDT [SERE]
started_VBD
during_PIN
2002_CD
and_CC
is_VPRT
continuing_VBG
into_PIN
2003_CD
._.
Turnover_NN
has_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
in_PIN
2002_CD
in_PIN
relation_NOMZ
to_PIN
this_DEMO
contract_NN
of_PIN
58.2_CD
m_NN [BEMA]
2001_CD
nil_NN
,_,
2000_CD
nil_NN
._.
b_NN
Baxter_NN
agreements_NOMZ
In_PIN
December_NN
2000_CD
,_,
Acambis_NN
entered_VBD
into_PIN
the_DT
following_VBG
series_NN
of_PIN
agreements_NOMZ
with_PIN
Baxter_NN
:_:
Baxter_NN
has_VPRT [PEAS]
invested_VBN
27.8_CD
m_NN [BEMA]
in_PIN
new_JJ
Acambis_NN
equity_NOMZ
._.
This_DEMO
subscription_NOMZ
was_VBD [BEMA]
payable_PRED
in_PIN
four_CD
instalments_NOMZ
between_PIN
December_NN
2000_CD
and_CC
,_,
at_PIN
the_DT
latest_JJ
,_,
June_NN
2003_CD
at_PIN
an_DT
average_JJ
price_NN
of_PIN
130p_CD
per_PIN
share_NN
._.
The_DT
first_JJ
instalment_NOMZ
of_PIN
10.4_CD
m_NN [PASS]
was_VBD [PASS]
made_VBN
in_PIN
December_NN
2000_CD
,_,
the_DT
second_JJ
instalment_NOMZ
of_PIN
3.5_CD
m_NN [PASS]
was_VBD [PASS]
made_VBN
in_PIN
June_NN
2001_CD
and_CC
the_DT
third_JJ
instalment_NOMZ
of_PIN
7.0_CD
m_NN [PASS]
was_VBD [PASS]
made_VBN
in_PIN
June_NN
2002_CD
._.
The_DT
fourth_JJ
and_PHC
final_JJ
instalment_NOMZ
totalling_VBG [WZPRES]
7.0_CD
m_NN [PASS]
was_VBD [PASS]
made_VBN
on_PIN
27_CD
March_NN
2003_CD
:_:
Acambis_NN
has_VPRT
the_DT
exclusive_JJ
rights_NN
to_TO
manufacture_VB
components_NN
of_PIN
certain_JJ
of_PIN
Baxters_NN
vaccines_NN
at_PIN
Acambis_NN
manufacturing_VBG [WZPRES]
facility_NOMZ
:_:
Acambis_NN
granted_VBD [SUAV]
Baxter_NN
an_DT
option_NOMZ
to_TO
be_VB [BEMA]
its_PIT
marketing_GER
partner_NN
for_PIN
the_DT
yellow_JJ
fever_NN
vaccine_NN
,_,
Arilvax_NN
,_,
in_PIN
the_DT
US_FPP1
subject_NN
to_PIN
approval_NN
from_PIN
PowderJect_NN
Pharmaceuticals_NN
plc_NN
PowderJect_NN
:_:
and_ANDC
Baxter_NN
licensed_VBD
to_PIN
Acambis_NN
the_DT
rights_NN
to_TO
use_VB
Baxters_NN
novel_NN
Vero-cell_NN
technology_NN
in_PIN
exchange_NN
for_PIN
royalty_NN
payments_NOMZ
to_PIN
Baxter_NN
._.
This_DEMO
currently_RB
applies_VPRT
to_PIN
the_DT
production_NOMZ
of_PIN
Acambis_NN
ChimeriVax-JE_NN
,_,
ChimeriVax-West_NN
Nile_NN
and_CC
smallpox_JJ
vaccines_NN
._.
Under_IN
the_DT
terms_NN
of_PIN
the_DT
agreement_NOMZ
entered_VBD
into_PIN
in_PIN
December_NN
2000_CD
,_,
in_PIN
2002_CD
,_,
the_DT
Group_NN
received_VBD
income_NN
of_PIN
1.3_CD
m_NN [BEMA]
2001_CD
nil_NN
in_PIN
relation_NOMZ
to_PIN
Baxters_NN
share_NN
of_PIN
the_DT
commissioning_VBG
of_PIN
Acambis_NN
manufacturing_GER
plant_NN
._.
This_DEMO
income_NN
has_VPRT [PEAS]
been_VBN [PASS]
netted_VBN
off_PIN
against_PIN
R&D_NN
costs_NN
on_PIN
the_DT
face_NN
of_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
No_SYNE
turnover_NN
was_VBD [PASS]
recorded_VBN
in_PIN
2002_CD
2001_CD
nil_NN
,_,
2000_CD
nil_NN
under_IN
this_DEMO
agreement_NOMZ
._.
In_PIN
November_NN
2001_CD
,_,
Acambis_NN
entered_VBD
into_PIN
a_DT
sub-contract_JJ
with_PIN
Baxter_NN
for_PIN
the_DT
purchase_NN
of_PIN
crude_JJ
bulk_NN
smallpox_NN
vaccine_NN
and_CC
the_DT
subsequent_JJ
assembly_NN
of_PIN
various_JJ
components_NN
into_PIN
multi-dose_JJ
kits_NN
of_PIN
smallpox_NN
vaccine_NN
._.
In_PIN
December_NN
2001_CD
,_,
Acambis_NN
entered_VBD
into_PIN
a_DT
long-term_JJ
lease-finance_NN
facility_NOMZ
with_PIN
Baxter_NN
in_PIN
respect_NN
of_PIN
Acambis_NN
manufacturing_GER
plant_NN
._.
Further_JJ
details_NN
of_PIN
this_DEMO
facility_NOMZ
are_VPRT [PASS]
described_VBN
within_PIN
Financial_NN
liabilities_NOMZ
in_PIN
note_NN
20_CD
._.
In_PIN
December_NN
2002_CD
,_,
Acambis_NN
entered_VBD
into_PIN
a_DT
distribution_NOMZ
,_,
manufacturing_GER
and_PHC
licence_NN
agreement_NOMZ
with_PIN
Baxter_NN
,_,
giving_VBG
Baxter_NN
exclusive_JJ
distribution_NOMZ
rights_NN
for_PIN
ACAM2000_NN
smallpox_NN
vaccine_NN
in_PIN
all_QUAN
countries_NN
of_PIN
the_DT
world_NN
excluding_VBG [WZPRES]
the_DT
US_FPP1
and_CC
the_DT
UK_NN
._.
In_PIN
2002_CD
,_,
turnover_NN
of_PIN
0.7_CD
m_NN [BEMA]
2001_CD
nil_NN
,_,
2000_CD
nil_NN
was_VBD [PASS]
recorded_VBN
under_IN
this_DEMO
agreement_NOMZ
._.
c_NN
Aventis_NN
Pasteur_NN
agreements_NOMZ
H._NN
pylori_NN
The_DT
arrangements_NOMZ
relating_VBG [WZPRES]
to_PIN
the_DT
Joint_NN
Venture_NN
,_,
called_VBD
Pasteur_NN
Mrieux-OraVax_NN
,_,
are_VPRT [PASS]
described_VBN
in_PIN
notes_NN
14_CD
d_SYM
and_CC
27_CD
._.
The_DT
Groups_NN
share_NN
of_PIN
the_DT
net_JJ
liabilities_NOMZ
of_PIN
Pasteur_NN
Mrieux-OraVax_NN
at_PIN
31_CD
December_NN
2002_CD
was_VBD [BEMA]
0.2_CD
m_NN [BEMA]
2001_CD
net_JJ
assets_NN
of_PIN
0.07_CD
m_NN
,_,
2000_CD
net_JJ
liabilities_NOMZ
of_PIN
0.04_CD
m._FW
During_PIN
2002_CD
,_,
the_DT
Group_NN
recorded_VBD
turnover_NN
of_PIN
0.3_CD
m_NN [BEMA]
2001_CD
0.5_CD
m_NN
,_,
2000_CD
2_CD
._.
._.
4m_NN
for_PIN
R&D_NN
costs_NN
incurred_VBN [WZPAST]
by_PIN
the_DT
Group_NN
and_CC
funded_VBN
by_PIN
Pasteur_NN
Mrieux-OraVax_NN
._.
The_DT
Group_NN
will_PRMD
share_VB
any_QUAN
revenues_NN
from_PIN
sales_NN
of_PIN
the_DT
final_JJ
product_NN
in_PIN
equal_JJ
proportions_NOMZ
with_PIN
Aventis_NN
Pasteur_NN
._.
45_CD
46_CD
FURTHER_NN
INFORMATION_NOMZ
REQUIRED_NN
BY_PIN
FORM_NN
20-F_JJ
unaudited_JJ
ChimeriVax-Dengue_NN
The_NN
Group_NN
has_VPRT
a_DT
licensing_GER
and_PHC
collaboration_NOMZ
agreement_NOMZ
with_PIN
Aventis_NN
Pasteur_NN
to_TO
employ_VB
the_DT
ChimeriVax_NN
technology_NN
to_TO
develop_VB
a_DT
vaccine_NN
against_PIN
dengue_NN
fever_NN
._.
Aventis_NN
Pasteur_NN
fully_AMP
funds_NN
all_QUAN
R&D_NN
costs_VPRT
incurred_VBN
on_PIN
the_DT
project_NN
._.
Previously_TIME
,_,
Aventis_NN
Pasteur_NN
also_RB
funded_VBD
the_DT
Groups_NN
Japanese_JJ
encephalitis_NN
project_NN
,_,
the_DT
rights_NN
for_PIN
which_WDT [PIRE]
were_VBD [PASS]
returned_VBN
to_PIN
Acambis_NN
during_PIN
2000_CD
._.
During_PIN
2002_CD
,_,
the_DT
Group_NN
has_VPRT [PEAS]
recorded_VBN
turnover_NN
of_PIN
3.3_CD
m_NN [BEMA]
2001_CD
2.6_CD
m_NN
,_,
2000_CD
3.0_CD
m_NN [BEMA]
for_PIN
R&D_NN
costs_NN
incurred_VBN [WZPAST]
by_PIN
the_DT
Group_NN
and_CC
funded_VBN
by_PIN
Aventis_NN
Pasteur_NN
under_IN
this_DEMO
agreement_NOMZ
._.
The_DT
Group_NN
has_VPRT
the_DT
ability_NOMZ
to_TO
receive_VB
clinical_JJ
and_PHC
regulatory_JJ
milestones_NN
through_PIN
to_PIN
product_NN
licensure_NN
in_CONJ
addition_NULL
to_PIN
royalties_NN
on_PIN
sales_NN
of_PIN
the_DT
actual_JJ
product_NN
._.
d_LS
Evans_NN
Vaccines_NN
agreement_NOMZ
In_PIN
September_NN
1999_CD
,_,
the_DT
Group_NN
entered_VBD
into_PIN
an_DT
agreement_NOMZ
with_PIN
Medeva_NN
Pharma_NN
Limited_NN
to_TO
obtain_VB
regulatory_JJ
approval_NN
in_PIN
the_DT
US_FPP1
for_PIN
Arilvax_NN
._.
Medeva_NN
Pharma_NN
Limited_NN
assigned_VBN
this_DEMO
agreement_NOMZ
to_PIN
Evans_NN
Vaccines_NN
Limited_NN
,_,
a_DT
wholly-owned_JJ
subsidiary_NN
of_PIN
PowderJect_NN
,_,
in_PIN
October_NN
2000_CD
._.
The_DT
Group_NN
is_VPRT
funding_VBG
100_CD
%_NN
of_PIN
the_DT
costs_NN
of_PIN
the_DT
clinical_JJ
trials_NN
and_CC
regulatory_JJ
submission_NN
._.
As_IN
described_VBN
in_PIN
note_NN
18_CD
,_,
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
within_PIN
one_CD
year_NN
,_,
the_DT
costs_NN
are_VPRT
being_VBG [SPAU] [PASS]
partly_DWNT
financed_VBN
through_PIN
an_DT
overdraft_NN
facility_NOMZ
up_IN
to_PIN
a_DT
maximum_NN
of_PIN
$_$
7m_CD
,_,
being_VBG [BYPA]
underwritten_VBN
by_PIN
PowderJect_NN
._.
PowderJect_NN
has_VPRT [PEAS]
granted_VBN [SUAV]
to_PIN
Acambis_NN
100_CD
%_NN
of_PIN
the_DT
marketing_GER
rights_NN
to_PIN
Arilvax_NN
in_PIN
the_DT
US_FPP1
,_,
whilst_OSUB
still_RB
retaining_VBG
an_DT
option_NOMZ
to_TO
buy_VB
back_RB
50_CD
%_NN
of_PIN
the_DT
profits_NN
from_PIN
the_DT
US_FPP1
sales_NN
in_PIN
return_NN
for_PIN
refunding_VBG
to_PIN
the_DT
Group_NN
the_DT
costs_NN
the_DT
Group_NN
has_VPRT [PEAS]
incurred_VBN
on_PIN
the_DT
Arilvax_NN
program_NN
._.
No_SYNE
turnover_NN
was_VBD [PASS]
recorded_VBN
in_PIN
2002_CD
2001_CD
nil_NN
,_,
1999_CD
nil_NN
under_IN
this_DEMO
agreement_NOMZ
._.
10e_CD
UK_NN
tax_NN
consequences_NN
of_PIN
owning_VBG
Acambis_NN
shares_NN
Taxation_NOMZ
of_PIN
dividends_NN
There_EX
is_VPRT
no_SYNE
withholding_GER
tax_NN
on_PIN
dividends_NN
paid_VBN [WZPAST]
by_PIN
a_DT
UK_NN
company_NN
._.
Under_IN
the_DT
provisions_NN
of_PIN
the_DT
income_NN
tax_NN
convention_NOMZ
currently_RB
in_PIN
force_NN
between_PIN
the_DT
UK_NN
and_CC
the_DT
US_FPP1
,_,
a_DT
US_FPP1
holder_NN
who_WP [WHSUB]
is_VPRT [BEMA]
an_DT
individual_JJ
or_CC
a_DT
corporate_JJ
portfolio_NN
holder_NN
,_,
who_WP
does_VPRT
not_XX0
own_JJ
10_CD
%_NN
or_CC
more_EMPH
of_PIN
the_DT
Acambis_NN
shares_NN
a_DT
Corporate_JJ
Portfolio_NN
Holder_NN
,_,
will_PRMD
be_VB [PASS]
entitled_VBN
to_TO
receive_VB
a_DT
payment_NOMZ
from_PIN
the_DT
UK_NN
Inland_NN
Revenue_NN
equal_JJ
to_PIN
the_DT
tax_NN
credit_NN
in_PIN
respect_NN
of_PIN
the_DT
dividend_NN
the_DT
Tax_NN
Treaty_NN
Payment_NOMZ
minus_PIN
a_DT
withholding_GER
of_PIN
15_CD
%_NN
of_PIN
the_DT
aggregate_NN
of_PIN
the_DT
dividend_NN
and_CC
the_DT
tax_NN
credit_NN
one-ninth_NN
of_PIN
the_DT
dividend_NN
,_,
meaning_VBG [PRIV]
that_THVC
the_DT
amount_NN
of_PIN
the_DT
withholding_GER
will_PRMD [SPAU]
effectively_RB
eliminate_VB
the_DT
amount_NN
of_PIN
Tax_NN
Treaty_NN
Payment_NOMZ
._.
Thus_CONJ
,_,
a_DT
US_FPP1
individual_NN
or_CC
US_FPP1
Corporate_NN
Portfolio_NN
Holder_NN
who_WP [WHSUB]
is_VPRT [PASS]
entitled_VBN
to_PIN
an_DT
80_CD
dividend_NN
paid_VBN [WZPAST]
by_PIN
Acambis_NN
will_PRMD
receive_VB
80_CD
._.
UK_NN
taxation_NOMZ
of_PIN
capital_NN
gains_NN
A_DT
US_FPP1
holder_NN
who_WP [WHSUB]
is_VPRT [BEMA]
not_XX0
resident_PRED
,_,
or_CC
ordinarily_RB
resident_JJ
,_,
for_PIN
tax_NN
purposes_NN
in_PIN
the_DT
UK_NN
will_PRMD
not_XX0
be_VB [BEMA]
liable_PRED
for_PIN
UK_NN
tax_NN
on_PIN
capital_NN
gains_NN
on_PIN
the_DT
disposal_NN
of_PIN
Acambis_NN
shares_NN
unless_COND
the_DT
US_FPP1
holder_NN
carries_VPRT
on_PIN
a_DT
trade_NN
,_,
profession_NN
or_CC
vocation_NOMZ
in_PIN
the_DT
UK_NN
through_PIN
a_DT
branch_NN
or_CC
agency_NN
and_CC
the_DT
Acambis_NN
shares_NN
are_VPRT
or_CC
have_VPRT [PEAS]
been_VBN [BYPA]
used_VBN
by_PIN [STPR]
,_,
held_VBN [PRIV] [PASTP]
by_PIN [STPR]
,_,
or_CC
acquired_VBN
for_PIN
use_NN
by_PIN
or_CC
for_PIN
the_DT
purposes_NN
of_PIN
such_JJ
trade_NN
,_,
profession_NN
,_,
vocation_NOMZ
,_,
branch_NN
or_CC
agent_NN
._.
UK_NN
inheritance_NN
tax_NN
on_PIN
estates_NN
and_PHC
gifts_NN
The_DT
estate_NN
and_PHC
gift_NN
tax_NN
convention_NOMZ
in_PIN
force_NN
between_PIN
the_DT
US_FPP1
and_CC
the_DT
UK_NN
provides_VPRT
that_DEMO
the_DT
UK_NN
tax_NN
to_PIN
which_WDT [PIRE]
the_DT
convention_NOMZ
applies_VPRT
is_VPRT
capital_NN
transfer_NN
tax_NN
and_CC
that_THVC
it_PIT
will_PRMD [SPAU]
also_RB
apply_VB
to_PIN
identical_JJ
or_CC
substantially_RB
similar_JJ
taxes_NN
which_WDT [WHSUB]
are_VPRT [PASS]
imposed_VBN
subsequently_TIME
._.
Capital_NN
transfer_NN
tax_NN
in_PIN
the_DT
UK_NN
has_VPRT [PEAS]
been_VBN [BYPA]
replaced_VBN
by_PIN
inheritance_NN
tax_NN
._.
It_PIT
is_VPRT [PASS]
understood_VBN [PRIV] [THATD]
that_DEMP
,_,
in_PIN
practice_NN
,_,
the_DT
US_FPP1
tax_NN
authorities_NOMZ
and_CC
the_DT
UK_NN
Inland_NN
Revenue_NN
apply_VB
the_DT
convention_NOMZ
on_PIN
the_DT
basis_NN
that_DEMO
inheritance_NN
tax_NN
has_VPRT [PEAS]
replaced_VBN
capital_NN
transfer_NN
tax_NN
as_IN
the_DT
tax_NN
to_PIN
which_WDT [PIRE]
the_DT
convention_NOMZ
now_TIME
applies_VPRT
,_,
although_CONC
the_DT
convention_NOMZ
has_VPRT [PEAS]
not_XX0
been_VBN [PASS]
amended_VBN
to_PIN
that_DEMO
effect_NN
._.
On_PIN
the_DT
basis_NN
of_PIN
that_DEMO
practice_NN
,_,
Acambis_NN
shares_NN
held_VBD [PRIV]
in_PIN
the_DT
US_FPP1
by_PIN
an_DT
individual_NN
who_WP [WHSUB]
is_VPRT [PASS]
domiciled_VBN
for_PIN
the_DT
purposes_NN
of_PIN
the_DT
estate_NN
and_PHC
gift_NN
tax_NN
convention_NOMZ
in_PIN
the_DT
US_FPP1
and_CC
is_VPRT [BEMA]
not_XX0
for_PIN
the_DT
purposes_NN
of_PIN
the_DT
convention_NOMZ
a_DT
national_JJ
of_PIN
the_DT
UK_NN
,_,
will_PRMD
not_XX0
be_VB [BEMA]
subject_PRED
to_PIN
inheritance_NN
tax_NN
on_PIN
the_DT
individuals_NN
death_NN
or_CC
on_PIN
a_DT
transfer_NN
of_PIN
the_DT
Acambis_NN
shares_NN
during_PIN
the_DT
individuals_NN
lifetime_NN
._.
However_CONJ
,_,
special_JJ
rules_NN
apply_VPRT
in_PIN
the_DT
case_NN
of_PIN
Acambis_NN
shares_NN
held_VBD [PRIV]
in_PIN
trust_NN
or_CC
as_IN
part_NN
of_PIN
the_DT
business_NOMZ
property_NN
of_PIN
a_DT
permanent_JJ
establishment_NOMZ
in_PIN
the_DT
UK_NN
or_CC
related_VBN
to_PIN
the_DT
fixed_VBN
base_NN
in_PIN
the_DT
UK_NN
of_PIN
a_DT
person_NN
providing_VBG [WZPRES]
independent_JJ
personal_JJ
services_NN
._.
UK_NN
stamp_VB
duty_NN
and_CC
stamp_VB
duty_NN
reserve_NN
tax_NN
Any_QUAN
transfer_NN
of_PIN
Acambis_NN
shares_NN
will_PRMD
result_VB
in_PIN
the_DT
stamp_NN
duty_NN
liability_NOMZ
at_PIN
the_DT
rate_NN
of_PIN
0.5_CD
%_NN
rounded_VBD
to_PIN
the_DT
nearest_JJ
5_CD
of_PIN
the_DT
consideration_NOMZ
which_WDT [WHOBJ]
liability_NOMZ
is_VPRT [BEMA]
generally_RB
payable_PRED
by_PIN
the_DT
purchaser_NN
of_PIN
the_DT
Acambis_NN
shares_NN
._.
There_EX
is_VPRT
no_SYNE
charge_NN
to_PIN
ad_NN
valorem_NN
stamp_NN
duty_NN
on_PIN
gifts_NN
._.
On_PIN
a_DT
transfer_NN
of_PIN
Acambis_NN
shares_NN
from_PIN
a_DT
nominee_NN
to_PIN
the_DT
beneficial_JJ
owner_NN
,_,
if_COND
the_DT
nominee_NN
has_VPRT
at_PIN
all_QUAN
times_NN
held_VBD [PRIV]
the_DT
Acambis_NN
shares_NN
on_PIN
behalf_NN
of_PIN
the_DT
transferee_NN
,_,
under_IN
which_WDT
no_SYNE
beneficial_JJ
interest_NN
passes_VPRT
and_ANDC
which_WDT
is_VPRT [BEMA]
neither_SYNE
a_DT
sale_NN
,_,
nor_SYNE
arises_VPRT
under_IN
or_CC
following_VBG
a_DT
contract_NN
of_PIN
sale_NN
,_,
nor_SYNE
is_VPRT [BEMA]
in_PIN
contemplation_NOMZ
of_PIN
sale_NN
,_,
a_DT
fixed_VBN
5_CD
stamp_NN
duty_NN
will_PRMD
be_VB [BEMA]
payable_PRED
._.
Stamp_NN
duty_NN
reserve_NN
tax_NN
,_,
generally_RB
at_PIN
a_DT
rate_NN
of_PIN
0.5_CD
%_NN
on_PIN
the_DT
consideration_NOMZ
,_,
is_VPRT [BEMA]
currently_RB
payable_PRED
on_PIN
any_QUAN
agreement_NOMZ
to_TO
transfer_VB
ordinary_JJ
shares_NN
or_CC
any_QUAN
interest_NN
therein_RB
unless_COND
:_:
an_DT
instrument_NOMZ
transferring_VBG [WZPRES]
the_DT
shares_NN
is_VPRT [SPAU] [PASS]
duly_RB
executed_VBN
and_PHC
stamped_VBN
within_PIN
the_DT
appropriate_JJ
time_NN
limits_NN
:_:
and_ANDC
stamp_VB
duty_NN
,_,
generally_RB
at_PIN
a_DT
rate_NN
of_PIN
0.5_CD
%_NN
rounded_VBD
to_PIN
the_DT
nearest_JJ
5_CD
of_PIN
consideration_NOMZ
or_CC
part_NN
thereof_RB
,_,
is_VPRT [PASS]
paid_VBN
._.
